Appraisal of the appropriateness of prescribing in community-dwelling oldest old (aged 80+) by Wauters, Maarten
Faculty of Medicine and Health Sciences
Heymans Institute of Pharmacology
Division of Clinical Pharmacology
2018
Promotors:  Prof. dr. R. Vander Stichele
 Dr. M. Azermai
Thesis submitted in fulfilment of the requirements 
for the degree of Doctor of Health Sciences
Appraisal of the appropriateness of 
prescribing in community-dwelling 
oldest old (aged 80+)
Maarten Wauters

Faculteit Geneeskunde en Gezondheidswetenschappen
Heymans Instituut voor Farmacologie
Onderzoekseenheid Klinische Farmacologie
2018
Promotors:  Prof. dr. R. Vander Stichele
 Dr. M. Azermai
Proefschrift voorgelegd tot het behalen van de graad 
van Doctor in de gezondheidswetenschappen
Beoordeling van de geschiktheid van 
voorschrijven bij thuiswonende oudste 
ouderen (80 jaar en ouder)
Maarten Wauters
Supervisors
Prof. dr. R. Vander Stichele
Ghent University, Heymans Institute of Pharmacology
Dr. M. Azermai
Ghent University, Heymans Institute of Pharmacology
Steering Committee
Prof. dr. M. Elseviers
University of Antwerp, Centre for Research and Innovation in Care (CRIC)
Ghent University, Heymans Institute of Pharmacology
Prof. dr. T. Christiaens
Ghent University, Heymans Institute of Pharmacology
Members of the Examination Committee
Prof. dr. J. Van de Voorde (Chairman)
Ghent University, Heymans Institute of Pharmacology
Prof. dr. K. Taxis
University of Groningen , Department of Pharmacy, Unit for Pharmacotherapy, 
Epidemiology & Economics
Prof. dr. J. De Lepeleire
University of Leuven, Department of Public Health and Primary Care
Prof. dr. T. Dilles
University of Antwerp, Centre For Research and Innovation in Care (CRIC)
Prof.dr. K. Boussery
Ghent University, Department of Bioanalysis, Pharmaceutical Care Unit
Prof.dr. M. Petrovic
Ghent University, Department of Internal Medicine, section of Geriatrics
Dr. P. Boeckxstaens
Ghent University, Department of Family Medicine and Primary Health Care
© Maarten Wauters
Appraisal of the appropriateness of prescribing in community-dwelling oldest old (aged 
80+) / M. Wauters
Universiteit Gent, Campus UZ Gent, Vakgroep Farmacologie – Heymans Instituut 
De Pintelaan 185, 9000 Gent
Thesis Universiteit Gent 2018 – with summary in Dutch
Lay-out & cover:  Dirk De Weerdt (www.ddwdesign.be)
Table of Contents
Chapter 1 Introduction 7
Chapter 2 Scope of this thesis 39
Chapter 3 Polypharmacy in a Belgian cohort of community-dwelling oldest 
old (80+) 47
Chapter 4 Mortality, hospitalisation, institutionalisation  in community-
dwelling oldest old:  The impact of medication 63
Chapter 5 Availability and actual use in the Belgian market of potentially 
inappropriate medications (PIMs) from the EU(7)-PIM list 79
Chapter 6 Too many, too few, or too unsafe? 
Impact of inappropriate prescribing on mortality and hospi-
talisation in a cohort of community-dwelling oldest old 85
Chapter 7 A novel scale linking potency and dosage to estimate 
anticholinergic exposure in older adults: the Muscarinic 
Acetylcholinergic Receptor ANTagonist Exposure (MARANTE) scale 105
Chapter 8 Anticholinergic exposure in a cohort of adults aged 80 and over. 
Associations of the MARANTE scale with mortality and 
hospitalisation 127
Chapter 9 General discussion 149











1.1  The oldest old, and health related problems 10
Clinical characteristics of the oldest old 12




1.2 Medication management, prescribing, and deprescribing 
16
Medication management process  17
Problems in the medication management 18
Medication errors and drug related problems 19
Deprescribing 20
1.3 Appraising the appropriateness of prescribing 21
Rational prescribing by physicians 22
Pharmaceutical care by pharmacists 23
Nurse involvement in pharmaceutical care 24
Multidisciplinary approaches 24
Defining the appropriateness of prescribing 26
Polypharmacy 26
Potentially Inappropriate Prescribing 28
1.4 Formalisation of the appraisal of appropriateness of 
prescribing 30
Purpose and aspects 31
Published lists for the appraisal of appropriateness 31
Implicit criteria  31
Explicit criteria 32
Inventory of lists of explicit criteria available 32
Formalisation of assessment of pharmacodynamic 
effects: 
the case of anticholinergics 34
Critical review of explicit criteria 36




n the past century, improvements on eco-
nomic, social and medical scale have led to 
an increase in life expectancy at birth and 
to an increased age at death. As people get 
older, the share of older adults (those aged 
65 years, and older) will increase [1]. For most West-
ern countries, the older population is ageing itself, 
as the share of the oldest old (those aged 80 years, 
and older) will increase greatly [1]. 
Ageing of the population is a challenge for 
health care systems. The higher number of older 
adults will lead to a higher number of older adults 
needing medical care. Treatment or prevention of 
disease will generally include the treatment with 
medications. Yet, older adults are more sensitive to 
the effects of medications and are therefore more at 
risk for medication related problems. 
In this introduction, an overview is given on the 
challenge of ageing, on how medications are pre-
scribed, and on what challenges arise in the rational 
prescribing process in older adults. Several methods 
to appraise the medication use are listed, with a spe-
cific focus on the formalisation of the assessment of 




1.1  The oldest old, and health related problems
Demographics of the oldest old
Ageing is an inevitable and continuous process that affects all organs 
and organ processes [2]. Ageing affects different aspects of life, including 
biological, psychological and social changes [3]. Biological changes refer 
to the gradual deterioration of the body. Decreasing sensory or perceptu-
al processes lead to a decrease in the adaptive capacity to new situations. 
Social changes concern the altering patterns in the role older adults take 
up in society [4]. A cut-off based on the calendrical age may not always be 
the correct indicator for physical and mental age groups, or for determin-
ing the retirement age. 
There is no consensus on how to define older adults or age groups. 
In earlier research, the term ‘elderly’ was used to define older adults, but 
is no longer indicated due to the pejorative connotation. Old age usually 
refers to the later part of life, but no universal definition was installed. The 
term ‘oldest old’ was introduced 30 years ago [5]. It generally encompass-
es the oldest age groups in the setting studied. Depending on the inclu-
sion criteria of studies, different age-groups can be used as a result (e.g. 
85 years, and older [6, 7]). The MeSH term states ‘aged 80 years, and older’, 
and equates it with the term ‘oldest old’, but not with the term ‘elderly’. 
In this thesis, we use 
‘adults, aged 65 years and older’ as the definition for old age and older adults
‘adults, aged 80 years and older’ as the definition for the oldest old. 
Currently, older persons (aged 65 years, and over) account for 8.3 % of 
the world population. This share of older persons is expected to increase 
to 11.7% by 2030 [8]. Europe (509 million inhabitants) has the highest 
prevalence of older adults (18.9%), and is expected to age more rapidly in 
comparison with other continents. Europop2013, and World Population 
Prospects 2017 indicate that the share of oldest old in Europe (aged 80 
years, and over), is to rise from 5.3% to 7.1% in 2030 (equalling 10.900.000 
oldest old extra in comparison with today) [9]. 
For Belgium, there are currently 2.063.000 Belgians aged 65 years and 
older (18.3% of the population), and 618.593 persons aged 80 and older 
(5.5% of the population, source: www.bestat.economie.fgov.be). This 
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Figure 1.1: Demographic evolution 
of the older global population.
Figure 1.2: Demographic evolution 
of the older population in Europe. 
Figure 1.3: Demographic evolution 



























































































































older population is ageing, as the share of the oldest old (80 years and 
older) within the older population is expected to increase. Demographic 
projections suggest that by 2030 around 22.7% of the population will be 
65 years and older [10]. The share of the oldest old will rise to 6.6%, equal-
ling approximately 120.000 people extra in comparison with 2014. 
Clinical characteristics of the oldest old
Health is defined in numerous ways. According to the World Health 
Organisation, health is a state of complete physical, mental and social 
well-being and not merely the absence of disease or infirmity. For older 
persons, health or being healthy is more difficult to define. With advanc-
ing age, the risk of developing clinical problems will rise. The oldest old 
are characterised by having various geriatric problems [11, 12] (e.g. 
cognitive, visual, and hearing decline; frailty; or disabilities), and almost 
all are diagnosed with at least one clinical problem. The prevalence of 
diabetes, osteoporosis, osteoarthritis, chronic kidney disease and hyper-
tension in the oldest old is higher compared to that of older adults [13]. 
In contrast, the prevalence of heart failure is lower in the oldest old [13]. 
The care for older adults is challenging due to the increased risk for 
a higher level of multimorbidity, disability, or frailty. These concepts are 
overlapping to some extent, but are distinct concepts [14]. A wide array 
of assessment methods are available, with varying levels of complexity. 
Multimorbidity can be measured with either a disease count, but also us-
ing more comprehensive methods that incorporate the impact on dif-
ferent body systems. Frailty can be measured by either just the physical 
skills of older adults, but also more comprehensive methods including 
the social status, nutritional status, cognition, and the medication intake. 
Disability usually gives an indication for the level of dependence. It can 
pertain to the competence to perform activities of daily living, but it also 
pertains to the social construct of disability.
The level of multimorbidity has been related with several patient-
outcomes (e.g. mortality and hospitalisation) [15]. Multimorbidity seems 
to be an important predictor for mortality, yet studies remain inconclu-
sive. The overall interpretation is limited because of the heterogeneity of 
assessment methods, or because a less clear definition of disease in the 
oldest old. Given example, cut-off values for diabetes or hypertension are 
still debated and are potentially a less clear predictor [16]. In addition, a 
‘survivor’ effect can complicate the interpretation. Some studies describe 
the decreasing physical abilities (e.g. grip strength, sarcopenia) as a major 
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predictor for mortality [16]. 
Ageing will inevitably lead to body changes affecting all body-sys-
tems, potentially limiting participation in physical activity or general ac-
tivities of daily living. Ageing can affect cognitive functioning due to cog-
nitive decline and the occurrence of dementia. A cognitive decline and a 
higher level of multimorbidity can impact daily life, by hindering possible 
participation in the community [17, 18]. A lower participation is a social 
risk factor and can lead to social isolation [19]. At a high age, people en-
counter personal losses at a higher rate. According to the SHARE data (a 
European survey of health, ageing, and retirement), most of the commu-
nity-dwelling oldest old live alone (56%). The remaining either lived with 
their significant other (27%) or with their relatives (16%, although more 
in Southern European countries). 
Surprisingly, despite increasing risks for developing disease and disa-
bility, studies characterise a large part of the oldest old as relatively fit and 
healthy [7, 11, 16]. And, despite personal losses, the oldest old perceive 
themselves as relatively happy [20]. Studies on older adults have shown a 
decreasing trend for doing activities of daily living (ADL or the independ-
ence in toileting, eating, mobility …) [21, 22]. Yet, in community-dwelling 
oldest old, the level of independence was found relatively high [23, 24], 
with up to 67% managing their activities of daily living with little to no 
limitations [22]. Possibly, due to a potential ‘survivor’ effect, only the most 
resilient or most healthy can live past a very high age. 
In Belgium, most of the older adults live at home, even with a relative 
high level of multimorbidity. According to the Belgian Health Interview 
Survey, almost half of the older population (48,8%) reported at least one 
chronic condition, predominantly arthrosis (78.2%), high blood pres-
sure (73.5%) and hyperlipidaemia (70.1%) [25]. In 2011, approximately 
120.000 people resided in nursing homes, equalling 5.8% of the Belgian 
population above 65 years [26]. The federal government aimed to reduce 
the rate of institutionalisation by broadening the range of home assis-
tance of nursing care at home and other formal care services [27, 28]. 
Multicomponent home care interventions (including case management, 
occupational therapy, rehabilitation) aimed to delay the institutionalisa-
tion of older adults [29]. 
Mortality events in 2013 occurred in nearly 61.000 Belgian oldest old, 
accounting for 56% of all mortality events that year (source: http://stat-
bel.fgov.be/nl/statistieken/cijfers/bevolking/). Most common causes of 
death were cardiovascular disease (35%), cancer (17%) or respiratory re-
lated diseases (12%) [30]. Most common place of death in Belgium is the 
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hospital (46.9%) and a nursing home (27.2%) [31]
Pharmacokinetics and pharmacodynamics in the oldest old
Pharmacokinetic aspects
Pharmacotherapy in older adults is a complex process, influenced 
by pharmacokinetic and pharmacodynamic changes when ageing [2, 
32–34]. Pharmacokinetic changes describe the processes of a drug in the 
body over the course of time, namely the absorption, distribution, trans-
formation, and finally clearance of a drug. When ageing, almost all these 
processes are affected. 
The rate of absorption of medications affects the time course and 
intensity of the initial drug action. Age-related changes in the absorp-
tion phase include changes in the gastric acidity and reduced mes-
enteric blood flow, absorption surface, and transport proteins. The 
absorption of medications can thus be altered by medications affect-
ing the gastric motility (e.g. anticholinergic drugs), or by medications 
affecting the gastric pH level (e.g. antacids can delay absorption of 
psychotropic drugs). 
The medication distribution is altered in the older body. As humans 
age, the mean body mass decreases and the body composition shifts 
towards a higher body fat mass. As a result, the half-life of lipid-sol-
uble medications (e.g. benzodiazepines) is prolonged, resulting in a 
higher serum level of hydrophilic medications (e.g. digoxin). Distri-
bution of medications is mediated through albumin or glycoprotein 
binding. Unbound medication concentrations determine the effect of 
the medication. Plasma albumin levels tend to decrease when ageing, 
while glycoprotein tends to increase. A reduction of these proteins 
(e.g. by ageing, or by malnutrition) might theoretically contribute to 
medication interactions, although their clinical effect is limited [35]. 
A decrease in liver mass and blood flow to the liver leads to an increase 
in bioavailability of those active medications undergoing first-pass 
metabolism (e.g. opioids). For some medications, metabolisation or 
enzymatic transformation (predominantly in the liver) is needed in 
order to have effect. In the case the medications are pro-drugs, de-
creased first pass metabolism may lead to less active medications (e.g. 
ACE inhibitors) [2, 33].
The predominant change in the older body is a decreased elimina-
tion of a vast array of medications [34]. A decreased liver mass and 
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decreased blood flow to the liver leads to a lower clearance of active 
substances that are metabolised by the liver (e.g. propranolol). Most 
importantly, the decline in renal function affects the elimination of 
medications, eliminated by the kidney (e.g. antibiotics, digoxin, beta-
blockers …). Due to a lower glomerular filtration rate, medications or 
metabolites can accumulate in the body. The accumulation of medi-
cations with a narrow therapeutic margin (e.g. digoxin) can lead to 
adverse effects [35, 36]. 
Pharmacodynamic aspects
Pharmacodynamics describe the reaction of the human body to med-
ications. Clinical observations indicate that older adults are more sus-
ceptible to the effects of medications. Age-related pharmacodynamic 
changes include a down- or upside regulation of receptors, a different 
receptor sensitivity, and a reduced homeostatic response in the older 
body [2]. There is however limited data available on pharmacodynamic 
differences in very old persons [37], but studies reported a number of 
drug effects in older adults (predominantly more intense sedative, an-
ticholinergic or extrapyramidal effects). 
Most commonly anticoagulants, cardiovascular and psychotropic 
drugs are linked with altered (usually increased) pharmacodynamic prop-
erties. Older persons have a higher risk of bleeding when taking antico-
agulants (e.g. warfarin) [38], due to an increased risk of a vitamin K deficit, 
less coagulation factors in the blood, and a potential interaction between 
coumarine derivates and for instance NSAIDs. Benzodiazepines can lead 
to an increased level of sedation in older persons [39], because of a po-
tential accumulation in the body and an associated prolonged duration 
of effect. 
The case of anticholinergics
Medications with anticholinergic effects or anticholinergics have been 
linked to pharmacodynamic-induced adverse effects, and may depend 
on age-related pharmacodynamic changes, due to variations in receptor 
abundance, binding affinity, receptor displacement by other drugs, and 
physiological factors [40].
Anticholinergics were introduced in the past 50 years, but some were 
also withdrawn due to increasing evidence of high risks for side effects 
[41]. Medications with anticholinergic properties interact through com-
petitive antagonism with cholinergic receptors (either nicotinergic or 
muscarinic) in the human body [42–48], and the effects are more severe 
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in older adults [43, 49–52].
Based on the location and subtype of muscarinic receptors, different 
physiological responses are mediated [53]. Central anticholinergic side 
effects include a decreased cognitive functioning in older adults (atten-
tion loss, psychomotor speed, working memory, , …) [54, 55], a higher 
risk for delirium [56], and a 2.8 times increased risk for being hospitalised 
for confusion or dementia [57]. In addition, a higher exposure to anticho-
linergics has been associated with altered emotions and behavioural dis-
turbances [58, 59], impaired physical functioning [60–62] and a poorer 
performance on instrumental activities of daily living [63]. Peripheral 
anticholinergic side effects can also affect older adults and their quality 
of life. Dry mouth, the most prevalent side-effect, can be bothersome as it 
can lead to food ingestion problems, speech problems, or increased risks 
for oral infections due to a decreased saliva flow [64]. Constipation is also 
a prevalent symptom, that may have a significant impact on the quality 
of life [65]. Anticholinergics can also affect the eye, leading to dryness 
and blurred vision [66], and thus increasing the risk for having a fall. 
1.2 Medication management, prescribing, and 
deprescribing
The general practitioner (GP) usually has an important role in the care 
for older adults, for the first diagnosis of clinical problems and the pre-
scribing of medications. Older adults in Belgium see their GP on average 
every month, and more than 60% consults a medical specialist yearly [67]. 
The intake of medications is a daily routine in 51% of all Belgian in-
dividuals [25], and the number of prescribed medications is likely to rise 
with ageing [68]. According to data from the National Institute for Health 
and Disability (NIHDI, RIZIV in Dutch), 19% of all older adults have polyp-
harmacy (the intake of multiple medications, most commonly defined as 
five or more). These older adults represent a major cost for the national 
health care system. The yearly pharmacological reimbursement costs for 
older patients with polypharmacy are an estimated 420.000.000€ (not in-
cluding other health care usage) [69].
The oldest old are generally prescribed cardiovascular, nervous sys-
tem, alimentary or blood(forming) medications [70–72]. The majority 
(71%) of community-dwelling older adults (in Italy) have at least one car-
diovascular medication prescribed, predominantly ACE-inhibitors, diu-
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retics, Beta-blocking agents or lipid-modifying agents [71]. Belgian older 
adults of 75 years and older reported use of predominantly lipid-modify-
ing drugs (35%) and Beta-blocking agents (32%). Nervous system medi-
cations predominantly include hypno-sedatives (17% - 43%) [73, 74], and 
analgesics (45%) [75]. For Belgium, a high use of hypno-sedatives (20%) 
and antidepressants (12%) among older adults of 75 years and older was 
noted [25]. Alimentary medications generally include proton-pump in-
hibitors [76]. 
Medication management process 
The process of setting a diagnosis and choosing appropriate medica-
tion in older adults is complex. The World Health Organisation defines the 
rational prescribing of medication as choosing the right medication, for 
the right patient, for the right indication at the right dosage in the right 
form and at the right price [77]. It involves not only the choice, but also 
the decision of optimal dosing and scheduling, informing and educating 
the patient, and doing the follow-up of the effectiveness of the medica-
tions. 
Bell proposed a framework, consisting of five main domains, for the 
evaluation of medication prescriptions (Figure 1.4). 
The first main domain is the act of prescribing by clinicians. Clinicians 
need to assess and fill in the needs for a medication therapy, and the 
patient’s preferences. The combined data input of medication data, 
patient data and possible drug formulary restrictions yield the out-
put (a prescription). Potential threats for errors during electronic pre-
Figure 1.4. A functional model of the medication management process 
(source: Bell, Cretin, Marken & Landman, 2004).
Chapter 1
18
scribing are mistakes during the selection of patients (wrong patient), 
clinical problems (wrong diagnosis, or not reporting a diagnosis), or 
medication selection (wrong dosages). 
The second domain is the transmission of the prescription. In prima-
ry care, patients usually perform this domain themselves, although 
telephoning or secure emailing of prescriptions by clinicians to phar-
macists are possible. Potential threats include transcribing errors.
The dispense activity can be done by clinicians (when medications 
are available on hand), or by pharmacists. Pharmacists more and more 
employ electronic systems to store and to access the same informa-
tion as in the prescribing step. Potential threats include errors in the 
drug choice, meaning dispensing other medications.
The administration of the medication involves the patient, and 
sometimes a wide range of other allied health personnel (e.g. nurses 
in the home or hospital setting). Potential beneficial aspects include 
the generation of medication administration aids, reminders for re-
newals, or the consultation of educational material. Potential threats 
mainly refer to adherence. 
Finally, the monitoring involves the patient and a clinician, but can 
also involve other allied health personnel. Feedback during this step 
could yield changes in the prescriptions of a patient. Potential benefi-
cial aspects include the generation of alerts when a renewal of a med-
ication was not done, the automated generation of questionnaires to 
detect adverse effects, or corollary orders (e.g. monitoring tests). Po-
tential threats include the negligence to report adverse effects by the 
patient or health care professionals or non-adherence to medications. 
Electronic systems can aid medication prescribers and dispensers 
during the whole process. Potential beneficial aspects of electronic sys-
tems include safety alerts (based on known allergies, interactions, labora-
tory tests), formulary alerts (e.g. to improve medication adherence), or 
the automatic possibility of dosage calculations.
Problems in the medication management
Older adults will have more complex clinical problems for which 
they may need multiple medication prescribers, who are neither geri-
atricians nor specialists in old age [84]. More medication prescribers can 
complicate the process of an optimal medication management in the 
care for poly-medicated older patients with multimorbidity. Medication 
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prescribers are generally not aware of potentially inappropriate prescrib-
ing [85].
Decreased cognitive and physical capabilities linked to ageing can af-
fect the handling of medications (e.g. opening blisters, using an insulin 
gliding scale) and can lead to a lower medication adherence [86]. Edu-
cating older adults of the potential risk and benefits of medications and 
offering tools (e.g. medication boxes, …) can change their health beliefs 
and can increase adherence [87]. Older adults generally manage their 
medication intake themselves [88]. The major reason for non-adherence 
is forgetfulness [89, 90].
Medication errors and drug related problems
There are various definitions for medication errors. One definition is 
‘a medication error is a failure in the treatment process that may or may 
not lead to an adverse event’ [91]. Errors can be classified according to 
whether they are mistakes, slips or lapses [92]. 
Drug Related Problems (DRPs) are defined as all events or circum-
stances that interfere with the patient experiencing the optimal outcome 
of pharmaceutical care [93]. The definition of DRPs is sometimes restrict-
ed to problematic actual outcomes, but can also include process aspects 
(e.g. potentially inappropriate prescribing, or distribution errors). 
A recent systematic literature study reviewed 20 classification sys-
tems, of which seven were selected (overlapping different health care 
settings, countries, and development methods) for the construction of 
a new classification system for DRPs [94]. This new comprehensive clas-
sification system lists actual or potential DRPs according to two methods; 
either DRPs resulting from not reaching the treatment goals, or either 
that a drug treatment causes an undesirable effect [93]. Nine causes of 
DRPs have been identified, aiming to cover all events during all aspects 
of pharmacotherapy from the prescribing, the dispensing, monitoring, 
and to the incorrect usage of a medication (e.g. non-adherence), to even 
include unexpected effects of medications [93]. 
DRPs can arise during the prescribing phase in case of contra-indica-
tion (e.g. Beta Blocking agents and second or third degree heart block), 
in the absence of an indication, in case of an inappropriate combination 
with food/alcohol/other medications (e.g. NSAIDS in combination with 
warfarin), when an indication is not treated (e.g. no anticoagulant thera-
py in case of atrial fibrillation), or when a preventive therapy is not started 
(e.g. not prescribing statins for secondary prevention of cerebrovascular 
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problems). During the selection of the drug form, DRPs can arise when an 
inappropriate or suboptimal form is selected (e.g. for older adults, choos-
ing a long-acting hypno-sedative agent). During the dose selection, DRPs 
can arise when choosing a dose that is either too low or too high. Alterna-
tively, if the dose regimen is too frequent or not frequent enough, or sub-
sequently if the dosage is not adapted to a changed disease state. During 
the selection of the dosage duration, DRPs can arise when the duration 
is either too short, or too long. DRPs can also arise during the transmis-
sion phase, during the dispensing of medications (e.g. incorrect delivery 
of medication packages), during the administration (e.g. non-adherence, 
or incorrect application/usage), or during the monitoring phase (e.g. no 
follow-up). 
For the remainder of this thesis, focus is on DRPs during the prescribing phase.
Older adults are more sensitive to encounter DRPs, due to the 
pharmacokinetic- and dynamic changes, and the presence of multiple 
co-morbidities and medications. DRPs are a known risk factor for hospital 
admissions. DRPs have also been linked with increased risks for mortality 
[95, 96].
The medication groups most involved in DRPs are psychotropic 
agents, antiplatelet agents, hypoglycaemic medications and hypno-
sedatives [97], which are among the highest consumed groups of medi-
cations by Belgian older adults [98]. These medication groups can lead 
to unwanted symptoms such as dehydration, confusion, hallucinations, 
bleeding and increased risk of falls, and in return, these side effects can 
lead to the start of a prescribing cascade [99]. A prescribing cascade 
occurs when the adverse effect of medications is misinterpreted as a 
symptom of a new disorder: e.g. prescribing metoclopramide can induce 
Parkinson like symptoms (extrapyramidal symptoms) in older adults, for 
which levodopa can be prescribed [100]. The prescribing of new medi-
cations during a prescribing cascade can again lead to another adverse 
event.
Deprescribing
The medication management process is a cyclical process, where 
medications are reviewed and can be changed, altered in dosage or du-
ration, or discontinued based on the occurrence of DRPs or on the needs 
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of the patient. 
The actual process of deprescribing is little studied. Deprescribing 
has no official definition, but it generally encompasses the act of dis-
continuation of medications in favour of more benefits and less risks, in 
the light of the perceived life expectancy. Studies on deprescribing are 
heterogeneous in interventions and time, and methodological quality is 
low [78]. Deprescribing seems difficult to implement, but may be feasi-
ble. Scott, Hilmer, Reeve, Potter & Le Couteur have described essential 
steps for the discontinuation of medications [79, 80]. First, all medica-
tions a patient takes should be identified and matched with the indica-
tion before starting a new medication. Medication reviewers should an-
swer questions as why and when a medication was started, or consider if 
a medication is part of a prescribing cascade. A second step is to ascertain 
the overall risk of drug induced harm. Medication reviewers should con-
sider medication related factors (a high number of medications, high-risk 
medications) and patient related factors (high age, cognitive impairment, 
non-adherence …) to assess the overall risk for drug-induced harm. Third, 
the benefits and risks for all medications are to be determined. Addition-
ally, medication reviewers should also consider if the benefit outweighs 
the risk for non-adherence, the patient’s expected life span, and the pa-
tient’s own expectations. Using this information, the medication reviewer 
should prioritise the medications for deprescribing according to prag-
matic criteria; either greatest harm, least benefit, or medications easiest 
to discontinue (low risk for rebound effects or withdrawal symptoms), or 
according to the patient his wishes (most willing to discontinue). Finally 
a deprescribing plan can be installed to cease medications one at a time, 
whilst following and monitoring the patient closely for improvement in 
outcomes or onset of adverse effects.
Current evidence suggests deprescribing is safe and may be benefi-
cial in older adults (65 – 79 years). In the oldest old, the few existing stud-
ies indicate that deprescribing does not modify mortality [81, 82]. Inter-
vention techniques adapted to prescribers’ beliefs, attitudes, knowledge, 
skills or behaviour may enable a more successful implementation [83]. 
1.3 Appraising the appropriateness of prescribing
Context
Researchers are faced with a lack of evidence found in medical sci-
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entific literature regarding geriatric pharmacotherapy. Older adults are 
generally underrepresented in clinical studies, due to methodological 
challenges; a high non-response due to a high level of multimorbidity, 
a lower functional status, mental problems, hearing and/or visual prob-
lems. As a result, only a few studies have a unique focus on the commu-
nity-dwelling oldest old [17, 101, 102]. Clinical trials on medication use 
do not aim to get a representative sample of the population in their stud-
ies, and exclude those too old (generally over 65 years), or too sick [103]. 
Also, most research focused on generating evidence based-treatments 
of a single medical condition (single disease guidelines), instead of the 
treatment of patients with multiple conditions [104].
Because of increasing age, age-related changes in pharmacokinetics 
and pharmacodynamics, co-occurrence of medical problems, and the po-
tential intake of multiple medications, the risk of an adverse drug event 
can increase [105]. Adverse drug events are common (up to 23%) in older 
adults, and most (53%) are deemed preventable [105, 106]. Main risk fac-
tors for the occurrence of an adverse drug event are a higher number of 
medications, an impaired renal function, and potentially inappropriate 
prescribing [107]. The occurrence of an adverse event from correct thera-
py is possible and part of the normal risk/benefit assessment of therapy. 
It is an acceptable risk and can be appropriately managed by changes in 
dosage or active substances. On the contrary, adverse events stemming 
from inappropriate prescribing are much more problematic, and espe-
cially unacceptable, when not appropriately managed. 
Rational prescribing by physicians
Following the guidelines from the World Health Organisation (WHO), 
rational prescribing starts with defining the patient’s problem and formu-
lating a working diagnosis. For each patient and their specific problem 
a therapeutic objective should be stated that is suitable for the patient 
in terms of effectiveness, safety and preferences. When the treatment is 
started, information and instructions should be given to the patient, and 
the treatment should be monitored. 
The WHO defined six steps to optimise the process of rational pre-
scribing. It starts (step 1) with defining the problem of the patient and 
(step 2) selecting the therapeutic objective (e.g. preventive, symptomatic, 
curative). Then, GPs need to (step 3) assess whether the selected therapy 
is indicated for the patient, and is as effective, safe, suitable and cheap as 
possible for an individual patient before prescribing a medication (step 
4). Next, the phase of information giving, instruction giving (step 5) is 
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needed, so patients are knowable of the effects, side-effects, and dura-
tion of the therapy. Finally, (step 6) the monitoring of the treatment takes 
place, so that the treatment can be altered for a better outcome to be 
more safe or more convenient, or the treatment can be stopped. 
Prescribing of medications is linked with every aspect of general prac-
tice, including clinical skills, knowledge of epidemiology, the patient, & 
the therapeutic arsenal. 
Pharmaceutical care by pharmacists
Improving the quality of prescribing should not merely be the sole 
responsibility of medication prescribers. In addition, the role of commu-
nity-pharmacists could potentially be enhanced (from patient education 
to guidance in the medication discontinuation). Pharmaceutical care in-
volves the processes when pharmacists cooperate with patients and/or 
other professionals in the design, implementation, and monitoring of a 
therapeutic plan in order to yield specific therapeutic outcomes for pa-
tients [108].
In other words, pharmacists can aid patients by detecting and pre-
venting potential and actual drug related problems. The basic pharma-
ceutical care pharmacists can provide is the assessment of a patients’ 
problem, and providing the patient with tailored advice, or medication 
counselling. Advance pharmaceutical care envelops the individual and 
patient-centred care for patients with specific medical problems. 
Pharmacists have a valuable place in the optimisation of medication 
therapies in older adults. Pharmacists in the community have the pos-
sibility to perform a medication review by screening medications for any 
DRPs. 
Recently, the role of automatic decision support systems during the 
dispensing phase have been studied, with significant results for the ma-
jority of outcomes [109]. Interventions were introduced for pharmacists 
in the Netherlands to perform a medication review (‘Medicatiebeoorde-
ling’ from the Royal Dutch Pharmacist Association), and also the Belgian 
Pharmacist Association strives for an optimisation of the medication use 
[110]. An electronical screening tool was developed recently in belgium, 
the Ghent Older People’s Prescriptions community Pharmacy Screening 
tool (GheOP³S) [111], that encompasses 83 explicit criteria, suited for an 
evaluation in community-pharmacies (predominantly medication-only). 
It is validated [112] and has shown a potential added value for screening 




The hospital pharmacist or the pharmacists in nursing homes have 
the opportunity to closely interact with clinicians, nurses, and patients, 
and so, to promote the rational prescribing of medications [114]. Hospital 
pharmacists can perform an expert pharmacist review; the standardised 
pharmaceutical assessment of older peoples’ prescriptions. This method 
has shown some improvements in the appropriateness of prescribing 
[115, 116], but it relies on interdisciplinary team work in a well organised 
clinical environment. Associations with improved clinical outcomes has 
also not been established [114]. 
Nurse involvement in pharmaceutical care
Nurses have a predominant role in the administration and monitoring 
of medications. Nurses can also be instrumental in detecting and report-
ing medication related problems, and can thus influence the choice of a 
medication during the prescribing step.
The job expectations of nurses regarding the medication manage-
ment may not always be clear to them, creating different barriers in 
medication safety [117]. Nurses’ knowledge on psychotropic pharmacol-
ogy and geriatric pharmacology is low [118, 119]. Nurses perceive their 
knowledge on these topics most often as subpar, indicating the need 
for further education [118]. Nurses can influence the prescribing of more 
(psychotropic) medications when the care burden is too high [120, 121]. 
Recently, Pharmanurse was created to help nurses in the detection and 
reporting of adverse drug reactions, using a standardised method for the 
communication with the prescriber [122]. Pharmanurse supports and 
facilitates the interdisciplinary medication monitoring process through 
resident-specific screening lists for adverse drug reactions (ADRs) [123], 
although the valorisation work needs to be continued. 
Multidisciplinary approaches
The first step in multistep multidisciplinary approaches is often the 
identification of older adults at risk for an adverse drug reaction 
[124]. The inherent difficulty is the differentiation between drug induced 
symptoms and non-drug related symptoms (so that a prescribing cas-
cade will not take place). There are tools available for the detection of any 
potential ADRs, and for the detection of patients at risk. These tools in-
clude the GerontoNet ADR Risk Score [125] or the Brighton Adverse Drug 
Reaction Risk Model (BADRI) for the oldest old [126], or more specifically 




A second step is the identification of any drug related problems follow-
ing the medication choice, so that the risk for potentially inappropriate 
medications is minimised [124]. This can either be done in a medication 
review (multidisciplinary, pharmacist-led, nurse-led, or physician-led), 
through educational interventions, using tools, or using computer-
ised decision support tools. The PCNE (Pharmaceutical Care Network 
in Europe) defines a medication review as ‘the evaluation of all the pa-
tient‘s medicines with the aim of optimising medicines use and improv-
ing health outcomes. This entails detecting drug-related problems and 
recommending interventions’ [128]. The evidence for medication reviews 
is not convincing in terms of decreasing the number of medications or in 
clinically relevant endpoints [129]. These interventions are complex, and 
more research was deemed needed to test the effectiveness and feasibil-
ity [129].
Optimizing the pharmacotherapy should encompass all domains of 
health care, from a better communication between general practition-
ers and nurses in primary care, to structured medication reviews in the 
hospital setting. Within the hospital setting, several steps are possible to 
appraise the medication use and several tools are available that suggest 
improvements to reduce the clinical impact of DRPs. 
The starting point in the prevention of ADRs is the consideration of 
the medical complexity of the patient before prescribing medications 
[124]. One option is the integrated medication management, where an 
unobstructed information flow is possible between all health care pro-
fessionals, both inside or outside the hospital setting. Another approach 
is the Comprehensive Geriatric Assessment (CGA) [130]. This multi-
disciplinary consult involves nurses and other allied health personnel. 
During a CGA, all problems regarding the functioning of older adults are 
explored, including care dependency and the potential need for support. 
The aim is to achieve an individualised and integral care plan, that does 
not limit to pharmacological care. For pharmacotherapeutic adapta-
tions, the quality of life, the life expectancy and patient preferences are 
taken into account. A CGA may therefore result in an improved quality 
of prescribing, and a reduction of overall drug-related illnesses [131]. In 
the CRIME study (CRIteria to assess appropriate Medication use among 
Elderly complex patients), the effect of CGA showed a 35% risk reduction 
for serious ADRs, and a significant reduction of potentially inappropriate 
medications [132]. 
It must be remembered that none of the approaches above have a 
clearly shown benefit on the patient’s health if applied in isolation [124]. 
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Appraising the appropriateness of geriatric pharmacotherapy must be 
embedded within a global assessment of the patient’s clinical and func-
tional characteristics. The combined knowledge and skills of different ac-
tors in the medication management process can prove beneficial for the 
patient [124]. 
Defining the appropriateness of prescribing
From a pharmacological perspective, a medication is appropriate if 
the potential benefit outweighs the potential risk of a medication [133, 
134]. Within the pharmacological perspective, several methods have 
been developed to assess the appropriateness of medications, either by 
assessing the appropriateness of the number of medications (e.g. polyp-
harmacy), by using tools for the assessment of potentially inappropriate 
medications (e.g. implicit and explicit screening methods).
Polypharmacy
Definition
One of the key concepts in assessing the medication use of older adults 
is polypharmacy. The term polypharmacy has different definitions. Most 
commonly, the definition of ‘the use of five or more medications’ [135] is 
used, although ‘four or more’, ‘nine or more’[136], or ‘more medications 
than clinically indicated’ [137] have been used as well. Following this set 
of definitions, polypharmacy has a negative connotation, indicating an 
inappropriate medication use. The concept of ‘polypharmacy’ can refer to 
the overuse of excessive, unnecessary, multiple or unindicated medica-
tions [138]. It is a multifactorial problem, present in a variety of settings 
and conditions [139–142]. 
In this thesis, we use
‘the intake of 5 or more chronic medications with systemic effect’ 
as the definition of polypharmacy
Context of polypharmacy
Comparing studies focusing on polypharmacy is difficult. Apart from 
the different definitions available, there are also conflicting definitions 
for the medications included: some studies count the number of tablets 
ingested, some include topical medications, while others include only 
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medications with systemic effects.
Prevalences of polypharmacy in older adults ranged between 26 
– 58%, with the upper limit of this range noted in older adults admit-
ted to a hospital [143–150]. Large Swedish registry based studies (n = 
1.358.486) in persons aged 75 years or older found that 52 – 57% of the 
population had polypharmacy [143, 151]. In a five year follow-up study 
of older Finnish people, the prevalence of polypharmacy in the oldest 
old was 66% [72]. The prevalence of polypharmacy remained stable after 
five years, only significant changes in the prevalence of excessive poly-
pharmacy (ten or more medications) were found [72]. The prevalence 
of polypharmacy (five or more medications) in the Belgian population 
increases steadily with higher age. According to the Belgian Health Sur-
vey, approximately a third of people aged 75 years or older had polyphar-
macy [25]. The PHEBE (Prescribing in homes for the elderly in Belgium) 
study demonstrated that the medication use in nursing homes may be 
even higher, where a mean of 7.3 chronic medications was noted, with 
a predominant high prevalence of psychotropic medication users (79%) 
[152, 153]. An overview of recent studies reporting polypharmacy in old-
er adults is given in table 1.
Polypharmacy is a major contributing factor for encountering an 
adverse drug event [154–157]. A population based study of outpatients 
showed an 88% increased risk for encountering an ADR for those with 
a higher medication use compared to those with a low medication use 
[158, 159]. With more medications prescribed, the risk of encountering 
potential medication interactions will rise as well. Up to 40% of older 
adults have potential medication interactions [160, 161], possibly leading 
to more medication-related hospitalisation [162]. The number of medi-
cations was determined as the main contributing factor for ADR related 
hospitalisations [163]. In a retrospective cohort study, polypharmacy was 
associated with a four times increased risk for unplanned hospitalisations 
[164], leading to higher health care costs. Multiple medications can lead 
to increased health expenditure [165, 166]. 
Polypharmacy is also associated with a low functional capability. A 
prospective cohort study demonstrated associations between polyphar-
macy and a higher care dependency for instrumental activities of daily 
living (e.g. housekeeping, transportation, …)[167]. Also a poor cognitive 
status is associated with polypharmacy [168]. In a prospective cohort of 
community-dwelling older adults, polypharmacy was also associated 




Another strategy is the identification of problematic prescribing, 
meaning prescribing that could lead to higher risks of adverse events. 
The act of prescribing medications can thus be considered as a process, 
and describing the qualitative characteristics of prescribing is the evalu-
ation of a process [170]. Also, the distinction should be made between 
the problematic choice of a pharmacotherapy and the problematic ex-
ecution of chosen pharmacotherapy [170]. In the former definition, this 
concept is related to the potential overuse, underuse or misuse of medi-
cations, while the latter is related to (non)adherence, and the monitoring 
or documenting of pharmacotherapy.

















65 – 95 46 (≥ 5)
Iwata 
(2006)
Japan 403 Rx In hospital ≥ 85 27 (≥ 6)
Jyrkka 
(2006)
Finland 601 Rx + IN Population based 80 – 84 61 (≥ 5)
Johnell & Klarin 
(2007)
Sweden 732 228 Rx Registry based ≥ 85 73 (≥ 5)
Quato 
(2008)
USA 878 Rx Population based 75 – 85 37 (≥ 5)
Schuler 
(2008)
Austria 543 Rx In hospital ≥ 75 58 (≥ 5)
Moen 
(2009)
Sweden 348 Rx + OTC
Community-
dwelling
65 – 75 26 (≥ 5)
Kim 
(2011)
Korea 319 185 Claims database ≥ 65 86 (≥ 6)
Herr 
(2014)
France 2 350 RX + OTC ≥ 70 67 (≥ 5)
Moriarty 
(2015)
Ireland 133 884 Rx + OTC Population based ≥ 65 60 (≥ 5)
Charlesworth 
(2015)
USA 13 869 Rx
Community-
dwelling
≥ 65 39 (≥ 5)
Wang 
(2015)
China 1 562 Rx + IN
Geriatric 
outpatient clinic
≥ 80 70 (≥ 6)
Rx: Only medications on prescription. IN: If needed medications. OTC: over the counter medications. 
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The choice of medications that can lead to actual or potential adverse 
effects has been of interest since a couple of years. Several methods exist 
that specifically help clinicians identify potentially inappropriate medi-
cations (PIMs), defined as medications with no clear evidence-based in-
dication, that carry a high risk of adverse side effects or medications that 
are not cost-effective [171]. 
The concepts regarding a problematic choice (underuse, misuse, and 
overuse) are not clearly defined. Misuse and overuse are related to a sub-
optimal choice when prescribing medications, while underuse is related 
to a suboptimal choice for not prescribing a medication. 
Underuse
Underuse of medications is an aspect that only recently has been put 
more in the highlight, and may be understated [172]. This aspect of po-
tentially inappropriate prescribing resolves around the omission of medi-
cations that are indicated, unless there is a contraindication [134]. Later, 
underuse was also defined to medications that have a proven efficacy in 
patients with a significant life expectancy [171, 173]. Underuse can thus 
pertain to medications that are not prescribed in case of a present indica-
tion, or to non-prescribed prophylactic medication therapies. Prescribing 
omissions or underuse of medications is seldom the focus of interest in 
studies, possibly because of the lack of any appropriate tools to assess 
underuse. 
In this thesis, we use 
‘the absence of prescriptions for medications that are clearly indicated and likely 
to benefit the patient’ as the definition of underuse
Misuse
Misuse generally refers to medications that are prescribed that may 
potentially lead to Drug Related Problems. It encompasses the use of 
PIMs, inappropriate dosages, or inappropriate durations [134]. Regard-
ing the choice, it is considered to be misuse of medications when more 
effective medications or medications with lower risks are available. Next, 
the dosage (too high, too low) or the dosage scheme (too frequent, not 
frequent enough) can be suboptimal as well. Finally, it also includes an 
imbalanced benefit/risk ratio, due to potential interactions (e.g. drug-
food, drug-drug, or drug-disease), or known allergies [174]. 
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In this thesis, we use
‘the suboptimal choice of an active substance, it’s dosage, or its duration’ as the 
definition of misuse.
Overuse
There is no standard definition for the overuse of medication. Some 
sources pertain to overuse when treatments are given without a medical 
justification. This approach can be regarded as similar to one of the defini-
tions of polypharmacy (more medications than indicated). According to 
the MeSH term, overuse indicates the use of a medication in an amount 
more than as prescribed, pertaining more to the overconsumption in dos-
ages or duration (source: https://www.ncbi.nlm.nih.gov/mesh/2009720). 
More recently, the definition of overuse was further refined:
A medication therapy that is continued, despite lacking indication.
The use of a combination therapy, where monotherapy might be suf-
ficient.
Medications in a prescribing cascade, medications that are initiated to 
counter the side effects of other medications
The definitions for misuse and overuse are sometimes overlapping. 
The first aspect refers to an incorrect duration, and the second aspect to 
a suboptimal choice of medications. For the remainder of this thesis, we 
made the choice to use misuse to refer to a suboptimal choice of active 
substance, duration or dosage. 
1.4 Formalisation of the appraisal of appropriateness of 
prescribing
Recently, several lists, criteria or tools have been developed to im-
prove patient safety. All these efforts estimate a patient’s exposure to 
potentially inappropriate medications, in order to prevent any medica-
tion errors by potentially inappropriate prescribing. These lists, criteria or 





Their intended purpose can be either the manual application by ex-
perts and clinicians in the light of a preparation for a medication chart 
review or for research purposes. The choice of the most appropriate med-
ication for an individual patient in order to achieve the desired therapeu-
tic outcomes is a major challenge in daily practice. 
The appropriateness or inappropriateness of medications can be as-
sessed using implicit (judgement based) and explicit (algorithms based 
on theory) tools. Explicit tools are criterion based, developed from pub-
lished reviews, expert opinion, but more often based on consensus [174]. 
Both implicit and explicit criteria can cover different aspects of poten-
tially inappropriate prescribing, including the choice of a medication, the 
dosage, the duration, medication duplication, drug-disease interaction, 
drug-drug interaction, drug-food interaction, overprescribing, underpre-
scribing, cost-effectiveness, non-adherence and the proposal of alterna-
tive therapies. Ideally, it should cover all aspects, it should be evidence-
based, and it should show significant correlation with clinical outcomes, 
and finally, it should be applicable beyond research conditions, and thus 
in clinical practice [174].
Most tools cover the different aspects to some extent. There are nu-
merous tools available, with varying levels of comprehensiveness and 
complexity [174]. Most are regarded as a useful aid for clinicians to opti-
mise the prescribing of medications, yet no ideal tool is available that 
covers all aspects [174].
Published lists for the appraisal of appropriateness
Implicit criteria 
Implicit tools are judgement based, and pertain to the clinical review 
of a medication chart in individual patients. The most used tool for im-
plicitly assessing the appropriateness of medications is the Medication 
Appropriateness Index, MAI [175]. 
The MAI focusses on specific elements of prescribing, covering indi-
cation, effectiveness, dose, duration, applicability, potential interactions, 
duplication, and costs. The MAI has undergone extensive validation and 
can aid medication reviewers to adjust the medication chart. It is how-
ever time consuming and requires extensive patient knowledge and ex-
perience [176]. The MAI has not been tested in an electronic version, pos-
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sibly since some items require clinical judgement; only some items (e.g. 
dosage, duration, drug-drug interactions, duplication) can be applied in 
an electronic application. 
Explicit criteria
Explicit criteria were introduced as important, simple, yet effective 
strategies in reducing potentially medication related problems in older 
adults [133]. Explicit criteria are more generally applicable in a stand-
ardised way, are quick to apply, and more suited for research purposes. 
Explicit criteria were generated through expert opinion and expert con-
sensus, but are now more and more based on evidence [177]. Explicit 
criteria have shown potential as electronic applications [178]. The main 
limitations are the lack of transparency in the development process of 
the expert panels, and poor interrater reliability [179]. Another main con-
sideration when applying explicit criteria to screen for potentially inap-
propriate medications is that patient preferences and the whole clinical 
history of a patient are not taken into account. 
Inventory of lists of explicit criteria available
Some lists pertain to medication-only criteria (EU(7)-PIM, ZHAN, La-
roche, PRISCUS) [180–183], while others incorporate clinical data (e.g. 
Beers, ACOVE, BEDNURS, McLeod, …) [97, 184–186]. Some pertain to the 
misuse of medications only (e.g. STOPP), while others look at potential 
medication omissions or underuse (e.g. ACOVE, START)[171, 187, 188]. 
Beers criteria
The Beers criteria are a set of explicit criteria, developed in 1991, with 
the aim to assess the quality of prescribing in older adults. Since then, it 
has been updated several times, with the latest update in 2015. It lists 
medications or medication classes that are to be avoided, to be avoided 
in case of specific clinical problems, and medications to be used with cau-
tion. In the 2015 version, more specific focus was given to a universal ap-
plicability of the criteria, and the quality of evidence was added to the 
criteria.
The Beers criteria are among the oldest criteria available. The main 
limitation to the Beers criteria is their limited transferability to other med-
ication markets, since it was developed in the United States. Validation 
of the criteria was done in an American expert panel. There is some evi-
dence that Beers’ criteria (1991, 1993 and 2003 criteria) of inappropriate 
medication use is associated with adverse healthcare impact in commu-
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nity-dwelling older adults, although the predictive validity is still ques-
tioned [189].
STOPP/START criteria
The STOPP/START criteria were developed by geriatricians in the re-
public of Ireland, as a European counterpart of the American Beers list. 
These criteria are intended for patients older than 65 years, and address 
both misuse (STOPP; Screening Tool of Older Person’s Prescriptions) and 
underuse (START; Screening Tool to Alert doctors to the Right Treatment)
[171]. They were originally based on expert opinion. In 2014, a revised 
version has been released, where references are added to the explicit 
criteria (but not including a strength of recommendation) [187]. The 
STOPP/START criteria have been validated and show good interrater reli-
ability [190–192]. The STOPP/START criteria have shown a higher sensi-
tivity at detecting potentially inappropriate prescribing in different set-
tings [193]. Underuse and misuse has been linked with an increased risk 
of ADRs [194] and a subsequent risk for hospitalisation [195]. However, 
the specificity of the STOPP/START criteria in detecting potentially inap-
propriate medications that are related to adverse outcomes is yet to be 
established. Another limitation to the STOPP/START criteria is the num-
ber of criteria involved. The length of the lists (81 for STOPP-2, and 34 
for START-2) make the manual application time-consuming and requires 
a high level of familiarity [178]. In most of the studies, clinical pharma-
cists, physicians or researchers apply explicit criteria in a medication chart 
review [196]. This is also reflected in research studies, where generally a 
subset of the criteria is taken [197], possibly due to the (un)availability of 
medications or clinical data. 
Many studies have used the STOPP/START criteria to assess potential-
ly inappropriate medication use in older adults. In community-dwelling 
older adults, misuse ranged between 20 – 79%, and underuse ranged 
between 23 – 74% [198, 199], with the upper limit observed in patients 
entering a nursing home. Most commonly involved STOPP-1 criteria were 
the long-term prescribing of proton-pump-inhibitors, benzodiazepines 
or neuroleptics [199–201]. Most commonly involved START-1 criteria in-
volved the omission of calcium/vitamin D in osteoporosis patients, and 
statin therapy in cardiovascular and diabetes patients [201–203]. 
Studies generally use a sample of community-dwelling adults, aged 
65 and older. The general conclusion is that there is an increasing preva-
lence of PIMs with more medications [198], a higher level of multimor-
bidity [198, 204] and a higher age [202, 205, 206]. Studies focussing on 
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community-dwelling oldest old are in contrast scarce, and even fewer 
studies look at long-term outcomes [197]. 
EU(7)-PIM
The EU(7)-PIM list was the first attempt to unify other lists of explicit 
criteria on potentially inappropriate medications. The general basis of 
the EU(7)-PIM list derives from the earlier developed German PRISCUS list 
[183], but has now integrated criteria from the Beers list (United States), 
McLeods (Canada), and Laroche list (France) [133, 182, 186].
The aim was to make a medication-only repository, available for dif-
ferent countries in Europe (the original seven countries included Estonia, 
the Netherlands, Finland, France, Spain, Sweden and Germany), which 
can be used for analyses and comparative studies on prescribing pat-
terns throughout Europe, or as a guide in clinical practice. The EU(7)-PIM 
lists 282 active substances (including seven medication classes), of which 
some are accompanied with dosage information. An additional strength 
of this method, is the proposed dosage adjustment for each medication, 
as well as the option of an alternative medication or therapy [180]. 
Formalisation of assessment of pharmacodynamic effects: 
the case of anticholinergics
Anticholinergics are, because of an increased risk for potentially ad-
verse effects, being introduced into lists of potentially inappropriate 
medications for older adults. Sometimes, they are introduced as medi-
cation-only PIMs (Beers, version 2015), and sometimes in combination 
of clinical problems (e.g. glaucoma, urine retention, … in the STOPP-2 
criteria) [187, 207]. In some, a (non-exhaustive) list of active substances 
is given (Beers, FORTA), and in others, they are referred to as a medica-
tion group (without specific enumeration of included medications, e.g. 
STOPP) [180, 208]. However, the clinical applicability is low since there 
isn’t much agreement, and explicit criteria are often not explicit enough. 
See table 2 for an overview of anticholinergics mentioned in PIM lists.
Findings of studies suggest the need for methods to identify an-
ticholinergics. Sometimes the anticholinergic activity of commonly used 
medications is not properly known by prescribers, leading to a risk for 
concomitantly prescribing anticholinergics [58]. Estimates suggest that 
8 to 37% of the older population consume at least one anticholinergic 
[209–211]. Despite the known side effects, anticholinergics are widely 
prescribed in older adults. An Italian study found that 14 out of the 25 
most prevalently prescribed medications had anticholinergic properties 
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[212]. The high prevalence of anticholinergic use can be explained that 
anticholinergics can be both the reason and the result of a prescribing 
cascade. Cholinesterase inhibitors (e.g. donepezil, rivastigmine) are pre-
scribed more in older adults with dementia, but can cause urge urinary 
incontinence [213], which can be treated in return with another anticho-
linergic (e.g. oxybutynin, tolterodine) [214]. 
Table 1.2. Overview of anticholinergics mentioned in PIM-tools.
STOPP-2
7 explicit criteria 5 explicit criteria listing anticholinergics in combination with clinical 
problems (including prostatism, urinary retention, delirium, demen-
tia, constipation, glaucoma).
1 explicit criterion listing anticholinergics in a prescribing cascade 
(e.g. extrapyramidal side-effects of neuroleptic medications)
1 explicit criterion listing the concomitant use of anticholinergics.
2 explicit criteria with specific enumeration of active substances
Beers (2015)
Mentioned in several tables: 
medications to avoid, medica-
tions to avoid in presence of 
a clinical problem, and as a 
separate table of medications 
with strong anticholinergic 
properties
1 table depicting medications with strong anticholinergic properties. 
Specific enumeration of medication classes and active substances: 
Antihistamines (n=13 active substances), Antiparkinsonian agents 
(n=2), Skeletal muscle relaxants (n=2), Antidepressants (10), Antipsy-
chotics (n=7), Antiarrhythmic (n=1), Antimuscarinics (n=7), Antispas-
modics (n=9), Antiemetic (n=2)
FORTA
3 medications with anticholiner-
gic properties mentioned.
Doxepin (2 times), olanzapine, biperidene
EU(7)-PIM
74 medications with anticholin-
ergic properties mentioned. 7 
mentioned in the abbreviated 
version (most common PIMs)
Metoclopramide, oxybutynin, levomepromazine, clozapine, ami-
triptyline, paroxetine, promethazine, hydroxyzine mentioned in the 
most common PIMs
Several methods have been developed to quantify the exposure to 
medications with anticholinergic properties [41, 210, 215–223]. The gold-
en standard to quantify the exposure remains the time consuming and 
invasive in vivo measurement of anticholinergic activity in blood [224, 
225]. Other methods resolve to a theoretical approximation based on 
the intrinsic potency or by the combination of potency with the dosage 
in which the medication was prescribed. The anticholinergic potency of 
medications indicates the activity or affinity at the receptor level. 
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In this thesis, we use
‘the extent to which the patient is exposed to anticholinergics, by an assessment 
of the number of anticholinergics (and their potency and dosage) on the medica-
tion list’ as the definition for the anticholinergic exposure
Exposure to several different anticholinergics may cause culminating 
side-effects [226], perceivable by the patient and resulting in constant 
bother, and impact on quality of life. Direct questioning of the patient can 
be used as measure for anticholinergic burden. 
In this thesis, we use
‘the burden perceived by patients of the (side)-effects of anticholinergics’
as the definition for the anticholinergic burden
Critical review of explicit criteria
High quality research is needed for an optimal understanding of the 
validity of explicit PIM criteria. To date, the clinical relevance and poten-
tial of PIM lists has not been fully studied.
The prevalence of potentially inappropriate prescribing has been re-
ported to rise with increasing age, and level of multimorbidity. Accord-
ing to a recent systematic review, the average prevalence of potentially 
inappropriate prescribing in community-dwelling adults across Europe is 
22.6% (with studies ranging between 0 and 98%) [154]. The prevalence 
of inappropriate prescribing in nursing homes can be even higher, with 
up to 50% of nursing home residents having at least one potentially in-
appropriate medication (PIM) [227]. Predisposing factors for potentially 
inappropriate prescribing is a higher medication use, e.g. polypharmacy, 
having a depression and being in poor physical or functional health [154].
A systematic review of 12 observational studies and 1 randomised 
controlled trial examined the evidence of impact of the STOPP/START-1 
criteria on clinical outcomes [193]. Patients with potentially inappropri-
ate prescribing (defined by the STOPP-1 criteria) had an 85% increased 
risk for adverse drug events, but evidence was considered limited. With 
the addition of three RCTs in a meta-analysis [228], the results remained 
inconclusive, as the researchers were unable to define the relation of the 
STOPP/START-1 criteria with outcomes mortality and quality of life, pos-
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sibly due to bias in the selected randomised controlled trials [229–232], 
and the heterogeneity of the four RCTs [197]. 
Little prospective longitudinal research is available. Available longi-
tudinal studies mostly use un-validated explicit criteria from diverse PIM-
lists, most commonly derived from the Beers list, and found weak asso-
ciations with adverse health care impact [189, 233, 234]. In a prospective 
cohort study in Ireland, the potentially inappropriate medication use (de-
fined by the STOPP/START-1 criteria) in older adults was explored. One of 
the main findings was that misuse and underuse were independently as-
sociated with a higher health care usage (more GP or emergency depart-
ment visits). Underuse was also associated with functional decline, and a 
lower quality of life [235]. However, studies could not establish long-term 
associations with outcomes yet. 
Another option is the automatic application in automated health sys-
tems. These computerised decision support systems aim to assist clini-
cians in selecting the correct medication when prescribing, in order to re-
duce medication errors or increase the appropriateness [124]. This aspect 
as well has potential limitations, since most decision support systems use 
different algorithms to identify potentially inappropriate medication use. 
Also, in order to have maximal benefit, the integration of clinical charac-
teristics with prescribing information should be achieved (e.g. guidance 
in selecting the dosage based on laboratory testing) [124]. Only recently, 
studies have been published that looked into the benefit of computerised 
prescribing systems, and some showed promising results [236]. However, 
focus until now was focused at certain medications or medication classes 
(in casu, psychotropic medications). 
Explicit criteria are still in development. For a an optimal implemen-
tation of explicit criteria, these should be made as specific, explicit and 
universally adaptable as possible [237].
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1.5 Choices made in this thesis
For the course of this manuscript, we made the choice for a specific 
focus on the domain of appraising the medication use during the pre-
scribing phase in the drug choice process. In order to appraise the medi-
cation use, we relied on explicit criteria for both misuse and underuse 
of medications; namely the EU(7)-PIM list and STOPP/START-2 criteria. 
The STOPP/START-2 criteria were selected for further exploration cho-
sen because of their focus on misuse and underuse, their clinical focus, 
and because they are more adapted to the European medication market 
in comparison with the American based Beers list. The EU(7)-PIM in con-
trast is relatively new, and has a sole focus on explicit criteria for misuse, 
without the need for clinical data. It is based on the German PRISCUS list, 
which was based in return on the Beers list [180]. Of these two PIM lists, 
we explored explicit criteria that are suitable for the appraisal of data in 
automated analysis, for future benchmarking (to facilitate internal 
medical audit) and for individual per-patient feedback purposes.
We decided also to further develop the assessment of pharmaco-
dynamics interactions among anticholinergics. Although several lists 
of explicit criteria contain criteria on anticholinergics, their operationali-
sation is poorly developed, and do not provide the basic elements for a 
proper application in automated analyses. 
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2.1 Rationale for engaging this thesis
T
he main goal in this thesis is to appraise the appropriate-
ness of prescribing of medications in the oldest popu-
lation. We focused therefore on polypharmacy in older 
adults and on potentially inappropriate medication use, 
in terms of underuse and misuse. We limited ourselves to 
explicit criteria from European lists for appraising potentially inappropri-
ate medications with a recent update.
The clinical relevance and validity of lists of explicit criteria for assess-
ing potentially inappropriate medication use is still debated. Currently, 
not a single list has been described as the golden standard to use. In this 
thesis, we focused on two European lists of explicit criteria, namely the 
STOPP/START-2 (focusing on misuse and underuse) and the EU(7)-PIM list 
(focusing on misuse). We used explicit criteria from these lists that were 
suitable for automatic application in order to describe the prevalence of 
polypharmacy, underuse, and misuse, and to explore the possible rela-
tionship with outcomes (mortality, hospitalisation, and institutionalisa-
tion).
The automatic electronic analysis of the medication use is hardly stud-
ied. Our secondary goal is to explore its validity, by exploring whether the 
possible relationship with outcomes is maintained in the light of present 
limitations (use of secondary data, semantic interoperability, use of a sub-
set of explicit criteria of START/STOPP-2, …). 
Explicit criteria are not always explicit. Anticholinergics are widely 
prescribed in older adults, yet are known to cause unwanted and poten-
tially severe anticholinergic symptoms. Explicit criteria on anticholiner-
gics do not enumerate on the specific medications or active substances 
involved, limiting the universal application of explicit criteria regarding 
anticholinergics. In a tertiary goal, we explore possible adjustments to 
the identification of anticholinergics and possible adjustments to explicit 
criteria in PIM lists.
The population of interest here are the oldest old (aged 80+). Only 
recently, longitudinal studies are undertaken to gain more insights in the 
clinical, and functional profile of this under-represented but growing age 
segment. In pharmacological research, the community-dwelling oldest 
old are seldom the focus of interest. Most research involves either nursing 
home residents, or hospitalised patients. 
In this thesis, our main interest is on the oldest old, still living at home 
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and participating in the community. We use data from the Belfrail study, 
an observational longitudinal cohort study of community-dwelling older 
adults (aged 80, and older).
2.2 Source of the data used in this thesis
To reach our goals, we used data from the Belfrail study, an observa-
tional longitudinal cohort study. The Belfrail cohort study was designed 
to acquire a better understanding of the epidemiology and pathophysi-
ology of chronic disease in the community-dwelling oldest old, and in 
the relationship between chronic disease, frailty and disability in a multi-
system approach [238]. General practitioners (GPs) were responsible for 
the selection of patients (November 2008 – September 2009). At baseline, 
personal, clinical, functional and medication data were collected. The GPs 
recorded the clinical status and the chronic medication use from their 
medication records. Clinical research assistants collected functional data 
using standardised tests (questionnaires and examinations). All patients 
were followed for five years, for which the GP was responsible to collect 
outcome data (date of death, date of first unplanned hospitalisation, date 
of moving into a nursing home). 
The original goals of the Belfrail study were not intended for the ap-
praisal of the medication use. The results of our thesis are based on the 
clinical problems in the Belfrail database (consisting of codified diagno-
ses, and multimorbidity measures, used for other research purposes) and 
on the codified medication data (codification in the ATC classification, 
done by our research group). The medications of patients were recorded 
in a data-entry programme, based on the Belgian medication market. All 
medications were translated into the Anatomical Therapeutic Chemical 
(ATC) classification (WHO ATC/DDD index, version 2013). 
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Table 2.1. Overview of data collected in the Belfrail study.
Personal data included age, date of birth, level of education, marital status, living status, 
receiving nursing care, alcohol consumption (during one week), place of living, ethnical 
status, and work history. 
Clinical data included active and past clinical problems. 
Functional data included care dependency (Katz Activities of Daily Living, ADL; 
Instrumental ADL, IADL), physical activity (LASA Physical Activity Questionnaire, LAPAQ; 
Barthel Index, and performance-based tests), cognitive impairment (Mini Mental State 
Examination, MMSE), depressive symptoms (Geriatric Depression Scale, GDS-15), the 
sense of coherence, and the level of frailty (Groningen Frailty Indicator, GFI). Additionally, 
the Clinical Research Assistants recorded biometry, grip strength, blood pressure, vision 
and hearing test, and did a risk estimation for falls (Tinetti test). 
Medication data were recorded by the GPs from their patient records. They recorded all 
current chronic medications that were prescribed using the brand or generic name, the 
dosage, and the frequency of administration. 
Follow-up data were collected using an extensive follow-up questionnaire for the GPs, 
and a new assessment of the functional profile (Barthel, ADL, MMSE, GDS-15, …). GPs 
had to report back on the health status, the date of death, the date of institutionalisation, 
and the date of a first unplanned hospitalisation.
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2.3 Research questions 
The specific research questions for this thesis were as followed:
1. What is the prevalence of polypharmacy in the community-dwelling old-
est old (aged 80 years, and over) in Belgium, and what patient-related 
factors attribute to a higher medication intake? 
More specifically: 
- How many and which medications do the oldest old community-
dwelling in Belgium take? 
- What is the distribution of therapeutic medication subgroups? 
- Are personal/clinical/functional characteristics of patients related to 
polypharmacy? 
2. Is there a relationship between polypharmacy and health related out-
comes (hospitalisation, institutionalisation, and mortality) in the commu-
nity-dwelling oldest old? 
More specifically:
- Is there a relationship between polypharmacy (the number of medi-
cations, the prevalence of polypharmacy, or the presence of specific 
medication groups) and outcomes (hospitalisation, institutionalisa-
tion, and mortality)?
- Is the relationship, apart from a higher level of multimorbidity, influ-
enced by personal/clinical/functional patient-related factors?
3. Which medications mentioned in international lists of explicit criteria of 
(in)appropriate prescribing are applicable to the Belgian therapeutic ar-
senal?
More specifically:
- Which medications singled out by the international lists are available 
in Belgium?
- Which medications have a meaningful prevalence of use in the oldest 
old? 
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4. What is the prevalence of use of potentially inappropriate medications 
(PIMs) in the community-dwelling oldest old, and is there a relationship 
between potentially inappropriate prescribing (misuse and underuse) 
and hospitalisation and mortality? 
More specifically:
- What is the prevalence of automated explicit criteria of PIMs for mis-
use (STOPP-2 or the EU(7)-PIM list), and PIMs for underuse (START-2)?
- With regard to the application of a limited set of explicit criteria gen-
erated in automated analysis, is there a relationship between PIMs for 
misuse and underuse and outcomes (hospitalisation and mortality)?
5. Can an automated tool be developed that quantifies the anticholinergic 
exposure in old age?
More specifically
- What are the anticholinergic medications in Belgium and the Nether-
lands? 
- How can the anticholinergic exposure be quantified, taking potency 
and the dosage spectrum of medications into account? 
6. What is the prevalence of the anticholinergic use in the community-
dwelling oldest old (aged 80 years, and older), and is there a relationship 
of the anticholinergic exposure with hospitalisation and mortality. 
More specifically
- How many and which anticholinergic medications do the oldest old 
community-dwelling in Belgium take? 
- Are personal/clinical/functional characteristics of patients related to 
anticholinergic exposure? 
- Is there a relationship between the anticholinergic intake (either po-
tency, dosage or total anticholinergic exposure) and outcomes (hos-
pitalisation, and mortality)?
In addition to these research questions, we will review the results of 
our studies for our secondary goal. In the discussion, we review whether 
the automatic electronic appraisal of potentially inappropriate medica-
tion use is feasible, informative, or valid as an adjunct-strategy to expert 
medication chart review, in the light of present limitations. 
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3.1 Abstract
Objectives: Polypharmacy is highly prevalent among older people (65+), 
but little is known on the medication use of the oldest old (80+). This 
study explores the medication use of the Belgian community-dwelling 
oldest old in relation to their demographic, clinical and functional char-
acteristics.
Methods: Baseline data was used from the BELFRAIL study; a prospective, 
observational population-based cohort of Belgian community-dwelling 
patients (80+). General practitioners recorded clinical problems and 
medications. Medications were coded by the Anatomic Therapeutic 
Chemical classification.
Results: Participants’ (n = 503) mean age was 84.4 years (range 80–102) and 
61.2% was female. Median chronic medication use was 5 (range 0–16). 
Polypharmacy (≥5 medications) was high (57.7%), with excessive poly-
pharmacy (≥10 medications) in 9.1%. Most commonly used medication 
group were antithrombotics, but also benzodiazepines and antidepres-
sants were frequently consumed. Demographics related to polypharma-
cy (univariate analysis) were female gender, low education and moderate 
alcohol use.
Age, care dependency and cognitive impairment showed no association 
with polypharmacy. In multivariate analysis, the predominant association 
with polypharmacy was found for multimorbidity (OR 1.78, 95% CI 1.5–
2.1), followed by depression (OR 3.7, 95% CI 4.4–9.7) and physical activity 
(OR 0.8, 95% CI 0.7–0.9).
Conclusions: Polypharmacy was high among Belgian community-dwelling 
oldest old (80+). Determinants of polypharmacy were interrelated, but 
dominated by multimorbidity. On top of the burden of multimorbidity, 
polypharmacy was independently associated with less physical activity, 





n highly developed countries, the number of oldest old (80+ 
years) is increasing. For Belgium, the oldest old represent 5.4% of 
the population in 2014 and their number is expected to rise to 
6.6% of the population in 2030 [10, 239]. Recent government ini-
tiatives expanded formal nursing and care services at home, en-
couraging older people to stay at home [27, 240]. In this shifted primary 
care focus, general practitioners (GPs) are considered as key players. 
Ageing is associated with the development of multiple chronic dis-
eases or multimorbidity, accumulating over time [241]. Multimorbidity 
can mandate the necessity for multiple medications [242]. It has a ma-
jor impact on the choice, dose and frequency of medication prescribing 
[243, 244]. Additionally, multimorbidity increases the risk of polypharma-
cy, and associated drug related problems in older patients. These drug 
related problems are associated with increased morbidity, mortality and 
a higher use of healthcare services [106, 245]. Therefore, medication pre-
scribing in the oldest old (80+) is regarded as a challenge in primary care 
[246]. 
Although the oldest subpopulation (80+) is growing, and is character-
ised by more multimorbidity, their medication use remain understudied. 
Several studies in younger (65+) population have linked polypharmacy 
separately with demographic characteristics [246], multimorbidity [247], 
clinical outcomes [248], and health status,[168]. Yet, these conclusions 
cannot be extended to the oldest old (80+) living in the community [72, 
168, 246, 249–251]. Bahat et al. (2013) postulate that the oldest old were 
survivors of comorbidities and polypharmacy effects [247], yet no study 
has linked the functional profile, multimorbidity and polypharmacy of 
the oldest old. Using general practitioners as primary source, this study 
aims to explore the medication use and particularly polypharmacy of the 
community-dwelling oldest old (80+) in relation to their demographic, 
clinical and functional characteristics.




This study uses baseline data from the Belfrail study, a prospective, 
observational population-based cohort study. The Belfrail cohort was se-
lected using GPs from three Belgian regions. For a full methodological 
description, see Vaes et al. 2010 [252]. For this study, all non-institution-
alised patients with medication records available were included, yielding 
the Belfrail-MED cohort (n=503). Of those, we explored the chronic medi-
cation use, in relation to demographic, clinical and functional character-
istics at baseline. 
Sampling
Selection of participants was done by 36 GPs, between November 
2008 and September 2009 (see Vaes et al., 2010). Eligible participants 
were at least 80 years old and able to visit their GP. Exclusion criteria were: 
known presence of severe dementia (Mini Mental State Examination 
<15/30), in need of acute medical care or palliative care.
Data collection
Data collection was done by GPs (structured data collection and 
clinical examination) and by clinical research assistants (standardised 
tests: questionnaires and examinations). GPs recorded demographic 
characteristics and listed all chronic medications as prescribed by the 
GP). Medication data included product name, active substance, and pre-
scribed daily dose.
First, a structured questionnaire was used. GPs assessed clinical prob-
lems and comorbidities collecting data of the clinical chart of patients. 
The clinical problems were encoded by two independent researchers 
[14]. Multimorbidity was measured using the Cumulative Illness Rating 
Scale (CIRS, see Box 2.1) [253]. The CIRS categorises these problems with-
in 14 body systems and counts the body systems affected by at least one 
chronic active disease [254], yielding a range from 0 to 14[14]. 
Functional data included care dependency, physical activity, cogni-
tive impairment, and depressive symptoms. Care dependency was meas-
ured using activities of daily living (ADL KATZ-scale)[255], physical ac-
tivity using the LASA Physical Activity Questionnaire (LAPAQ) [256, 257]. 
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Cognitive status was assessed with the Mini Mental State Examination 
(MMSE) [258], adjusted for age and education according to Crum [259]. 
Depressive symptoms were assessed using the Geriatric Depression 
Scale-15 (GDS-15) [260, 261]. For identification of risk factors to polyphar-
macy, we used the diagnosis of depression (as categorised by the treat-
ing GP) rather than the GDS-15. GPs have, due to the long term follow-up 
and more frequent visits, an understanding of the mental status of their 
patients. For a full overview on the ranges, direction and established cut-
offs of each test, see Table 3.1. 
Table 3.1. Standardised tests and scales used in the Belfrail-MED cohort.
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symptoms in primary 
care[260]
Functional and mood 
symptoms
[0-15]
0 (lowest probability of 
depressive symptoms)
≥ 5: moderate to high risk
*Range legend: [..] shows the range of the standardised tests and scales. 
 Italic writing indicates the meaning of lowest scores.
Normal writing indicates established and validated cut-offs.
Data handling
Medications were recorded using the brand or generic name in 
a data-entry program, based on the official register of medications on 
the market from the Belgian Centre for Pharmaceutical Information. The 
medication was translated into the Anatomical Therapeutic Chemical 
(ATC) classification (WHO ATC/DDD index, version 2013). Focus was on 
anatomical main groups (first ATC level) and therapeutic subgroups (sec-
ond ATC level). 
For the operationalisation of a high medication use, polypharmacy 
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was defined as a daily medication intake of ≥5 medications[242], and 
excessive polypharmacy as the daily medication intake of ≥ 10 [149]. 
Duplicate therapy was defined as concomitant use of ≥ 2 agents within 
therapeutic subgroups (second ATC level).
Statistical analysis
For all variables, there was less than 5% missing data [252]. Data were 
inserted by a data manager, and data verification and quality control was 
enhanced by trained researchers. Data analysis was performed with IBM 
Statistical Package of Social Sciences 21.0 (SPSS Inc., Chicago, IL, USA). 
T-tests and χ2 tests were used for comparing means and percentages 
respectively, and non-parametric tests in case of skewed data. Relation-
ships between skewed data were tested using Spearman rank correla-
tions. A significance level of p <0.05 was used. 
Multivariate logistic risk profiles for polypharmacy were analysed 
using the variables, which were significant in univariate analysis. In the 
endeavour to search for variables, other than clinical characteristics in 
relation to polypharmacy, two models were constructed. One with the 
most prevalent (≥10%) clinical problems and one model with the CIRS, as 
a summarising indicator with continuous properties for multimorbidity. 
 Physical activity (LAPAQ) scores were divided in deciles to create semi-
quantitative data (highest decile indicating the most physically active). 
For care dependency (KATZ ADL) four groups were created, based on the 
observed distribution. The models were corrected for age, plus all sig-
nificant demographic characteristics. The ‘Enter’ method was used. Each 
item was carefully weighed until a steady Nagelkerke R² was reached.
Ethical approval
The study protocol was approved by the Biomedical Ethics Commit-
tee of the Medical School of the Université Catholique de Louvain (UCL), 
Brussels (B40320084685, on 27/10/2008) and later by the Ethics commit-
tee of Ghent University Hospital (B670201421408, on 26/06/2014). All re-




Table 3.2 presents demographic, clinical, and functional characteris-
tics of the community dwelling oldest old (80+). Participants’ mean age 
was 84.4 years (range 80.0 – 101.8) and 61.2% was female. The majority 
had a lower level of education (≤8 years, 69.2%). Moderate alcohol use 
(≥1 daily unit) was present in 32.5% (including 9.3% of the population 
who drank more than 2 daily units). Median level of multimorbidity was 
4 (CIRS, range 1-9) with hypertension (70.4%), osteoarthritis (57.1%) and 
hyperlipidaemia (44.1%) as predominant clinical problems. 
Table 3.2. Demo graphics, clinical, and functional characteristics of the 
study population (n=503) in the Belfrail-MED cohort.
Demographic % (n=503)
Mean age in years ± SD* (range) 84.4 ± 3.6 (80 - 102)
Gender (% female) 61.2
Living alone 43.3
Nursing care at home 36.8
Moderate alcohol use (≥1 unit a day) 32.5
Low education (≤8 years) 69.2
Clinical1 %




Heart Failure (NYHA3 > 0) 38.4
Obesity (BMI > 30kg/m²) 27.9
Osteoporosis 20.9
Diabetes 18.9
Post myocardial infarction / post stroke 17.7
COPD / asthma 13.1
Depression 12.7
Chronic renal failure 11.1
Functional Median (IQR*)
Activities of daily living, ADL 6 (6 - 8)
Physical activity, LAPAQ 70 (30 – 102)
Mental status, MMSE 28 (26 – 29)
Depressive symptoms, GDS-15 2 (1 – 4)
1 Clinical problems with prevalence above 10% are listed.
2 Multimorbidity was defined by the CIRS
3 New York Heart Association (NYHA) functional classification of heart failure
* SD: standard deviation, IQR: Inter quartile range
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With regard to activities of daily living, the median ADL was 6 (IQR 
6-8), with 9.1% identified as care dependent (ADL>13). The majority was 
physically active. The median LAPAQ was 70, equivalent of daily walking 
two hours (IQR 30 – 120). In the lowest decile (most physically inactive) 
LAPAQ scores did not exceed 3, or equivalently no more than 45 minutes 
of physical activity in the past two weeks. Cognitive impairment was pre-
sent in 14.7% (median MMSE 28, IQR 26-29). 
General medication use
A total of 2730 chronic medications were recorded, with a mean of 5.4 
medications (range 0-16) per patient. Less than 1% used no medication. 
Polypharmacy (≥5 medications) was present in 57.7 %, and excessive 
polypharmacy (≥10 medications) in 9.1 %. Just 0.8% of the population 
had no chronic medications. 
Cardiovascular medication was most commonly used (86.3%), then 
haematological medication (56.1%) and nervous system medication 
(54.5%, see Table 3.3). At therapeutic subgroup level, antithrombotic 
medication was most prescribed (54.5%, see Figure 3.1), predominantly 
Table 3.3. Chronic medication use and use of anatomical main groups 
(1st ATC level).
Chronic medication use %
Mean medication use (range) 5.4 (0-16)
Polypharmacy (≥ 5 medications) 57.7
Excessive polypharmacy (≥ 10 medications) 9.1
ATC anatomical main groups %
C Cardiovascular 86.3
B Blood and blood forming 56.1
N Nervous system 54.5
A Alimentary tract and metabolism 50.1
M Musculo-skeletal system 23.5
R Respiratory system 15.9
H Systemic hormonal preparations 11.7
G Genito-urinary system and sex hormones 10.3
L Antineoplastic and immunomodulating agents 3.6






acetylsalicylic acid (34.6%), and vitamin K antagonists (10.3%). Use of 
benzodiazepines (35.6%) and antidepressant (16.1%) was high, with a 
concomitant use of 12.3% and 12.2% respectively. Chronic antipsychotic, 
anti-dementia medication and laxative use was low (less than 5%).
 Figure 3.1. Therapeutic subgroup medication (2nd ATC level), commonly used in the oldest old.
Characteristics related to polypharmacy in univariate analysis
Demographic factors associated with polypharmacy were female 
gender (OR 1.6, 95% CI 1.1 – 2.3), and low level of education (≤8 years, OR 
1.5, 95% CI 1.0 – 2.2, see Table 3.4). Age was not linearly associated with 
polypharmacy. The mean medication use per 5 years age category was 
5.4 (80-84 years), 5.6 (85-89), 5.0 (90-94) and 4.5 (95+). Clinical problems 
were, with exception of obesity, all positively associated with polyphar-
macy. 
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Table 3.4. Univariate analysis of demographic, clinical and functional characteristics factors 
of the Belfrail-MED cohort (n=503) in relation to polypharmacy.
Demographic characteristics
Polypharmacy use?







Mean age (in years) 84.5 84.3 0.536 1.02 (0.97 – 1.07)
Female gender 65.9 54.9 0.005 1.58 (1.10 – 2.28)
Moderate alcohol use 29.3 39.8 0.019 0.63 (0.43 – 0.93)
Low education (≤8 years) 73.7 64.9 0.035 1.52 (1.03 – 2.23)
Clinical 
Mean comorbidity, CIRS 4.3 3.0 <0.001 1.82 (1.56 – 2.10)
Hypertension 76.2 62.7 0.004 1.90 (1.29 – 2.80)
Osteoarthritis 62.7 52.2 0.019 1.54 (1.07 – 2.21)
Hyperlipidaemia 56.3 29.9 <0.001 3.02 (2.07 – 4.42)
Heart Failure 47.2 26.3 <0.001 2.51 (1.71 – 3.68)
Osteoporosis 29.7 14.1 <0.001 2.58 (1.61 – 4.12)
Obesity 29.8 26.9 0.481 1.15 (0.78 – 1.72)
Diabetes 26.0 9.5 <0.001 3.35 (1.97 – 5.69)
Post myocardial infarction, post stroke 24.7 10.3 <0.001 2.86 (1.67 – 4.89)
COPD/Asthma 24.7 10.3 <0.001 1.90 (1.09 – 3.31)
Depression 18.1 5.7 <0.001 3.26 (1.73 – 6.14)
Chronic renal failure 16.5 4.3 <0.001 4.36 (2.09 – 9.12)
Functional (mean score)
Care dependency1 8.2 8.1 0.901 1.00 (0.97 – 1.04)
Physical activity2 56.6 81.7 <0.001 0.85 (0.79 – 0.90)
Cognitive impairment3 26.7 26.8 0.699 0.99 (0.94 – 1.05)
1 According to the ADL
2 Physical activity was expressed using the LAPAQ. Test scores were divided into deciles for univariate analysis (most 
physically active meaning highest decile)
3 According to the adjusted MMSE  
In terms of functional characteristics, more physical activity had a 
negative association with polypharmacy (OR 0.9, 95% CI 0.8 – 0.9). Nei-
ther cognitive impairment (MMSE) nor care dependency (Katz ADL) 
showed an association. Moderate alcohol use (≥1 unit daily, OR 0.6, 95% 




Collinearity was checked (see Table 3.5). Respondents with higher 
multimorbidity were more care dependent, more inactive or showed 
more depressive symptoms. Patients with more depressive symptoms 
showed lower physical activity and more cognitive impairment.
Multivariate analysis for the risk of polypharmacy
Two multivariate logistic regression models were performed (see Ta-
ble 3.6), with correction for significant demographic characteristics (fe-
male gender, alcohol use and the level of education) and for age. The first 
model constructed around the level of multimorbidity (CIRS) explained 
30.3% (Nagelkerke R², p<.001) of the variance. Apart from this clinical 
characteristic, only physical activity was withheld, showing a negative as-
sociation. There was 77% more chance for having polypharmacy for eve-
ry higher level of multimorbidity (CIRS, OR 1.8, 95% CI 0.5 – 2.1), and every 
higher decile of physical activity was associated with a 17% decreased 
chance of having polypharmacy (LAPAQ, OR 0.8, 95% CI 0.8 – 0.9).
In a second model, individual comorbidities were analysed instead 
of multimorbidity. This model explained 39.6% (Nagelkerke R², p<.001). 
Physical activity had the strongest (negative) association (LAPAQ OR 0.8, 
95% CI 0.7 – 0.9) , followed by hyperlipidaemia (OR 3.4, 95% CI 2.0 – 5.9) 
and depression (OR 3.7, 95% CI 1.4 – 9.7). In this second model, every 
higher decile of physical activity was associated with a 22% decreased 
chance of having polypharmacy, and people with depression were 3.7 
times more likely to have polypharmacy.
Table 3.5. Correlation matrix taken between multimorbidity, functional characteristics, 
and the number of medications.
CIRS ADL LAPAQ GDS-15 MMSE
Multimorbidity CIRS –
Activities of daily life ADL .35** –
Physical activity LAPAQ -.23** -.25** –
Depressive symptoms GDS–15 .21** .26** -.38** –
Cognitive impairment MMSE -.11* -.18** .22** -.30** –
Number of medications taken .47** .23** -.29** .28** -.09
All variables are expressed as continuous variables. 
* Significant correlation at the p<0.05 level ** Significant correlation at the p<0.001 level
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3.5 Discussion
To the best of our knowledge, this is the first study exploring medi-
cation use in the community-dwelling oldest old, attempting to unravel 
the complex interactions between demographic, clinical, and functional 
characteristics of polypharmacy. Although the oldest subpopulation 
(80+) is growing, and is characterised by more multimorbidity, they re-
main underrepresented in scientific literature. This population is encour-
aged to stay at home for as long as possible, underlying the importance 
of GPs as key players in primary care for this population.
In this sample of community-dwelling older adults, where those with 
severe dementia were excluded, we found a relatively high proportion of 
healthy and active people aged 80 or more. Although the high propor-
tion of healthy or active older people, polypharmacy was present in the 
majority, yet still less than in long-term care residents[152, 153]. The med-
ication use did not increase in this age group with advancing age as well. 
Cardiovascular (particularly antithrombotic medication) and nervous 
system medication were most used, similar to findings by others[246]. 
Antidepressant, and benzodiazepines (+ derivates) use was high, with 
 Table 3.6. Multivariate logistic regression models for the association with 
polypharmacy (≥5 medications).
Multivariate odds ratio (95% C.I.)
Model 1
Multimorbidity (CIRS) 1 1.77 (1.49 – 2.10)
Physical activity (LAPAQ) 2 0.83 (0.76 – 0.90)
Nagelkerke R² 0.303
Model 2
Hyperlipidaemia 3.42 (1.98 – 5.91)
Osteoporosis 2.02 (1.03 – 3.93)
Diabetes 2.71 (1.23 – 5.98)
Post myocardial infarction, post stroke 3.09 (1.45 – 6.57)
COPD/Asthma 2.86 (1.32 – 6.19)
Depression 3.73 (1.43 – 9.73)
Chronic renal failure 3.44 (1.23 – 9.66)
Physical activity (LAPAQ) 2 0.78 (0.71 – 0.87)
Nagelkerke R² 0.396
* The models were corrected for age, gender, alcohol use, level of education. 
1 Multimorbidity was expressed using the CIRS.
2 Physical activity was expressed using the LAPAQ. Test scores were divided into deciles in 
multivariate analysis (most physically active meaning highest decile).
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substantial concomitant use within these groups.
This study aimed to search for all patient related risk factors. No linear 
association was found with age, as medication use decreased in late-life. 
This could be explained by a possible survivor-effect or possible depre-
scribing in the oldest old. The most dominant relationship was found for 
multimorbidity, indicated by the positive associations with most preva-
lent clinical problems. Apart from the obvious relationship between 
clinical characteristics, physical activity and depressive symptoms were 
the only other characteristics associated with polypharmacy. Depressive 
symptoms (GDS-15) and the diagnosis of depression were both positively 
associated with polypharmacy. Only physical activity (LAPAQ) was nega-
tively associated, either suggesting a protective effect for polypharmacy 
or it is a result of low medication use. 
Strengths and limitations
The oldest old are an underrepresented segment of the population 
in scientific literature. Using validated and standardised tests, a complete 
picture was obtained of the demographic, clinical, and functional status 
in the oldest old still living at home. GPs, whom older Belgians regularly 
visit, collected most data [67, 262]. To the best of our knowledge, this 
study is the first to give a complete overview of patient-related charac-
teristics (personal, clinical, and functional) in association with polyphar-
macy, as a dedicated sample of this particular age group, is given. The 
independent associations of physical activity, and depression with poly-
pharmacy are important for further research. 
Because of the cross-sectional design, causality could not be investi-
gated. This study was limited to an analysis of patient-related character-
istics associated with polypharmacy. Neither did we focus on prescriber 
characteristics, since a high medication use is also shaped by physician 
prescribing preferences (medication knowledge, experiences, peer influ-
ence of prescribers, monitoring methods, attitude to deprescribing, and 
patterns of reactions to complaints). In this study only chronic medica-
tion was registered, excluding over-the-counter drugs and pro re nata 
drugs (defined as medication that should be taken when circumstances 
arise, or as needed).
Another limitation is the absence of a distinction between appropri-
ate and inappropriate medication prescribing. Our aim was to gain in-
sights in patient related characteristics explaining a higher medication 
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use in older adults, expressed by polypharmacy. This term is often used 
to describe the prescription of too many medications, but does not dis-
tinguish whether each medication has been prescribed appropriately or 
not. The results of this study must be interpreted with caution, as it is 
possible that in a number of patients with polypharmacy, all medicines 
prescribed are appropriate.
Comparison with existing literature
The medication use of community-dwelling oldest old is high, but 
lower than the medication use of older adults in nursing homes. The 
mean chronic medication intake of the oldest old was 5.4, compared to 
a mean of 7.6 medications of a cross-sectional sample of residents of 76 
nursing homes in Belgium[152]. The prevalence of excessive polyphar-
macy (more than 10) in community-dwelling older adults was 9.1%, con-
siderably lower than nursing home residents, where one in three nurs-
ing is prescribed at least 10 medications. The medication intake differed 
as well. Nervous system drugs were less prescribed in the community-
dwelling cohort, particularly the use of antipsychotics was clearly lower 
(2.4% versus 32.9% in 2005, or 26.2% in 2011)[153, 263]. Laxatives were 
also much less prescribed (4.4% versus 49.8% of nursing home residents).
As found in other studies [72, 153], we found a late life decrease in 
medication use. Women were more likely to have polypharmacy than 
men, as was also indicated by others [149, 246, 264]. The observed associ-
ation between polypharmacy and multimorbidity is obvious and plausi-
ble, and consistent with existing literature [265, 266]. Depression was also 
identified as an independent risk factor of polypharmacy before[149].
Physical activity showed independently a possible protective influ-
ence on polypharmacy independently. The correlation between activity 
and health in older persons is well known [267, 268]. We also found a 
negative association with moderate alcohol use and polypharmacy. Oth-
ers found that older people attending social activities are more likely al-
cohol users [269]. This leads us to the assumption that moderate alcohol 
use among the oldest old is a proxy for a healthy, social, and active life. 
Sicker older people with more medications could participate less in social 




The quest for risk factors of polypharmacy is a complex endeavour. 
More longitudinal research is needed to delineate the consequences on 
mortality or other major life events (hospitalisation, institutionalisation) 
of polypharmacy and medication use over time, incorporating physician 
prescribing preferences. Follow-up research should include the level of 
(in)appropriateness of prescribing. Both primary care and long-term care 
settings are to be compared more intensively, in order to gain insights in 
changing medication patterns across settings. Interventional research is 
needed to establish whether active management of physical inactivity or 
adequate treatment of depression may reduce polypharmacy.
3.6 Conclusion
Polypharmacy was high among Belgian community-dwelling oldest 
old (80+). Determinants of polypharmacy were interrelated, but domi-
nated by multimorbidity. On top of the burden of multimorbidity, poly-
pharmacy was independently associated with less physical activity, and 
with more depressive symptoms. 
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4.1 Abstract
Background: High drug use and associated adverse outcomes are common 
in older adults. This study investigates association of medication use with 
mortality, hospitalisation, and institutionalisation in a cohort of commu-
nity-dwelling oldest old (aged 80 and over).
Methods: Baseline data included socio-demographic, clinical, and function-
al characteristics, and prescribed medications. Medications were coded 
by the Anatomic Therapeutic Chemical classification. Survival analysis 
was performed at 18 months after inclusion using Kaplan-Meier, and 
multivariate analysis with Cox regression to control for covariates.
Results: Patients’ (n=503) mean age was 84.4 years (range 80 – 102), and 
61.2% was female. The median medication use was 5 (0 – 16). The mor-
tality, hospitalisation, and institutionalisation rate were 8.9%, 31.0%, and 
6.4% respectively. The mortality and hospitalisation group had a higher 
level of multimorbidity and weaker functional profile. Adjusted multi-
variate models showed an 11% increased hospitalisation rate for every 
additional medication taken. No association was found between high 
medication use and mortality, nor with institutionalisation. A higher as-
sociation for mortality was observed among verapamil/diltiazem users, 
hospitalisation was higher among users of verapamil/diltiazem, loop 
diuretics and respiratory agents. Institutionalisation was higher among 
benzodiazepines users. 
Conclusion: In the community-dwelling oldest old (aged 80 and over), high 
medication use was clearly associated with hospitalisation, independent 
of multimorbidity. The association with mortality was clear in univariate, 
but not in multivariate analysis. No association with institutionalisation 
was found. The appropriateness of the high medication use should be 
further studied in relation to mortality, hospitalisation, and institutionali-





he oldest old (defined as individuals aged 80 and over) 
are characterised by a high level of multimorbidity, re-
sulting in possible high medication intake [241, 242]. In 
this age group, medications are prescribed even though 
the benefit-risk profile is not always fully understood 
[270, 271]. Age related changes in pharmacokinetics and –dynamics alter 
the sensitivity for the therapeutic effects and often increase the side ef-
fects.
High medication use and polypharmacy (defined as the daily intake 
of five medications or more [135]), increases the risk of inappropriate 
prescribing (including overuse, underuse and misuse), drug interactions, 
and adverse effects in older adults [272, 273]. This can again contribute to 
drug related problems (DRPs) [274, 275]. DRPs alter the expected bonus 
of medications on their health into a possible risk. Due to a worsening 
clinical or functional profile of those aged 80 and more, DRPs will become 
more prevalent, and potentially impede with the beneficial influence of 
medications on their health [276].
Both the beneficial and harmful effects of medication on outcomes 
have been explored in younger populations (aged 65 and over). In this 
age group, high medication use has been associated with hospitalisation, 
mortality, and increased health care costs [277, 278]. In Belgium, medica-
tion related hospital admissions account for 20.9% of all hospitalisations 
in adults aged 65 years and over[96]. 
However, studies exploring the medication use in relation to relevant 
outcomes in the oldest old (aged 80 and over) are limited, as well as 
studies exploring the specific role of medications and their effect on out-
comes. Studies either failed to disentangle the independent role of medi-
cations, due to the strong interrelationship with multimorbidity [279, 
280], or studies focussed primarily on the appropriateness of prescribing 
[281, 282]. Therefore, this study aims to explore the association of medi-
cation use (number of medications, polypharmacy, specific medication 
groups) in the community-dwelling oldest old (aged 80 and over) with 
mortality, hospitalisation, and institutionalisation during a follow-up pe-
riod of 18 months, and taking into account the role of multimorbidity, 
and demographic, clinical, and functional characteristics.
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4.3 Methods
This study uses data of the Belfrail-cohort [252], a prospective, obser-
vational population-based cohort study. In summary, eligible patients 
were adults aged 80 years and older, without known dementia, and not 
in acute or palliative care. Inclusion of patients was done by general prac-
titioners [252]. For this study, all community-dwelling patients with medi-
cation records available were selected, yielding the Belfrail-MED cohort 
(n=503). 
Baseline data 
General practitioners and clinical research assistants collected the 
data (structured questionnaire, clinical examination, and standardised 
tests). Baseline data collection consisted of socio-demographic, clinical, 
and functional data described in the baseline study of the Belfrail-MED 
cohort [283]. 
Socio-demographic data included age, gender, level of education, 
level of education, whether they lived alone, or received nursing care at 
home. 
Clinical characteristics were collected from the standardised medi-
cal history and the list of current clinical problems. Multimorbidity was 
operationalised using the Cumulative Illness Rating Scale (CIRS) [253]. 
The CIRS measures the chronic medical illness burden while taking into 
consideration the severity of chronic diseases (Hudon, Fortin, and Soubhi 
2007). The CIRS counts the number of 14 body systems affected with 
moderate disability, morbidity or extremely severe disease (severity score 
at least 3) [254] (possible range: 0 to 14) [14]. 
Functional characteristics included Activities of Daily Living (ADL, 
derived from the KATZ scale), physical activity (LASA Physical Activity 
Questionnaire, LAPAQ), cognitive status (Mini Mental State Examination, 
MMSE, adjusted for age and level of education) [259], and fall risk (Tinetti). 
Medication data included all chronic medications at baseline. The 
brand name, active substance, and the prescribed daily dose were re-
corded by the general practitioners.
Follow-up data
Follow-up data was collected using standardised questionnaires, 
filled in by the general practitioners. The original follow-up period was 5 
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years. For this study, we defined a cut-off at 18 months, because in longer 
follow-up periods, associations with baseline characteristics are expect-
ed to fade away. Patients who died, who were institutionalised, or were 
hospitalised during the 18 months follow-up period were considered as 
‘events’. 
The data on mortality included date and cause of death. Data on hos-
pitalisation (defined as unplanned hospital stays lasting longer than 1 
day) included the date of the first hospital stay. Institutionalisation was 
defined as entering the nursing home for permanent stay. The date of 
entering a nursing home was recorded. 
Medication handling
All drugs were recorded by brand or compound name. They were en-
tered into a data program based on the official register of medications on 
the Belgian market (source: https://www.ehealth.fgov.be). The medica-
tion was translated into the Anatomical Therapeutic Chemical classifica-
tion (WHO ATC/DDD 2013) [284].
For the analysis of the medication use in association with the out-
comes, we used three models: the number of medications, polypharma-
cy, and medication subclasses. Polypharmacy was defined as the chronic 
intake of ≥5 medications [2]. For the medication subclasses, we analysed 
the first (main anatomical groups) and second ATC level (therapeutical 
main groups). Subsequently, we analysed medications at the third ATC 
level (therapeutic subgroup) or lower for medications or medication 
groups that are specifically mentioned in Potential Inappropriate Medica-
tion (PIM) lists (BEERS, STOPP/START)[133, 187]. Additionally, we created 
a dichotomous variable including all medications with anticholinergic 
properties, according to the study of Duran et al. (2010) [215].
Functional data handling
The KATZ ADL-scale and the LAPAQ scores were divided into smaller 
groups to determine those with the highest care dependency, and those 
with the lowest physical activity respectively. 
The KATZ ADL-scale (range 6 – 30) has six domains (bathing, clothing, 
toileting, transferring, continence, and feeding), and a higher domain or 
overall score signifies being more care dependent. We identified those 
care independent (KATZ ADL score 6, scoring 1 at all six domains), the 
somewhat care dependent (KATZ ADL scores 7 - 12), and those most care 
dependent (scoring 13 and more).
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The raw LAPAQ scores (range 0 - ∞) were divided into quartiles. The 
lowest quartile was identified as those with the lowest physical activity. 
Finally, the MMSE was used for identification of cognitive impairment, 
with a cut-off adapted to the age and level of education of the respond-
ents [259]. 
Statistical analysis
SPSS 21.0 (Statistical Package for Social Sciences, SPSS Inc., Chicago, 
IL, USA) was used for statistical analysis. 
For descriptive statistics means, medians or proportions were used. 
Comparison of continuous data was done using t-tests or non-parametric 
tests in case of skewed data. Analysis of categorical variables was done 
using chi² tests. 
The Kaplan-Meier method was used to estimate survival. For the as-
sessment for the difference of survival between the groups with and 
without polypharmacy, the log-rank test was used. The censor date was 
set at 18 months after inclusion, and time to event was calculated for the 
three outcomes. For the calculation of the observation periods for both 
hospitalisation, and institutionalisation, censoring was done for deaths. 
The date of death was then regarded as the end of the observation pe-
riod. For all others, censoring was set at 18 months after inclusion. The 
mean time to death, first hospitalisation or institutionalisation was cal-
culated. 
A Cox proportional hazard models was used to calculate univariate 
and adjusted multivariate Hazard Ratios (HRs). Two multivariate models 
were constructed, one using the number of medications as the continu-
ous independent variable, and the other using therapeutic medication 
subclasses. To study the specific role of medications, all models were 
adjusted for multimorbidity, and additional confounding demographic 
variables. 
Ethical considerations
The study protocol was approved by the Biomedical Ethics Commit-
tee of the Medical School of the Université catholique de Louvain (UCL), 
Brussels (B40320084685, on 27/10/2008) and later by the Ethics Commit-
tee of Ghent University Hospital (B670201421408, on 26/06/2014). All pa-




Description of the study population
An overview of the socio-demographic, functional, and clinical char-
acteristics and the medication use of the participants are provided in 
Table 4.1. The mean age was 84.4 years (range 80 – 102), 61.2% was fe-
male. The median level of multimorbidity (defined by CIRS) was 4 (range 
1 – 9), with hypertension as the most prominent clinical problem. The 
mean number of medications was 5.4 (range 0 – 16) and polypharmacy 
Table 4.1. Demographical, clinical, and functional characteristics, and 
medication use at baseline (n= 503).
Demographical %
Mean age in years (range) 84.4 (80 - 102)
Gender (% female) 61.2
Living alone 43.3
Low education (≤8 years) 69.2
Clinical1 %




Heart Failure (NYHA > 0) 38.4
Diabetes 18.9
Post infarct / post stroke 17.7
COPD / asthma 13.1
Chronic renal failure 11.1
Functional Median (IQR range)
Activities of daily living, ADL 6 (6 - 8)
Physical activity, LAPAQ 70 (30 – 102)
Mental status, MMSE 28 (26 – 29)
Medication use3 %
Median number of medication (range) 5 (0-16)
Polypharmacy (≥5 drugs daily) 57.7
ATC C - Cardiovascular 86.3
ATC B - Blood and blood forming 56.1
ATC N - Nervous system 54.5
ATC A - Alimentary tract and metabolism 50.1
ATC M - Musculo-skeletal system 23.5
ATC R - Respiratory system 15.9
ATC H - Systemic hormonal preparations 11.7
ATC G - Genito-urinary system and sex hormones 10.3
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(≥5 medications) was present in 57.7% of the population. Cardiovascular, 
haematological, and nervous system drugs were most used.
Mortality
The mortality rate was 8.9% (n=45) at 18 months. Most prominent 
causes of death were cardiovascular and/or cerebrovascular events 
(48.9% of deaths), followed by cancer (20.0%), respiratory problems 
(13.3%), and general deterioration (6.7%). 
The deceased patients were older, and received more nursing care at 
home. They also had a higher mean level of multimorbidity (CIRS). Within 
the separate clinical problems, only chronic renal failure was significantly 
associated with higher mortality. All the functional characteristics were 
associated with higher mortality (see Table 4.2).
The survival rate 18 months after inclusion differed significantly be-
tween those with polypharmacy and those without (93% versus 88% re-
spectively, p=0.049). 
In univariate analysis, mortality was significantly associated with 
high medication use. At medication subclass level, mortality was higher 
in those taking high-ceiling or loop diuretics, selective calcium channel 
blockers with a direct cardiovascular effect, predominantly verapamil/
diltiazem use , antidepressants, and anticholinergics, see Table 4.3.
In multivariate analysis, no association with mortality was found for 
the number of medications (Hazard Ratio 1.05, 95% CI 0.94 – 1.18), af-
ter correction for multimorbidity, age, and gender. At medication sub-
class level, selective calcium channel blockers, predominantly verapamil/
diltiazem, were associated with increased mortality (HR 2.84, 95% CI 1.10 
– 7.36), see Table 4.4. The additional introduction of specific clinical prob-
lems (heart failure) into the model, yielded similar results. 
Hospitalisation
The hospitalisation rate in the Belfrail-MED cohort was 31.0% (n=156). 
Those hospitalised received more nursing care at home, had a higher 
level of multimorbidity, and had more clinical problems. They showed a 
weaker functional profile, were more care dependent, less physically ac-
tive, more cognitively impaired, and had a higher risk of falling (see Table 
4.2). 
The hospitalisation rate after 18 months differed significantly between 
those with polypharmacy and those without (75% vs 63%, p=0.001).


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































high medication use (see Table 4.3). Hospitalisation was significantly as-
sociated with the use of mineral supplements, loop diuretics, verapamil/
diltiazem, antidepressants, drugs for obstructive airway diseases, and an-
ticholinergic agents, see Table 4.3. 
In multivariate analysis, hospitalisation was significantly associated 
with high medication use (HR 1.11, 95% CI 1.03 – 1.18). For every addi-
tional medication taken at baseline, there was an 11% increased hospi-
talisation rate. At medication subclass level, hospitalisation was also as-
sociated with the use of verapamil/diltiazem (HR 2.14, 95% CI 1.10 – 4.16), 
loop diuretics (HR 2.24, 95% CI 1.48 – 3.40), and medications used in ob-
structive airway diseases (HR 1.76, 95% CI 1.12 – 2.79), see Table 4.4. The 
additional introduction of specific clinical problems (heart failure, COPD/
Asthma) into the model, yielded similar results.
Institutionalisation
The institutionalisation rate after 18 months was 6.4% (n=32). Those 
entering a nursing home were older, female, lived alone, and received 
more nursing care at home. Their level of multimorbidity was equal to 
those who remained at home. Having diabetes or using medications for 
diabetes had a negative association with institutionalisation. The institu-
tionalised were less physically active, more cognitively impaired, had a 
high risk of falling, but were not more care dependent (see Table 4.2). 
There was no difference in institutionalisation rate 18 months after 
inclusion among those with polypharmacy and those without (94% vs 
93%, p=0.654, see Figure 4.1). 
In univariate analysis, institutionalisation was not associated with 
high medication use. Increased institutionalisation was associated with 
the use of at least 1 psychotropic medication, predominantly due to a 
higher benzodiazepine use, see Table 4.3. 
Multivariate analysis showed no associations with high medication 
use (HR 1.00, 95% CI 0.90 – 1.09). At medication subclass level, institution-
alisation was only associated with the use of benzodiazepines (HR 1.62, 
95% CI 1.01 – 2.60), see Table 4.4. 
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Figure 4.1. Kaplan-Meier Survival analysis of time to death (A), time to the 
first hospitalisation (B), and to institutionalisation (C) for patients having 
polypharmacy (≥5 medications) and patients without polypharmacy.
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Table 4.4. Multivariate analysis of medication use in association with mortality (9.3%), hos-
pitalisation (31.0%), and institutionalisation (6.4%) after 18 months in a cohort of oldest old, 
aged 80 and over.
Mortality Hospitalisation Institutionalisation
Model 1 Number of medications 1.05 (0.94 – 1.18) 1.11 (1.03 – 1.18) 1.00 (0.90 – 1.09)
Model 2 C08D – Selective Calcium 
channel blockers
2.84 (1.10 – 7.36) 2.14 (1.10 – 4.16) -
C03CA - Loop diuretics - 2.24 (1.48 – 3.40) -
R03 - Agents in obstructive 
airway diseases
- 1.76 (1.12 – 2.79) -
Benzodiazepines1 - - 1.62 (1.01 – 2.60) 
The models were adjusted for age, gender, and for multimorbidity (using the CIRS). 
1 Benzodiazepines are defined as ATC classes N05BA, N05CD, N05CF.
4.5 Discussion
This study explored association of high chronic medication use with 
three different outcomes (mortality, hospitalisation, and institutionalisa-
tion) during an 18 months observation period in a cohort of community-
dwelling oldest old, defined as persons aged 80 years and over. 
Main finding of this study
To the best of our knowledge, this is the first longitudinal study in-
vestigating these associations in a cohort of community-dwelling oldest 
old. Our main finding is that in this oldest old cohort, every additional 
medication used at baseline did increase the rate of hospitalisation with 
11% after an observation period of 18 months
At the level of specific medication groups in multivariate analysis, the 
use of verapamil/diltiazem showed associations with increased mortality. 
The use of verapamil/diltiazem, loop diuretics and asthma/COPD-medi-
cations were independently associated with higher hospitalisation rate. 
Finally, benzodiazepines were associated with higher institutionalisation 
rate. 
What this study adds
The major strengths of this study are the longitudinal design, and the 
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exclusive cohort of oldest old (aged 80 and over), and the multivariate 
analysis, adjusted for multimorbidity. This study provides new informa-
tion in this specific subpopulation, where little is known on medication 
related outcomes [285]. 
Limitations of the study
Limitations are the observational nature, not allowing causal inter-
ference. We had data on chronic baseline medication use, but no data 
on over-the-counter drugs or pro re nata drugs (medication that is taken 
when needed, or if the situation arises). 
What is already known
Medication is given to treat or prevent disease, with the aim to lower 
the risk of mortality, and hospitalisation. The beneficial effect of medi-
cations can be jeopardised by the increasing presence of drug related 
problems with increasing higher medication use. In younger populations 
(aged 65 and over) the association of polypharmacy with hospitalisa-
tion and mortality is more clear [286–288]. In the oldest old (aged 80 and 
over), the association with hospitalisation remained, but there was no as-
sociation found with mortality for the number of medications. 
One may speculate why in the oldest old (aged 80 and over), high 
medication use, was not clearly associated with mortality. Only looking 
at the number of medications may be too crude to address the complex 
relationship with mortality, as it does not take into account the role of 
inappropriate medications or the role of not-used medications (either 
by not prescribing, or by deprescribing). It is possible that patients with 
high medication use are well treated in a well-balanced therapy with little 
excess risk of mortality [244], as well as those with a low medication use 
miss beneficial, necessary medications. In following studies, we will ad-
dress the role of inappropriate medications, and inappropriate prescrib-
ing by both looking at misused and underused medications.
The observed association between institutionalisation and cognitive 
impairment and use of benzodiazepines suggests that cognitive prob-
lems, but not the level of multimorbidity and care dependency, is the 
dominating reason for older adults to move from home care to the nurs-
ing home [289]. The puzzling association with anti-diabetic drugs might 
be explained by the focused and continuous home care provided for 
older community-dwelling diabetes patients in Belgium [290].
In our univariate analysis, all aspects of functional profile in the oldest 
Chapter 4
78
old were strongly associated with mortality, hospitalisation, and institu-
tionalisation. Other findings also suggest that more functionally active 
oldest old benefit in terms of reduced mortality or hospitalisation risks 
[291]. However we could not confirm this association in multivariate anal-
ysis, after the introduction of multimorbidity.
4.6 Conclusion
In the community-dwelling oldest old (aged 80 and over), high medi-
cation use, independent of multimorbidity, was clearly associated with 
hospitalisation The association with mortality was present in univariate 
analysis, but not in multivariate. There was no association with institu-
tionalisation. The appropriateness of the high medication use should be 
further studied in relation to mortality, hospitalisation, and institutionali-
sation for this specific age group aged 80 and over.
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I
nappropriate prescribing puts older adults (≥ 65 years) at risk for 
adverse drug reactions [183]. Recently, a European list of Poten-
tially Inappropriate Medications (PIMs) was developed; the EU(7)-
PIM list [292]. Experts from the seven participating countries (EE, 
NL, FI, ES, FR, SE, DE) screened their medication market for PIMs, 
using existing lists of explicit criteria [133, 182, 183, 186]. The experts de-
veloped the EU(7)-PIM list using a two-round Delphi panel. See Box 5.1 
for more details on the development and content. 
Our first aim was to check the Belgian market on the availability of 
potentially inappropriate medications as listed in the EU(7)-PIM list. Sec-
ond, we studied the actual use of PIM products in a cohort of oldest old 
(≥80 years). 
To check the availability, we cross-referenced the official register of 
medications in Belgium (coded in ATC) to the EU(7)-PIM list. Of the 275 
active substances in the EU(7)-PIM list, 157 were available in Belgium. Of 
those, 139 products were only available on prescription. The seven medi-
cation classes in the EU(7)-PIM list contain a total of 60 active substances 
in the ATC classification, of which 21 were available in Belgium (three 
antacid combinations and complexes, five proton-pump inhibitors, two 
iron supplements, four estrogens, and seven triptanes). The medication 
classes of antacids containing aluminium compounds, and quinine and 
derivates, were not available in Belgium as registered medications.
To check the actual use of PIM products, we used the Belfrail-MED co-
hort of 503 Belgian community-dwelling oldest old (≥ 80 years, range 80 
– 102 years) [252, 283]. See Box 5.2 for more background on the Belfrail-
MED cohort. For this, all prescribed, chronic medications with systemic 
action in this population were recorded, coded into ATC, and cross-refer-
enced to the EU(7)-PIM list. In the oldest old, the mean number of medi-
cations was 5.4 (range 0 – 16). Of the possible 157 PIM-products in Bel-
gium, 77 were identified in this cohort. All 5 available medication classes 
were identified as well. In this cohort, 72,8% of patients took at least one 
PIM-product. Lorazepam was the most prescribed PIM product (10.7% of 
patients), and proton pump inhibitors the most prescribed medication 
class (17.3% of patients). 
While scanning the Belgian medication market, we identified a few 
other potentially inappropriate medications, not considered in the EU(7)-
PIM list, because possibly not available in the participating countries. See 
Box 5.3 for possible additions to the EU(7)-PIM list.
Also, PIM-products available in combination products should be dis-
cussed. For instance, loperamide (A07DA03) is listed as a PIM-product, 
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but the combination of loperamide in the same dose with simethicone 
(A07DA53) is not. For the Belgian situation, there are 61 combinations 
containing a PIM-product. 
We encourage other European countries, not (yet) participating in the 
EU(7)-PIM list, to repeat this exercise, to gain insights in remaining over-
laps or gaps of PIMs available in each national medication market. We 
urge the authors of the EU(7)-PIM list to (1) explicitly list all active sub-
stances in the medication classes, and (2) to address the problem of com-
binations containing PIMs. Also, (3) a procedure must be considered for 
the evaluation of additional potentially inappropriate active substances, 
which are not in the EU(7)-PIM list but used in substantial quantities in 
other European countries.
Box 5.1. Additional information on the development and content of the EU(7)-PIM list.
The EU(7)-PIM list is based on the German PRISCUS list of potentially 
inappropriate medications. Additionally, explicit criteria from other exist-
ing PIM lists were selected from the Beers (US), McLeods (CA) and Laro-
che (FR). For the content validation of each criterion, a two-round Delphi 
panel was constructed with experts from seven different countries (EE, 
NL, FI, ES, FR, SE, DE). All invited experts were selected on their experi-
ence in geriatric prescribing. The experts (n=27) evaluated each criterion 
on the appropriateness of medications, dose adjustments in older adults, 
and gave suggestions for alternative (mostly medication) therapies. 
Eight experts suggested additional criteria to be added to the EU(7)-PIM 
list. Finally, twelve experts completed a brief final survey to decide upon 
issues requiring further consensus.
The EU(7)-PIM list contains 282 criteria; 275 active substances and 
7 broad medication classes (defined in the Anatomical Therapeutic 
Chemical (ATC) classification, yet without explicit enumeration of active 
substances within the medication classes). Criteria were predominantly 
medication-oriented, limited to information on the nature of the active 
substance, and occasionally on duration or dosage, but not on clinical 
data.
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Box 5.2. Additional information on the Belfrail-MED cohort of oldest old (≥80 years).
The Belfrail-MED cohort (n=503) originated from the Belfrail study, a 
prospective, observational population-based cohort study. General prac-
titioners from three Belgian regions were responsible for the selection 
of patients. Eligible participants were at least 80 years old and had to be 
able to visit their GP. Further inclusion criteria were being non-institu-
tionalised, and having a medication record available. Exclusion criteria 
were: known presence of severe dementia (Mini Mental State Examina-
tion <15/30), in need of acute care or being in palliative care. The general 
practitioners were also responsible for recording the chronic medica-
tion use (medication being used for longer than 3 months and without 
known stop date).
The study protocol was approved by the Biomedical Ethics Commit-
tee of the Medical School of the Université catholique de Louvain (UCL), 
Brussels (B40320084685, on 27/10/2008) and later by the Ethics commit-
tee of Ghent University Hospital (B670201421408, on 26/06/2014). All re-
spondents provided informed consent.
Box 5.3. Possible obsolete medications in Belgium, but not on the EU(7)-PIM list.
The following products have been considered obsolete in Belgium by 
the drug information centre (BCFI): 
• Complex painkiller combinations (e.g. paracetamol + aspirine + ca-
feine)
• nasal sprays or throat pastilles with antibiotics
• Combined cough preparations with an antitussivum, mucolyticum or 
expectorans (and possibly antipyretica, H1-antihistaminica, anticho-





• Oral Lysate of bacteria (Broncho-vaxom® and Uro-vaxom®)
Note: Some of the products may only be obsolete, but not specifically harmful 
for elderly. 
Note: Metamizol is considered obsolete in Belgium (and Finland[292]). In the 
EU(7)-PIM list it is only listed as inappropriate if not used in adequate doses (as 
suggested by the Spanish experts in the Delphi panel).
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6.1 Abstract
Aims: Little is known about the impact of Inappropriate Prescribing (IP) in 
community-dwelling adults, aged 80 and older. The prevalence at base-
line (November 2008 – September 2009) and impact of IP (misuse, and 
underuse) after 18 months on mortality, and hospitalisation in a cohort 
of community-dwelling adults, aged 80 and older (n=503) was studied. 
Methods: Screening Tool of Older People’s Prescriptions (STOPP, misuse) 
and Screening Tool to Alert to Right Treatment (START, underuse) criteria 
were cross-referenced and linked to the medication use (in Anatomical 
Therapeutic Chemical-coding) and clinical problems. Survival analysis 
until death or first hospitalisation was performed at 18 months after in-
clusion using Kaplan-Meier, with Cox regression to control for covariates.
Results: Mean age was 84.4 years (range 80 – 102). Mean number of medi-
cations prescribed was 5 (range 0 – 16). Polypharmacy (≥5 medications, 
58%), underuse (67%), and misuse (56%) were high. Underuse and mis-
use coexisted in 40%, and were absent in 17% of the population. A higher 
number of prescribed medications was correlated with more misused 
medications (rs=.51, p<.001), and underused medications (rs=.26, p<.001). 
Mortality and hospitalisation rate were 8.9%, and 31.0% respectively. After 
adjustment for number of medications and misused medications, there 
was an increased risk of mortality (HR 1.39; 95%CI 1.10 – 1.76), and hos-
pitalisation (HR 1.26; 95%CI 1.10 – 1.45) for every additional underused 
medication. Associations with misuse were less clear.
Conclusion: IP (polypharmacy, underuse and misuse) was highly prevalent 
in adults, aged 80 and older. Surprisingly, underuse and not misuse, had 





ppropriate prescribing of medications is a major chal-
lenge in the care for older adults. Older adults are more 
sensitive to the effects of medications, and have a higher 
prevalence of comorbidities [293]. Hence, older adults 
will have a higher medication intake, potentially putting 
them at risk for adverse drug events [183], increased morbidity, health 
care utilisation, and mortality [177]. Yet, polypharmacy cannot be equat-
ed with Inappropriate Prescribing (IP). IP is possible in polypharmacy, yet 
not every person with polypharmacy will have IP [265].
Prescribing can be potentially inappropriate if the potential benefits 
are outweighed by the harms, if there is evidence for an equal or more 
effective, yet lower-risk alternative [36, 184] or if omission of potentially 
beneficial medications is present [294]. Tools were developed to identify 
inappropriate prescribing in older adults, focussing on polypharmacy, 
underuse, and misuse [174]. Most of these tools consist of lists of explicit 
criteria of potentially inappropriate medications, often without clinical 
data required. Some criteria address underuse instances, always requir-
ing clinical data [133, 182, 187], and are designed to alert clinicians when 
to drop or add a medication in individual patients. 
The clinical relevance of screening tools for inappropriate prescribing 
based on these explicit criteria is not yet fully explored. Most studies were 
cross-sectional. Gaps in evidence remain, as data from prospective long-
term cohort studies are scarce [195, 230, 231, 295]. Moreover, the oldest 
old (aged 80, and over) have been rarely studied as a separate group in 
primary care settings [85, 205, 296]. Finally, polypharmacy, underuse, and 
misuse, although part of the definition of inappropriate prescribing, are 
seldom concomitantly studied [154].
This study aims to explore the prevalence of inappropriate prescribing 
(misuse and underuse) in a prospective cohort of community-dwelling 
oldest old (aged 80, and over), and to explore associations with mortality, 
and hospitalisation after 18 months. 
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6.3 Methods
The Belfrail-MED cohort [252, 283] was used (n=503), consisting of 
Belgian community-dwelling patients aged 80, and over. All subjects 
were primary care patients, recruited by their own general practitioner. 
Patients were selected between November 2008 and September 2009. 
Exclusion criteria were known dementia, and in palliative care.
The general practitioners (GPs) were responsible for the collection 
of baseline (demographic, clinical, and medication data) and follow-up 
data (date and cause of death, date of the first hospitalisation). Clinical re-
search assistants were responsible to collect data from the patients, using 
clinical examinations (e.g. blood pressure, …), and standardised scales 
(to measure physical activity, activities of daily living…). GPs used their 
medical records.
Medication handling
The general practitioner recorded all chronic medications at baseline, 
using the generic name. All chronic medications were codified entered 
into the Anatomical Therapeutic Chemical Classification (WHO ATC/DDD 
2013) [284], based on the official register of medications on the Belgian 
market (source: https://www.ehealth.fgov.be). 
Polypharmacy was defined as the daily intake of 5 medications or 
more [135].
Assessing inappropriate prescribing
Inappropriate prescribing was operationalised by the computerised 
application of criteria for misuse and underuse. For misuse, we applied 
the clinically oriented Screening Tool for Older Person’s Prescriptions 
(STOPP-2 criteria). For underuse, we applied the Screening Tool to Alert 
doctors to Right Treatment (START-2). These criteria are suitable for use 
in European countries [297], have been applied and validated in several 
studies [171, 190, 193], and were recently updated [187]. 
To assess the prevalence and impact of inappropriate prescribing, the 
STOPP/START–2 criteria were cross-referenced and linked to the baseline 
medications and clinical problems.
This was not possible for all criteria, as only a subset of the STOPP/
START–2 criteria could be applied (see Figure 6.1). For the START criteria, 
13 out of 34 criteria could be used for our analysis, and for the STOPP 
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criteria, 46 out of 81. Reasons to omit criteria included the absence of 
data in our database required by the criteria: (1) clinical test results, (2) 
severity of disease data, (3) short duration of medication, and (4) criteria 
on rank ordering of first choice medications. Other reasons to omit cri-
teria were the unclear definition of clinical problems. Criteria pertaining 
to diseases excluded in our cohort (e.g. dementia) could also not be ap-
plied. Additionally for the STOPP criteria, we omitted one extra criterion 
because of possible duplication in scoring: criterion 32 (benzodiazepines 
for ≥ 4 weeks) and 74 (benzodiazepines could increase the risk of fall in-
cidents) were considered too similar. For further analysis, only the former 
was taken into account. 
Outcome parameters
Follow-up data was collected using standardised questionnaires, 
filled in by the general practitioners. Data collection on mortality includ-
ed date and cause of death. Data on hospitalisation included the date of 
the first unplanned hospital stay (longer than 1 day). The full follow-up 
period of the Belfrail-study was 5 years [252], but to observe direct associ-
ations with baseline medication use, a shorter follow-up period was used, 
setting a cut-off at 18 months after inclusion in the cohort. All further 
analyses used the 18 months cut-off, although we provided in the text 
data on the one-year-survival rate for future and external comparisons. 
Statistical analysis
SPSS 21.0 (Statistical Package for Social Sciences, SPSS Inc., Chicago, 
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IL, USA) was used for analysis.
For all variables, there was less than 5% missing data [252]. Normally 
distributed continuous variables were expressed as means and standard 
deviations. All skewed variables were expressed using the medians, and 
interquartile ranges. Categorical data was expressed using numbers and 
percentages. Both underuse and misuse were divided into three catego-
ries; no (0), low (1 – 2), and high (3 or more) underuse or misuse of medi-
cations. Relationships between skewed data were tested using Spearman 
rank correlations.
The Kaplan-Meier method was used to estimate the survival rate, 
with the log-rank test verifying the differences in survival time between 
groups. All deceased or hospitalised patients during the 18 months fol-
low-up period were considered as ‘events’. For hospitalisation, additional 
censoring was done for patients who have died. 
Cox proportional hazard models were used to calculate univariate 
and multivariate Hazard Ratios for associations with mortality, and hos-
pitalisation. In univariate analysis, we first tested the associations with 
inappropriate prescribing, expressed as a continuous variable. Second, 
we used the above described categories of underuse and misuse (no, 
low, and high), to explore the associations with possible trends in higher 
mortality and hospitalisation rates, for higher categories of underuse or 
misuse. 
Lastly, we tested the interaction between underuse and misuse, by 
multiplying the number of underused and misused medications of each 
individual. The statistical significance of each interaction term was evalu-
ated by the likelihood ratio test, comparing nested models with or with-
out inclusion of the interaction term.
A similar exercise was repeated in the multivariate models for both 
the continuous and categorical variables for underuse and misuse. Now, 
underuse and misuse (continuous and categorical) were corrected for 
the number of medications taken at baseline. Additionally, underuse was 
corrected for misuse, and misuse for underuse. 
Ethical approval
The study protocol was approved by the Biomedical Ethics Commit-
tee of the Medical School of the Université Catholique de Louvain (UCL), 
Brussels (B40320084685, on 27/10/2008) and later by the Ethics commit-
tee of Ghent University Hospital (B670201421408, on 26/06/2014). All re-




The patients in the Belfrail-MED cohort (n=503) had a mean age of 
84.4 years (range 80 - 102), and 61.2% were female. Hypertension was the 
most common clinical problem, followed by osteoarthritis, and hyperlipi-
daemia (see Table 6.1). 
The mean number of medications was 5.4 (range 0 – 16). Cardiovas-
cular (86.3%), haematological (54.5%), and nervous system drugs (54.5%) 
were most used. 
Prevalence of inappropriate prescribing
Polypharmacy (≥5 medications) was present in 57.7% of the popula-
tion. Using the START 2 criteria, underuse was identified in 67.0% of the 
population (range 0 – 5), and using the STOPP 2 criteria, misuse was iden-
Tabl e 6.1. Demographics and clinical characteristics of the study popula-
tion (n=503).
Demographic % (Total n = 503)
Median age in years (range) 83.9 (80 - 102)
Gender (% female) 61.2
Living alone 43.3
Nursing care at home 36.8





Heart Failure (NYHA²> 0) 38.4
Obesity (BMI > 30kg/m²) 27.9
Osteoporosis 20.9
Diabetes 18.9
Post myocardial infarction / post stroke 17.7
COPD / asthma 13.1
Depression 12.7
Chronic renal failure 11.1
1Clinical problems with prevalence above 10% are listed.
²New York Heart Association (NYHA) functional classification of heart failure
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tified in 56.1% (range 0 – 6). 
In 17.1% of the population, no underuse or misuse was found. Only 
underuse was present in 26.8%, and only misuse in 15.9%. The combina-
tion of underuse with misuse was present in 40.2% of the population (of 
which 31.4% had polypharmacy, and 8.7% low medication use). 
The most prevalent criterion for underuse was the absence of an 
Angiotensin Converter Enzyme Inhibitor in patients with systolic heart 
failure (26%), and the absence of an antiplatelet therapy in patients with 
documented coronary, or cerebral or peripheral vascular disease (24%). 
The most prevalent criterion for misuse (35%) was the intake of benzo-
diazepines for longer than 4 weeks (see Table 6.2 for the prevalence of 
other criteria). 
Association of inappropriate prescribing with the amount 
of medications taken
The Spearman rank correlation between the number of medications 
taken, underuse, and misuse is shown in Table 6.3. The number of medi-
cations showed a high positive correlation with misuse (rs 0.51, p<.001), 
and with underuse (rs 0.26, p<.001). Moreover, there was also a statisti-
cally significant correlation between underuse and misuse, in the positive 
direction (rs 0.19, p<.001).
Survival analysis of inappropriate prescribing on mortality, 
and hospitalisation
The mortality rate after18 months was 8.9% (n=45), and the hospitali-
sation rate 31% (n=156). Causes of death included cardiovascular and/or 
cerebrovascular related events (48.9% of deaths), cancer (20.0%),respira-
tory related events (13.3%), or general deterioration (6.7%). 
The survival analysis showed a significant difference between differ-
ent categories of underuse for both mortality, and hospitalisation (log 
rank p<.001). The survival rates for mortality after 18 months for those 
with no, low (1 – 2), and high underuse (3 or more) were respectively 97%, 
96%, and 88% (see Figure 6.2). The survival rates for hospitalisation after 1 
year were respectively 85%, 81%, and 59% (see Figure 6.3). 
For misuse, no significant difference was found for both outcomes.
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T able 6.2. Most identified STOPP/START–2 criteria.
Inappropriate 
prescribing
Most identified % of the popu-
lation (n=503)
Underuse Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart 
failure and/or documented coronary artery disease
26.2
Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) 
with a documented history of coronary, cerebral or peripheral 
vascular disease.
24.3
Statin therapy with a documented history of coronary, cerebral or 
peripheral vascular disease, unless the patient’s status is end-of-life 
or age is > 85 years
14.9
Regular inhaled 2 agonist or antimuscarinic bronchodilator (e.g. 
ipratropium, tiotropium) for mild to moderate asthma or COPD.
10.5
Vitamin D and calcium supplement in patients with known 
osteoporosis and/or previous fragility fracture(s) and/or (Bone 
Mineral Density T-scores more than -2.5 in multiple sites).*
9.1
Misuse Benzodiazepines for ≥ 4 weeks 35.2
Any duplicate drug class prescription e.g. two concurrent NSAIDs, 
SSRIs, loop diuretics, ACE inhibitors, anticoagulants
12.5
Antimuscarinic drugs with dementia, or chronic cognitive 
impairment or narrow-angle glaucoma, or chronic prostatism**
10.7
Use of regular (as distinct from PRN) opioids without concomitant 
laxative (risk of severe constipation)
7.8
Concomitant use of two or more drugs with antimuscarinic/
anticholinergic properties
3.4
* Only the clinical indicator osteoporosis could be used. Fragility fractures and Bone Mineral Density scores were not 
available. **The clinical indicator dementia was an exclusion criteria for this cohort.
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Table 6.3. Description of the medication use, and level of inappropriate prescribing.
Description of the medication use Mean (range)
Medication use 5.4 (0 – 16)
Underuse 1.2 (0 – 5)
Misuse 0.9 (0 – 6)
%
Polypharmacy (≥5 drugs daily) 57.7
ATC C - Cardiovascular 86.3
ATC B - Blood and blood forming 56.1
ATC N - Nervous system 54.5
ATC A - Alimentary tract and metabolism 50.1
ATC M - Musculo-skeletal system 23.5
ATC R - Respiratory system 15.9
ATC H - Systemic hormonal preparations 11.7
ATC G - Genito-urinary system and sex hormones 10.3
Inappropriate prescribing Underuse, % Misuse, %
0 33.0 43.9
1 – 2 52.7 46.7
3 or more 14.3 9.3
Combinations Low medication use  (0 – 4), % Polypharmacy (5 or more), %
No misuse or underuse 12.5 4.6
Only underuse 15.3 11.5
Only misuse 5.8 10.1
Underuse, and misuse 8.7 31.4
Correlations1 rs (p-value)
Underuse * Misuse .19 (<.001)
Underuse * Number of medications .26 (<.001)
Misuse * Number of medications .51 (<.001)
1All variables are expressed as continuous variables
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 Figure 6.2. Kaplan-Meier Survival analysis of time to death for groups of 
underuse (A), and groups of misuse (B).
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 Figure 6.3. Kaplan-Meier Survival analysis of time to first hospitalisation 
for groups of underuse (A), and groups of misuse (B).
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Univariate analysis for the impact of inappropriate prescribing
In our previous analysis of polypharmacy, we observed a significant 
association of the number of medications with mortality, and with hospi-
talisation [298] (in univariate analysis e.d.). Here, we also looked concomi-
tantly at the additional effects of underuse and misuse (see Table 6.4). For 
mortality, underuse expressed as a continuous variable, showed an in-
creased risk (HR 1.43, 95% CI 1.15 – 1.78). In categorical analysis, patients 
with high underuse (3 or more) had a 3.3 fold significantly increased risk 
for mortality, compared to those with no underuse. Misuse did not show 
a significant association with mortality. 
For hospitalisation, underuse expressed as a continuous variable 
showed an increased risk as well (HR 1.35, 95% CI 1.19 – 1.54). In categori-
cal analysis, patients with high underuse (3 or more) had a 2.8 fold signifi-
cantly increased risk for being hospitalised, compared to those with no 
underuse. Misuse, yet only when expressed by the continuous variable, 
showed an increased risk for hospitalisation (HR 1.20, 95% CI 1.06 – 1.36), 
but not for mortality.
 Table 6.4. Univariate Cox regression analysis of mortality (8.9%) and hospitalisation (31.0%) 
in association with inappropriate prescribing in a cohort of oldest old (n=503).
Mortality Hospitalisation
Continuous Range HR (95% CI) HR (95% CI)
Number of mediations 0 - 21 1.12 (1.02 – 1.22) 1.14 (1.08 – 1.20)
Underuse 0 – 5 1.43 (1.15 – 1.78) 1.35 (1.19 – 1.54)
Misuse 0 – 6 1.16 (0.92 – 1.47) 1.20 (1.06 – 1.36)
Interaction effects
Underuse*misuse 0 – 24 1.07 (1.00 – 1.15) 1.08 (1.04 – 1.12)
Categorical Cut-offs N
Underuse 0 166 1 1
1-2 265 .89 (.43 – 1.86) 1.17 (.81 – 1.71)
3 or more 72 3.33 (1.58 – 7.04) 2.79 (1.79 – 4.34)
Misuse 0 221 1 1
1-2 235 1.52 (0.80 – 2.90) 1.33 (0.95 – 1.86)
3 or more 47 1.95 (0.76 -5.03) 1.49 (0.87 – 2.55)
The associations of inappropriate prescribing was first tested, using the continuous variables for underuse and misuse. 
Using categorical analysis, trends were explored for a higher risk for mortality or hospitalisation with a higher degree 
of underuse, or misuse
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The interaction effect (multiplying underuse with misuse, range 0 - 
24) was significant as well, for both mortality (HR 1.07, 95% CI 1.00 – 1.15, 
p=0.044) and hospitalisation (HR 1.08, 95% CI 1.04 – 1.12). 
Multivariate analysis for the impact of inappropriate prescribing
The results of the multivariate analysis are shown in Table 6.5. After 
correction for the number of medications and for the number of mis-
used medications, underuse (expressed continuously and categorically) 
showed significant increased risks for mortality and hospitalisation. For 
every additional underused medication at baseline we observed a 39% 
increased risk for mortality, and a 26% increased risk for hospitalisation 
after 18 months. Compared to those with no underuse, those with high 
underuse (3 or more) showed a 2.9 fold increased risk for mortality, and a 
2.1 fold risk for hospitalisation. 
Misuse, after controlling for the number of medications and under-
use, did not show significant associations with both mortality, and hos-
pitalisation.
 Table 6.5. Multivariate Cox regression analysis of mortality (8.9%) and hospitalisation 
(31.0%) in association with inappropriate prescribing in a cohort of oldest old (n=503).
Mortality Hospitalisation
Continuous Range HR (95% CI) HR (95% CI)
Underuse 0 – 5 1.39 (1.10 – 1.76) 1 1.26 (1.10 – 1.45) 1
Misuse 0 – 5 0.93 (0.69 – 1.24) 2 0.98 (0.84 – 1.14) 2
Categorical N
Underuse 0 166 1 1
1 – 2 265 0.88 (0.41 – 1.90) 1.04 (0.71 – 1.53)
3+ 72 2.91 (1.28 – 6.61) 1 2.08 (1.29 – 3.36) 1
Misuse 0 221 1 1
1 – 2 235 1.16 (0.58 – 2.34) 0.96 (0.67 – 1.38)
3+ 47 1.07 (0.36 – 3.17) 2 0.74 (0.41 – 1.36) 2
The associations of inappropriate prescribing was first tested, using the continuous variables for underuse and misuse. 
Using categorical analysis, trends were explored for a higher risk for mortality or hospitalisation with a higher degree 
of underuse, or misuse. 
1Underuse was corrected for the number of medications, and for the number of misused medications. 




To the best of our knowledge, this study is the first prospective lon-
gitudinal cohort study of community-dwelling older adults, aged 80 and 
more, exploring the associations of inappropriate prescribing with mor-
tality and hospitalisation, using a computerised version of the STOPP/
START–2 criteria. 
Main findings
First, we observed a high prevalence of polypharmacy (58%), concur-
rent with a high prevalence of underuse (67%), and misuse (56%). The 
combination of polypharmacy, underuse and misuse was present in 31% 
of the population. Only in 9% of the population, no polypharmacy, no 
underuse and no misuse was observed.
Second, the Spearman rank correlations suggest that the number of 
medications was positively correlated with the number of misused medi-
cations, and also with the number of underused medications.
Lastly, our main finding is that every additional underused medica-
tion was associated with a relative increase in mortality rate of 36%, and 
in hospitalisation rate of 26% after 18 months, independent of the num-
ber of medications taken, and of the number of misused medications.
Limitations of this study
Results of this observational study do not allow infer causal relations. 
The relation between inappropriate prescribing and mortality and hos-
pitalisation was established out of the proof of a (chronic) inappropriate 
medication intake throughout the study period. Also, the results cannot 
be generalised beyond the population of cognitive fit community-dwell-
ing older persons. 
The negative results need to be interpreted with caution, especially 
the absence of associations with misuse, as the sample sise may have re-
sulted in underpowered statistical analysis for this aspect. Additionally, 
we did not use the full STOPP/START–2 criteria, only those that were ap-
plicable in our database, and suitable for the computerised evaluation. 
Also, other authors have made partial use of the STOPP/START criteria 
for pragmatic reasons [299]. However, the criteria applied in this study 
matched with the most prevalent criteria in other studies [154, 172, 187, 
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196, 229, 300]. Nevertheless, the true prevalence of inappropriate pre-
scribing could have been underestimated in this study. To check this is-
sue for misuse, we repeated the same analysis with the medication-only 
EU(7)-PIM list [292], also focussing on misuse. Again, only in univariate 
analysis, we observed only a limited association of misuse with hospi-
talisation, and not with mortality. All associations of misuse disappeared 
after entering the number of medications and underuse into the multi-
variate model.
In our database of prescriptions, over the counter drugs were not in-
cluded, also possibly underestimating the prevalence of misuse. 
Comparison with other findings
In our study, there was a high prevalence of polypharmacy (58%), un-
deruse (67%), and misuse (56%). Interpretation and comparison of the 
prevalence of inappropriate prescribing must be done with caution, since 
most studies either used younger aged populations, or used the STOPP/
START–1 criteria. In other studies, underuse ranged between 23 – 58% 
[85, 187, 198, 301, 302], and misuse ranged 21-60% [85, 198, 205, 302, 
303]. For underuse, our results were over the upper limit of this range, 
and the results for misuse were close to upper limit of the range.
Cross-sectional studies focussing on younger age groups, and using 
the Beers [304–306] or STOPP/START–1 [196] criteria, have shown higher 
prevalence of inappropriate prescribing in those that were hospitalised. 
Associations with mortality have been observed as well, although only in 
older hip fracture patients [234]. 
Comparison with the scarce existing longitudinal cohort studies is 
difficult, as these studies focussed on younger adults (65, and over), on 
those in nursing homes, or studied other outcomes such as adverse drug 
events, economic costs, or geriatric syndromes (falls) [195, 230, 231]. 
The impact of underuse has also been observed in another cohort, 
focussing on cardiovascular patients (aged 50 – 74 years) [295, 307, 308]. 
Implications for research
This study clearly indicated that higher underuse was associated with 
higher mortality and with higher hospitalisation rate. As this observation-
al study allows no causal inference, we can only formulate hypotheses for 
further research. 
The results of this study suggests that the underuse of medications, 
next to polypharmacy, is strongly associated with outcomes. An explana-
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tion could be the reluctance of general practitioners to prescribe addi-
tional medications in patients with a high multimorbidity and polyphar-
macy [309, 310], or of a possible aversion of patients for new therapies. 
The lack of clear evidence of some pharmacotherapies in the oldest age 
groups may explain reluctance of general practitioners to adhere to gen-
eral treatment recommendations in this age group [311]. However, most 
of the START criteria are evidence-based and should not be overridden. 
In addition, deprescribing or not starting medications , might be 
caused by a perception of futility in the face of approaching death in 
this population. In case this clinical perception is true, this could lead to 
a higher morbidity in the group of those with underuse, making mortal-
ity more the cause rather than the consequence of underuse. However, 
it should be remembered that this cohort was limited to community-
dwelling active and cognitively fit oldest old, not in palliative care. An-
other hypothesis could be that substandard prescribing in older adults 
is a physician trait [312], and an instrumental variable that leads to a 
combination of polypharmacy, underuse, misuse, and higher mortality/
hospitalisation. 
Applicability of the STOPP/START criteria in a particular patient has un-
til now most often based on the human judgement of a clinical pharma-
cologist (or similar). Our study indicates that the electronical application 
of the STOPP/START–2 criteria is feasible, but that further specification of 
clinical problems and medication groups in the light of computerisation 
is needed [178]. Large scale application on big data will need substantial 
progress in semantic interoperability of clinical data in heterogeneous 
electronic health records [178, 313, 314]. 
Implications for practice
The interpretation and transferability of the results to other care set-
tings or other patients must be done with caution. The Belfrail-MED co-
hort excluded those in nursing homes, those with known dementia and 
those in palliative care. These community-dwelling oldest old patients 
can be considered as the most active and healthy in this age segment.
The findings of our study are in favour of using the STOPP/START–2 
criteria in clinical practice, or for education purposes of clinicians. They 
are adapted to European medication markets, and can detect underuse.
Using a cut-off for polypharmacy, with a simple arbitrary point (e.g. ≥ 
5 medications) or as a sole indicator for quality is problematic. Polyphar-
macy can be a risk for worse outcomes, even when all prescribed medica-
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tions are justified. In this study, underuse of medications that should have 
been prescribed for a specific indication may also be hazardous. Our pre-
sent and previous results indicate that a more patient-tailored approach 
is needed to solve this dilemma [298]. The discussion on too much medi-
cation, or too unsafe needs more differentiation, and a clear assessment 
of misuse and underuse using full knowledge on the patient, his/her co-
morbidities, and his/her medications. Computerisation of the analysis of 
medication lists should be considered as a facilitator of the data collec-
tion process and the medication chart review, but not as a substitute for 
assessment of the pharmacological therapy of an individual patient. 
6.6 Conclusion
Inappropriate prescribing (polypharmacy, underuse and misuse) was 
highly prevalent in community-dwelling adults, aged 80 and older. Un-
deruse and misuse were highly correlated and coexisted in almost half 
of the population. Surprisingly, underuse, and not misuse, had strong as-
sociations with mortality and hospitalisation, even when controlling for 
polypharmacy and misuse. Incentives towards patient-tailored appropri-
ate prescribing in older adults are needed, taking the number of medica-
tions, underuse and misuse into account.
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7.1 Abstract
Background: Quantification of the anticholinergic exposure insufficiently 
or imprecisely incorporates dosage information, leading to inaccurate 
estimations.
Aim: To construct a novel scale, including potency and dosage for the quan-
tification of the anticholinergic exposure in older adults.
Methods: Potency information was retrieved from a previous systematic 
review. The dosage range for each drug was delineated in minimal, main-
tenance, and maximal dosage for adults and older adults. Dosage infor-
mation was collected from authorative sources and reviewed in an expert 
panel. The Muscarinic Acetylcholinergic Receptor ANTagonist Exposure 
(MARANTE) scale was tested for clinimetric properties using cohorts of 
community-dwelling older adults and nursing home residents.
Results: After 3 data collection rounds, data for the dosage ranges remained 
incomplete for 32 active substances. Remaining gaps were filled in, and 
11 dosage adjustments were proposed during the expert panel meeting. 
We chose the values {0; 1; 2) for the categories of potency and {0; 0.5; 1; 
1.5; 2) for the levels of dosage ranges, showing good clinimetric proper-
ties. 
Forty-one anticholinergic drugs were prescribed in the two cohorts. Most 
(61%) were low potency anticholinergics, used for depression (19%, e.g. 
citalopram). 
There were 31.8% (median MARANTE 1.5, IQR 1.5 – 2.5) and 37.6% (me-
dian 2, IQR 1.5 – 2.5) anticholinergic users in the community-dwelling co-
hort and nursing home cohort respectively. 
Conclusion: The MARANTE scale combines potency with the dosage spec-
trum, to quantify the anticholinergic exposure in older adults. An open 
feedback system on the list of anticholinergic and proposed anticholiner-





nticholinergics are a group of drugs that competitively 
inhibit the muscarinic or nicotinergic receptors in both 
the central nervous system (CNS) and in peripheral tis-
sues, resulting in an inhibition of the acetylcholine (Ach) 
pathways [42, 43, 46, 47, 61, 315]. Apart from the pure an-
ticholinergics, active substances with anticholinergic properties are used 
in a variety of diseases and symptoms (including depression, psychosis, 
Parkinson’s disease, allergy, pain, urinary incontinence, etc.[43, 48, 315]. 
Some anticholinergic drugs are used therapeutically for their anticholin-
ergic properties, while others have other primary mechanisms of action 
for their intended therapeutic goal, and only additionally anticholinergic 
properties. Therefore these drugs and their adverse effects are not always 
recognised as anticholinergic [43]. Depending on the receptors affected, 
several adverse effects are possible. Common muscarinic central adverse 
events include dizziness, nervousness, delirium and hallucination [43, 
48–50, 61] while the peripheral adverse events include dry mouth, con-
stipation, blurred vision and urinary retention. Impact on nicotinic recep-
tors might be responsible for long term negative effect on cognition [316, 
317].
Older adults (65 years or older) consume anticholinergics more than 
younger patients despite the fact that they are more sensitive to the 
effects of these drugs [43, 49, 61]. Age-related changes in pharmacoki-
netics lead a changed permeability of the blood-brain-barrier, and a de-
creased clearance, resulting in a higher serum and brain concentration 
[49, 246, 318, 319]. Moreover, changes in pharmacodynamics may further 
augment the risk of adverse events, as the cholinergic activity is reduced 
because of a decrease in the number and binding affinity of receptors, 
homeostatic mechanisms tend to fail, and signal transduction is dimin-
ished [320–326]. Additionally, older adults often have multimorbidity [49, 
246, 318, 319], resulting in concurrent use of multiple drugs (i.e. polyp-
harmacy) [49, 50, 61, 246], of which a number might produce anticholin-
ergic effects. 
Turheim stated that designing a general formula for dose adjustment 
in older adults is almost impossible [320–322], because of the additional 
complexity of interpersonal variation, and increasing prevalence of re-
nal and hepatic failure. Nevertheless, a number of tools have been de-
veloped to assess the intensity of the exposure to anticholinergic drugs, 
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and to estimate and manage the risk of anticholinergic adverse events 
in older adults. On the one hand, one of these tools is the determination 
of serum anticholinergic activity (SAA), in serum samples of individual 
patients [43, 61]. However, this is a time-consuming, invasive, expensive 
method, making it a less ideal method for clinical applications [43, 61]. 
On the other hand, Anticholinergic Risk Scales (ARS) identify anticholin-
ergics and quantify the exposure by categorising them on potency [41, 
210, 215–223]. Evidence suggest that higher potency scores can lead to 
an impaired cognitive and physical functioning [217, 319, 327] and an 
increased risk of falling, leading to increased hospitalisation or mortality 
rates [48, 328, 329]. A limitation to these ARS, is the variation in the num-
ber of included drugs (sometimes because of differences in availability of 
anticholinergics in the countries where the scales were developed) and 
the accuracy of determination of anticholinergic properties. Moreover, 
the daily dosage is generally not taken into account [215]. The anticholin-
ergic exposure cannot be thoroughly evaluated without precise dosage 
information [51].
In an attempt to simplify and standardise the evaluation of intrinsic 
potency, and to avoid inconsistencies in assigning drugs with anticho-
linergic properties, two systematic reviews were recently published [215, 
330]. These reviews combine active substances with anticholinergic ac-
tivity in an international standardised list, based on the integration of 
the results of previous developed ARSs. However, Salahudeen et al. lists 
all anticholinergics from the ARSs, without transparent enumeration on 
the level of evidence of the anticholinergic properties [330]. Both reviews 
categorised the intrinsic potency of each anticholinergic on the list into 
categories (Salahudeen in a 4-point scale, and Durán in a 3-point scale). 
The authors of both systematic reviews both refrained explicitly from ad-
dressing the issue of dosage in their publications. 
Until now, there is no method that combines both potency and the 
whole spectrum of dosage information of anticholinergic drugs, adapted 
for use in older adults (65 years, and older). This study therefore aims (1) 
to delineate the daily dosage spectrum, by setting four dosage ranges 
(low, moderate, high and very high) for active substances with anticho-
linergic properties identified in Durán’s list (2); to create a novel scale, 
the Muscarinic Acetylcholinergic Receptor ANTagonist Exposure scale 
(MARANTE), by choosing cut-off values for the dosage ranges of each 
anticholinergic drug, and (3) to construct and test clinimetric properties 
[331] and the distribution of scores on the MARANTE scale in two cohorts 
of older patients in Belgium (one cohort of community-dwelling oldest 
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old (aged 80 years or more) [283] and one cohort of nursing home resi-
dents [332]. 
7.3 Methods
Delineating the dosage spectrum of anticholinergics
The MARANTE scale is based on the anticholinergic potency of drugs, 
and on the daily dosage patients take of a drug. The daily dosage is the 
summation of all doses during the interval of a day, and a dose is the 
amount taken at one administration moment (expressed in mg). To or-
ganise our search for information for dosage instructions, we determined 
dosage concepts for younger adults (18 to 65 years), and for older adults 
(65 years and older). For means of this study, only the dosage concepts of 
older adults (indicated with the term ‘geriatric’) will be given in the results 
section, but we will give a comparison on the availability of data between 
younger and older adults. 
 The (Geriatric) Minimal Effective Dose: (G)MinEV
 The (Geriatric) Maintenance Dose: (G)MainD 
 the (Geriatric) Maximal Effective Dose: (G)MaxEV
When collecting dosage information, it was expected to find multi-
ple values for the same concept. For the (G)MinEV and (G)MainD, when 
sources contradict each other, a range was used (indicated by a lower 
and upper limit, or the lowest and highest value found for that concept 
respectively), or either a pin-point value. For the (G)MaxEV, a pin-point 
value was given, since little variation was expected.
The values of the three dose concepts determined four dose ranges: 
low, moderate, high, and very high. For use in the calculation of the MA-
RANTE scale, the lowest dose (e.g. the lower limit in the range mentioned) 
was used to indicate the cut-offs. The dosage concepts, and the dosage 
ranges are graphically presented in Figure 7.1. 
 Low: Higher than zero (0 mg) and less than the (G)MinEV;
 Moderate: Equal or higher than the (G)MinEV, but lower than the (G)
MainD 
 High: Equal or higher than the (G)MainD, but lower than the (G)MaxEV
 Very high: Equal or higher than the (G)MaxEV.
We limited our ambition to find dosage ranges for the subset of all ac-
tive substances with anticholinergic properties, defined in the systematic 
review of Durán et al. [333], and all anticholinergics that were observed 
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in the medication lists of two Belgian cohorts of older adults. All informa-
tion was collected for use of the daily dosage (meaning irrespective of 
the number of administration moments in one day).
To define dosage ranges for all selected active substances, informa-
tion on the dosage concepts was collected in three rounds from authora-
tive sources. All steps of data gathering were collected and documented 
in a transparent way. 
 In a first round, we collected dosage information for the main indi-
cation only from international reference sources. To determine the main 
indication, we consulted the World Health Organisation (WHO) Collabo-
rating Centre for Drug Statistics Methodology (http://www.whocc.no/atc_
ddd_index/). As international reference sources, we used the Drug Bank 
(www.drugbank.ca), Micromedex (http://www.micromedexsolutions.com/ 
); the Dutch website of Farmacotherapeutisch Kompas (FK; http://www.
farmacotherapeutischkompas.nl/), the Belgian drug reference book BCFI 
(http://www.bcfi.be/), and the British handbook Martindale [334].
In case the information in these reference sources was insufficient or 
inconsistent, in the second round we retrieved new information from the 
European Public Assessment Report (EPAR) and the Summary of Product 
Characteristics (SmPC) [335]. 
When neither of these documents contained decisive information, we 
consulted in a third round the Geriatric Formulary from the Dutch Exper-
tise Centre of Pharmacotherapy in Old Persons, Utrecht University (NL) 
(http://www.ephor.nl/eng) [336]. 
We organised an expert panel to discuss the remaining missing in-
formation and discrepancies. Six experts (a neurologist, a psychiatrist, an 
old age psychiatrist, a geriatrician/clinical pharmacologist, and two gen-
eral practitioners/clinical pharmacologists) were invited based on their 
expertise and experience on drug use in older patients. Prior to this ex-
F igure 7.1. Graphical representation of the dosage concepts, and 
the dosage ranges used in the calculation of the MARANTE scale.
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pert panel, the experts had to fill in all remaining gaps in dosage values 
based on their experience. During the expert panel, the experts cleared 
any discrepancies (overlapping dosage ranges, or non-specific recom-
mendations for dosage adjustments) through consensus. Finally, the 
experts also critically reviewed and controlled the remaining dosages of 
the remaining active substances in older adults for which data was avail-
able in the literature, to ensure uniformity. If no concrete dosage adjust-
ment could be proposed for older adults, it was decided to take half of 
the dosage of younger adults. In the light of changed pharmacokinetics 
and pharmacodynamics in the body of an older person (e.g. a decreased 
renal function), or from their own clinical experience, experts could pro-
pose additional dosage adjustments which were discussed in the panel. 
Creating the MARANTE scale
The MARANTE scale is intended to provide a clinical estimate of the 
exposure of an individual patient to anticholinergics. In later stages, it is 
intended to be used in the automated analysis of medication lists of older 
adults to create alerts for the drug prescribers.
Prerequisites are the correct identification of anticholinergics, the cor-
rect classification of their potency, as proposed by Durán et al. (2013), 
and the observation of the daily dosage, to determine its place in the 
four dosage ranges, as described above and illustrated in Figure 7.1. For 
each anticholinergic drug identified on a medication list, an anticholin-
ergic load will be calculated by multiplying the potency value with the 
dosage range value. 
The anticholinergic loads of all the anticholinergics on the medication 
list (with  indicating the number of drugs) are then summated to a score 
on the MARANTE scale, reflecting the intensity of exposure to all anticho-
linergics on the drug list, and thus deemed to be indicative of the risk of 
anticholinergic adverse events. 
MARANTE= (p x d )n n
n
1  n
The two categories of potency, as proposed by Durán et al. (2013) are 
low and high potency. We empirically checked the value sets of {1,2} and 
{1,3}. To quantify the dosage ranges (low to very high), we empirically 
checked approaches {0.5, 1, 1.5, 2}, {1,2, 3, 4}, and {1, 2, 4, 8}.
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Exploring the clinimetric properties of the MARANTE scale 
We explored the prevalence of anticholinergic drugs, and the distri-
bution of the MARANTE scale in two cohorts of older patients in Belgium, 
either community-dwelling (Belfrail-MED cohort) or nursing home resi-
dents (Ageing@NH cohort). The cohorts were selected because of avail-
ability of data, and the expected high prevalence of anticholinergic users. 
The mean age of the Belfrail-MED cohort was 84.4 years [283]. Further-
more, the majority of the population was female (61.2%) and used more 
than five drugs daily (57.7%). The study protocol for the BELFRAIL cohort 
was approved by the Biomedical Ethics Committee of the Medical School 
of the Université Catholique de Louvain (UCL), Brussels (B40320084685, 
on 27/10/2008) and later by the Ethics committee of Ghent University 
Hospital (B670201421408, on 26/06/2014). The secondary use of the 
dataset of this protocol was covered by this approval.
The second cohort used was a cohort of nursing home residents, de-
rived from the Ageing at a Nursing Home (Ageing@NH) cohort, a longi-
tudinal study of newly-admitted nursing home residents. The selection 
of residents was done between September and December 2013, and 
the cohort was followed for 2 years. At baseline, their mean age was 84.2 
years and 65.4% was female. For means of this study, the medication data 
of the surviving residents during the second follow-up year was used 
(n=755). The study protocol for the ageing@NH cohort was approved by 
the ethics committee of the Antwerp University Hospital Belgium (EC-
number 13/43/420)[332].
Clinimetric evaluation
We studied the clinimetric properties of the MARANTE scale by exam-
ining the histograms and skewness of the distribution of scores on the 
MARANTE scale (using The Kolmogorov-Smirnov test (K-S)). We examined 
different values sets for potency and dosage ranges For potency either {1 
or 2} and {1,2 or 3}. For dosage ranges either {0.5, 1, 1.5 or 2}, and {1,2, 3, 
4} or {1, 2, 4, 8}. Selection was based on the analysis of the histograms of 
scoring results in two large cohorts (see earlier). Value sets leading to dis-
tributions, with empty values, overly broad or multimodal distributions 
were not selected. 




Description of the selected anticholinergics 
Of the 100 active substances of the systematic review of Durán et al 
(2013), 71 were available on the medication markets in Belgium (n=63) 
and the Netherlands (n=64). 
Of the 71 active substances available in Belgium and the Netherlands, 
41 were actively prescribed in the two cohorts used. Some of these active 
substances were available in different routes of administration (e.g. aero-
sol therapy or nebulation in ipratropium), or in combination with other 
active substances (e.g. fixed dose combinations including codeine), or 
as a purified enantiomer of an active substance in Durán’s list (e.g. cit-
alopram and the S-enantiomer escitalopram). Of the 41 substances, 25 
(61 %) were classified as low potency and 16 (39%) were high potency 
anticholinergics. The main indications for which these formulations with 
anticholinergic properties were used included depression (18.8%, pre-
dominantly citalopram, escitalopram, amitriptyline, nortriptyline), pain 
(17.4%, predominantly fentanyl, tramadol, morphine), and obstructive 
airway diseases (15.9%, predominantly ipratropium, and theophylline). 
Results from the dosage information collection
After the first round of the dosage information collection, only 3 ac-
tive substances out of Durán’s list could be matched with all dosage ref-
erence points. For the others, precise values for these concepts were not 
available, and recommendations for dosage adjustments in older adults 
were absent or unspecific. 
After the second and third round, 6 more active substances had all 
dosage reference points filled in. This means that the remaining 32 ac-
tive substances had incomplete data for one or more dosage ranges. For 
the adults concepts, we missed values for 17% of the concepts, and for 
older adults, we missed 55%. These gaps were than discussed in the ex-
pert panel. 
After the expert panel, all drugs were matched with all dosage ref-
erence values. Also, all overlaps in dosages were clarified. Only for cit-
alopram, there was overlap between the ranges of the minimal effective 
dose and the maintenance dose. These ranges were concatenated and 
given the value of “low”. Other adaptations were proposed in the dos-
age ranges for older adults for drugs cleared by the kidney (e.g. cimeti-
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dine, tolterodine, …), where the dose ranges were lowered beyond the 
doses retrieved from the authorative sources. For 11drugs (e.g. triazolam, 
levomepromazine) the dosages of the geriatric minimal effective value 
were lowered, because the experts felt that the dosages retrieved from 
authorative sources were still too high, based on their clinical experience 
with older adults. 
The experts indicated that their decisions were made for use in the 
context of common clinical practice, but not of palliative care, since 
the focus of care is different. For this reason, they made suggestions for 
oxycodone to lower the dosages. For fentanyl, they suggested to only 
include the parenteral forms into the scoring for the anticholinergic ex-
posure, as the intramuscular injection or intravenous solution are more 
used in anaesthesia or palliative care. The changes made by the experts 
are listed in Appendix 1. 
The basic data for defining the dosage ranges for each of the identi-





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Example: Patient (82 years) takes on a daily basis Amitriptyline 25 mg for the treatment
of neuropathic pain, and Trihexyphenidyl 5 mg for the treatment of Parkinson’s disease.
Amitriptyline
Potency: Amitriptyline is classified as a high potency anticholinergic.
This would receive a potency score of 2.
Dosing: 25mg falls in the moderate category: equal or higher than the GMinEV.
This dosage would receive a scoring of 1.
The anticholinergic load for Amitriptyline 25 mg: 2 x 1 = 2
Trihexyphenidyl
Potency: Trihexyphenidyl is classified as a high potency anticholinergic.
This would receive a potency score of 2.
Dosing: 5mg falls in the high category: equal or higher than the GMainD.
This dosage would receive a scoring of 1,5.
The anticholinergic load for trihexyphenidyl 5 mg: 2 x 1.5 = 3
MARANTE scale: The finale score on the MARANTE scale equals the sum of all individual
anticholinergic loads: 2 + 3 = 5.
Figure 7.2. Example of the calculation of scores on the MARANTE scale.
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Figure 7.3. Histograms of the distribution of the scores on the MARANTE scale in the 
Belfrail-MED cohort (n=503) and the Ageing@NH cohort (n=755). Only those taking 




Histograms were used to demonstrate the clinimetric properties of 
several approximations for the calculations of the MARANTE scale, exam-
ining different values for both potency (either {1,2} and {1,3}), and dosage 
ranges (either {0.5, 1, 1.5, 2}, {1,2, 3, 4}, or {1, 2, 4, 8}). All models resulted 
in a positively skewed distribution of the scores on the MARANTE scale in 
both cohorts (with Kolmogorov-Smirnov test at the p<0.001 level, except 
for the combination of the {1,2} and {1,2, 3, 4} value set). 
The potency value set {1,3} was disregarded, as this approach yielded 
empty cells, and a multimodal histogram. 
The dosage value set {1, 2, 4, 8} created a multimodal histogram as 
well, with a broad dispersion of scores in both cohorts. In addition, it 
overemphasises the weight of the dosage versus potency. Therefore, this 
value set was disregarded. 
Finally, we selected the {0.5, 1, 1.5, 2} over the {1,2, 3, 4} dosage value 
set, as we wanted to treat the potency and the dosage value equipotent. 
So, for the calculation of the scores on the MARANTE scale, we decided 
to use the {1,2} value set for potency, and the {0.5, 1, 1.5, 2} value set for 
dosage. 
In the Belfrail-MED cohort, we observed a prevalence of 31.8 % users 
of anticholinergics with a median score of 1.5 (IQR 1.5 – 2.5, range 0 - 7). 
In the Ageing@NH cohort, the prevalence of anticholinergic users was 
higher: 63.5% users of anticholinergics with a median score of 2 (IQR 1.5 
– 3.5, range 0 – 10.5), probably due to a higher intake of drugs and more 
specifically of psychotropic drugs. The final histograms for both cohorts 
are presented in Figure 7.3. An example of the calculation of scores on the 
MARANTE scale is given in Figure 7.2.
7.5 Discussion
Main findings
In the present study, we developed a score to quantify the anticholin-
ergic exposure in individual patients. This MARANTE scale is designed for 
older adults (aged 65 years, and over), and combines both potency and 
the full spectrum of dosage ranges of anticholinergic drugs. It provides 
an instrument for large scale surveillance of the risk of exposure to the 
class of anticholinergics, which are widely used by older adults and are 
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known to cause a high risk of adverse events [48, 337]. 
The search for detailed dosage information proved to be a laborious 
task, with only limited information available on dose adaptations in older 
adults. The sources were often non-specific, inconclusive, and without 
specific recommendations for dosage adjustments in the older adults. 
Strengths & limitations
Strengths of the MARANTE scale are the introduction of four dosage 
ranges, based on 3 cut-off points, which lowers the chance of over- or un-
derestimation of the true anticholinergic exposure. Furthermore, dosage 
information for almost half of the currently used anticholinergic drugs 
was completed. 
We only completed the dosage information for a pragmatic sample 
of 41 active substances (out of the 100 anticholinergics, currently used 
internationally) which might be seen as a limitation. However, this work 
needs to be completed for all the 100 anticholinergic drugs identified on 
the list of Durán et al. (2013) and for any newly developed active sub-
stance with anticholinergic properties. In this endeavour, we strive to col-
lect dosage values for all remaining active substances in the following 
year. Next, we would like to invite the scientific community with an inter-
est in anticholinergics, to review our findings, in order to fine-tune the 
MARANTE scale. For this, we have created an online collaboration plat-
form (found at: https://secureramit.ugent.be/marante/ ). 
The starting point of this article was the systematic review of Anticho-
linergic Risk Scales, performed by Durán et al. (2013) [215]. The Durán’s 
list may not have included active substances with anticholinergic proper-
ties, currently prescribed in significant numbers in some countries [338], 
or active substances recently brought onto the market. Therefore, it is 
advisable that the list will be reviewed with regard to systemic anticho-
linergic effects and usage/ registration throughout the world. In addition, 
one may critique the simplified classification into low and high potency. 
Variable inter-individual effect of anticholinergics might be another 
difficulty [320–322]. This is not taken into account, as the MARANTE scale 
is designed for application in larger samples. Review at patient level must 
be done with caution, since individual variability in both pharmacokinet-
ics and pharmacodynamics is quite possible. The MARANTE scale is an 
approximation of the degree of exposure to anticholinergic drugs, and 
not an approximation of the patient’s body to the drugs.
Lastly, although the expert panel cleared out many inconsistencies 
and gaps, further evidence is needed for the confirmation of the dosage 
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ranges of the reviewed drugs. 
Comparison with other studies
Only Carnahan et al (2006) and the Drug Burden Index [319] incorpo-
rated the dosage of drugs into the quantification of the anticholinergic 
burden. Yet, Carnahan et al. (2006) uses only the maximal effective dos-
age as a reference point, possibly underestimating the true anticholin-
ergic burden [216]. In contrast, the Drug Burden Index standardises the 
actual daily dose of each drug for this minimal effective value [319], po-
tentially overestimating the true anticholinergic burden.
Additionally, the Drug Burden Index also includes drugs with dubious 
anticholinergic properties, treats all drugs as equipotent, and uses dos-
age reference points that were set for dosages in young adults [43]. 
Implications for further research
In a next step, the clinical implications of the MARANTE scale need 
to be investigated. Anticholinergics have been considered as potentially 
inappropriate [187, 207], and are widely regarded as to be used with cau-
tion in older persons. The relationship of anticholinergic exposure (either 
solely based on the potency of medications, or in combination with one 
dosage reference point) remain inconclusive, given different designs and 
Anticholinergic Risk Scales used [54, 329, 339–341]. We will investigate 
the clinical relevance of the MARANTE scale, by searching for associations 
with mortality and hospitalisation in the Belfrail-MED cohort. 
Clinical studies are needed to test the association between the MA-
RANTE scale as a measure of anticholinergic exposure, and the observed 
intensity of anticholinergic burden, that might affect the quality of life in 
older patients. In explorative observational studies of the association be-
tween anticholinergic exposure and hard outcomes (e.g. hospitalisation, 
mortality), the impact of the added precision and power of the MARANTE 
scale can be explored [342]. Additionally, it is important to replicate this 
present study and all above suggested studies in a population of younger 
adults. 
Implications for practice
By combining both potency and dosage information to calculate ex-
posure, an extra dimension was created. This novel MARANTE scale can 
aid practicing physicians in prescribing and reviewing patient’s drug lists, 
by implementation in medical software. The overview of all dosage ad-
justments in older patients can serve as a reference documents for pre-
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scribing in older adults. Also, prescribers can have better judgements of a 
patient’s exposure for possible anticholinergic exposure, to evaluate the 
patient’s response to anticholinergics.
To help prescribers, drug reference book committees, regulatory 
agencies, as well as the pharmaceutical industry should actively ex-
change knowledge on dose adjustments for older adults, to assure safer 
prescribing. 
Automated tools, based on the MARANTE scale could facilitate early 
recognition and monitoring of anticholinergic burden, and make more 
feasible the application of explicit criteria of inappropriate prescribing, 
as mentioned in STOPP-START, the Beers List, the EU(7)-PIM list [180, 187, 
207].
International cooperation is needed to constantly evaluate, adapt and 
update the basic information behind a tool, such as the MARANTE scale. 
Transparent management of modifications, trough interactive web-
based involvement of the global scientific community, could guaranty 
both editorial independence, and state-of-the-art quality of information. 
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8.1 Abstract
Background: Anticholinergics are frequently prescribed in older adults, and 
can lead to adverse drug events. The novel MARANTE (Muscarinic Acetyl-
cholinergic Receptor ANTagonist Exposure) scale measures the anticho-
linergic exposure by incorporating potency and dosages of each medica-
tion into its calculations. 
Aims: To assess prevalence and intensity of the anticholinergic exposure in a 
longitudinal cohort study of community-dwelling patients aged 80, and 
over (n=503), and to study the impact on mortality and hospitalisation.
Methods: Chronic medication use at baseline (November 2008 - Septem-
ber 2009) was entered and codified with the Anatomical Therapeutic 
Chemical classification. Time-to-event analysis until first hospitalisation 
or death was performed at 18 months after inclusion, using Kaplan-Meier 
curves. Cox regression was performed to control for covariates.
Results: Mean age was 84 years (range 80 – 102), and mean number of 
medications was 5 (range 0 – 16). Prevalence of anticholinergic use was 
31.8%; with 9% taking ≥2 anticholinergics (range 0 – 4). Main indications 
for anticholinergics were depression, pain & gastric dysfunction. Female 
gender, the level of multimorbidity, and the number of medications were 
associated with anticholinergic use.
Mortality and hospitalisation rate were 8.9%, and 31.0% respectively. 
After adjustment for the level of multimorbidity and medication intake, 
multivariable analysis showed increased risks for mortality (HR 2.3, 95%CI 
1.07 – 4.78) and hospitalisation (HR 1.7; 95%CI 1.13 – 2.59) in those with 
high anticholinergic exposure.
Conclusion: The longitudinal study among Belgian community-dwelling 
oldest old demonstrated great anticholinergic exposure, which was as-





Medications with anticholinergic properties (anticholinergics)block 
the effect of acetylcholine on the muscarinic and nicotinergic recep-
tors in central or peripheral organ systems, inhibiting the acetylcholine-
mediated response [42, 43, 46, 47, 61, 315]. Anticholinergics are widely 
prescribed in older patients [43, 49, 61] for several indications (including 
depression, psychosis, allergy, …). Often prescribers don’t perceive the 
prescribed drug as an anticholinergic [343].
On top of the higher level of comorbidities and the higher overall 
medication intake, older persons become more sensitive to the side-ef-
fects of anticholinergics due to a decreased elimination of medications, 
as well as an increased permeability of the blood-brain barrier [49, 246, 
318, 319]. Inhibition of acetylcholinergic mediated muscle contraction 
can lead to peripheral side effects, which include blurred vision, urine 
retention, or constipation. Competitive binding to muscarinic brain re-
ceptors can lead to central nervous symptoms, which include dizziness, 
hallucinations, or confusion. These side effects can again in the long term 
lead to the appearance of delirium [276], impaired cognitive function[59], 
an increased number of falls[344] and hospital readmission risk [345]. Us-
age of anticholinergics has been linked to an increased risk for mortality 
and hospitalisation [329, 346].
Only scoring the anticholinergic potency of medications to quan-
tify the anticholinergic exposure is deemed too simplistic, as it should 
also incorporate the dose-relationship [339]. In the past decades, sev-
eral Anticholinergic Risk Scales (ARS) have been created to measure the 
anticholinergic burden in older patients. All these tools list medications 
with anticholinergic properties and quantify the intrinsic burden of each 
medication[41, 209, 216, 218–221], but there is a significant variation on 
included drugs[215]. Dosage is only taken into account in two of them. 
The ARS by Carnahan et al. uses the maximal effective dosage, and it does 
not take dosage adjustments for older persons into account [216]. The 
Drug Burden Index (DBI) calculates the anticholinergic burden using only 
the minimal effective value of medications. However, the anticholinergic 
nature of the medications listed in the DBI is unclear[43]; the DBI does 
not incorporate the anticholinergic potency of medications, and finally 
the minimal effective value of medications was determined for a younger 
population. 
Results from studies using one dosage reference point did not vali-
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date whether a higher anticholinergic exposure is related to mortality 
or hospitalisation, neither in the short nor the long term [341, 344, 347, 
348]. Therefore, this study aims (1) to determine accurately the point-
prevalence and the intensity of the anticholinergic exposure using the 
Muscarinic Acetylcholinergic Receptor ANTagonist Exposure through the 
MARANTE scale in a prospective cohort of oldest old primary care pa-
tients (aged 80, and over), and (2) to investigate associations with mortal-
ity and first hospitalisation during an observation period of 18 months.
8.3 Methods
Sample 
We used the Belfrail-MED cohort [252, 283] of 503 Belgian commu-
nity-dwelling primary care patients aged 80, and over. All subjects were 
recruited by their own general practitioner between November 2008 and 
September 2009. Exclusion criteria were known dementia, and being 
treated in palliative care.
Data collection 
Baseline data included personal, clinical, functional, and medication 
data, and was collected by trained investigators and general practition-
ers (GPs). The trained investigators conducted structured questionnaires, 
and standardised tests to collect personal (age, gender, living situation, 
…) and functional data (physical activity, activities of daily living, and cog-
nitive impairment). GPs did clinical examinations, and used their medical 
records, to collect medication information and clinical data (current and 
past clinical problems, in order to assess the level of multimorbidity). For 
a full background on the data collection, and construction of the level of 
multimorbidity (Cumulative Illness Rating Scale, CIRS), see previous pub-
lications [14, 238].
The GPs recorded all chronic medications at baseline. Chronic medi-
cations were defined as entries on the medication list without a stop 
date. All chronic medications with systemic effect were codified into the 
Anatomical Therapeutic Chemical classification (WHO ATC/DDD 2013) 
[284], based on the official register of medications on the Belgian market. 
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Clinical and functional data handling
For a full background on the clinical and functional data handling, we 
refer to the original Belfrail-MED article [252, 283]. 
To measure the level of multimorbidity the Cumulative Illness Rating 
Scale (CIRS) was used [253]. The CIRS measures the chronic medical ill-
ness burden while taking into consideration the severity of chronic dis-
eases [254]. For the construction of the CIRS, all current and past medical 
problems were used. Out of 14 body systems, every body system affected 
with severe disease was counted, to a possible range of 14 [14, 254]. 
To measure the physical activity, the LASA Physical Activity Question-
naire (LAPAQ) was used [256]. For our calculations, we divided the raw 
LAPAQ scores (range 0 - ∞) into quartiles, to identify the lowest scoring 
quartile as those with the lowest physical activity . 
Activities of Daily Living (ADL) were derived from the KATZ scale, 
which measures the care dependency in six domains: bathing, clothing, 
toileting, transferring, continence, and feeding [255]. For our calculations, 
we divided the raw KATZ ADL scores (range 6 – 30), to identify those most 
care dependent (scoring 13 and more).
To identify cognitive impairment, we relied on the Mini-Mental State 
Examination (MMSE) [258]. A cut-off adapted to the age and level of ed-
ucation of the respondents was used to identify cognitive impairment 
[259]. 
Assessing anticholinergic exposure
To evaluate anticholinergic exposure, we used the MARANTE scale, 
based on the systematic review by Durán et al. (2013)[349] and a meth-
odological study by Klamer & Wauters [350]. Duran listed 100 active sub-
stances with anticholinergic properties originating from 7 anticholinergic 
risk scales (ARSs), and categorised them according to their anticholiner-
gic potency (low or high) [349]. In Klamer & Wauters’ study, for 41 active 
substances (increasing to 69 when counting variations of routes of ad-
ministration, pharmaceutical forms, or combination products) 3 dosage 
reference values were identified. All reference values were based on in-
formation from authorative sources, and then validated and completed 
by an expert panel. 
Calculating the anticholinergic exposure
The MARANTE scale is the summation of all anticholinergic loads in 
a patient’s medication list. The anticholinergic load is calculated by mul-
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tiplying the values of potency and daily dosage of each medication. Pa-
tients not taking anticholinergics receive a score of 0. A complete over-
view of the calculation of the score on the MARANTE scale is given in Box 
8.1.
Potency
For potency, we used the distinction between a low and high anticho-
linergic potency as suggested in Duran’s list and the Klamer & Wauters 
study [350], with a value of 1 for low potency, and 2 for high potency 
anticholinergics.
Box 8.1. Schematic overview of the construction of the MARANTE Scale.
1. Anticholinergic dosage terms and value scoring (per medication)
2. Anticholinergic load for one medication
potency × dosage score = (p × d)
3. Value scoring of the MARANTE scale 
Sum of all anticholinergic loads for n medications
Box legend: LL: Lower limit UL: Upper Limit. GMinV: Minimal geriatric effective value. GMainD: Maintenance geriatric 
dosage. GMaxEV: Maximal effective geriatric dosing. 
Dosage
For dosage, we determined the daily dosage per anticholinergic from 
the posology instructions in the medication list. The daily dosage equals 
the sum quantities of all doses given to a patient of a specific medication 
during the course of 1 day. 
This daily dosage is compared to the reference values (set in Kram-
er & Wauters et al., 2016), and based on the pharmacological concepts: 
minimal geriatric effective value (GMinEV), maintenance geriatric dosage 
(GMainD), and maximum geriatric effective value (GMaxEV). These refer-
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ence points permit to accord values for very low, low, high and very high 
daily dosage ranges. 
•  A dosage higher than 0mg, and below GMinEV received a dosage 
score of 0.5. 
•  A dosage equal/higher than GMinEV and below the maintenance 
geriatric dosage (GMainD) was scored 1. 
•  Equal/above GMainD and below the maximal effective geriatric dos-
ing (GMaxEV) was scored 1.5,
•  All dosages equal/above GMaxEV received a dosage score 2. 
Follow-up data
Follow-up data included data on mortality (date and cause of death), 
and hospitalisation (date of the first hospitalisation ) during an observa-
tion period of 18 months. . A hospitalisation was defined as an unplanned 
hospital stay, lasting longer than one day. Index date was the date of 
baseline assessment.
Statistical analysis
All statistical analyses were done using SPSS 21.0 (Statistical Package 
for Social Sciences, SPSS Inc., Chicago, IL, USA). For all variables, there was 
less than 5% missing data [252]. 
Descriptive statistics include means, and standard deviations or range 
for normally distributed data, and medians with interquartile range for 
skewed data. Categorical data was expressed using numbers and per-
centages. 
After calculation of all the scores of the MARANTE scale, the results 
were categorised in low and high anticholinergic exposure, based on the 
median of the distribution (lower to, and above of the median). For each 
patient, we also calculated separately the sum of the values for potency, 
and the sum of values for the dosage, to explore the impact of the two 
elements of the MARANTE scale. 
Time-to-event analysis was estimated using the Kaplan-Meier meth-
od, with the log-rank test verifying differences in time-to-event between 
groups (no vs low, low vs high, and no vs high anticholinergic exposure). 
A follow-up period of 18 months after inclusion was used to observe 
direct associations of mortality and unplanned hospitalisation with the 
baseline anticholinergic exposure of patients. Death or unplanned first 
hospitalisation were considered as events. For hospitalisation, additional 
censoring was applied for patients who died. All relations between an-
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ticholinergic exposure and outcomes were based on the baseline medi-
cation intake without proof of a continuous (chronic) anticholinergic in-
take throughout the study period. 
Univariable and multivariable analyses were done to calculate Haz-
ard Ratios for the associations with mortality and hospitalisation. The 
MARANTE scale was used in univariable and multivariable analysis as a 
continuous variable, but also as categorical variable. Categories dividing 
no, low, and high exposure were formed based on the distribution of the 
scores on the MARANTE scale. Categorical analysis was performed to ob-
serve trends in associations between anticholinergic exposure and out-
comes. In the multivariable analysis, we corrected the associations with 
outcomes, for the number of medications taken at baseline, and with the 
level of multimorbidity. The level of multimorbidity (CIRS, as a continuous 
variable) was chosen, because of the dominating association over other 
patient characteristics (for more background, see the original Belfrail-
MED paper [283])
 Ethical approval
The study protocol was approved by the Biomedical Ethics Commit-
tee of the Medical School of the Université catholique de Louvain (UCL), 
Brussels (B40320084685, on 27/10/2008) and later by the Ethics commit-
tee of Ghent University Hospital (B670201421408, on 26/06/2014). All 
participants provided informed consent.
8.4 Results
Description of the population 
The mean age of patients in the Belfrail-MED cohort (n=503) was 84.4 
years (range 80 - 102). The majority was female (61%), and had a low level 
of education (≤ 8 years, 69%). 
The median level of multimorbidity, expressed by the CIRS, was 4 
(range 1 - 9). The most common clinical problems were hypertension 
(70.4%), osteoarthritis (57.1%), hyperlipidaemia (44.1%), and heart failure 
(38.4%)
The mean number of chronic medications prescribed was 5.4 (range 
0 – 16). Prescribing of 5 or more medications was present in 57.7%, and in 
0.8% there was no chronic medication use. Predominant main anatomi-
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Table 8.1. Personal, clinical, and functional characteristics, and the general 
medication use of the study population (n=503).
Personal %
Mean age in years (range) 84.4 (80 - 102)
Gender (% female) 61.2
Low education (≤ 8 years) 69.2
Living alone 43.3
Clinical1




Heart Failure (NYHA²> 0) 38.4
Obesity (BMI > 30kg/m²) 27.9
Osteoporosis 20.9
Functional Median (IQR*)
Activities of daily living, ADL 6 (6 - 8)
Physical activity, LAPAQ 70 (30 – 102)
Mental status, MMSE 28 (26 – 29)
Medication use
Mean number of chronic medications 5.4 (range 0 – 16)
Patients with polypharmacy (5 or more) 57.7
Most prevalent prescribed medication subclasses (>15%)
Antithrombotic agents 54.5
Beta blocking agents 41.9
Medications acting on RAAS 41.9
Benzodiazepines and Z-drugs 35.6
Lipid modifying medications 33.2
Diuretics 32.0
Drugs for acid related disorders 24.5
Calcium channel blockers 24.3




Medications used in diabetes 15.9
1Clinical problems with prevalence above 20% are listed.
²New York Heart Association (NYHA) functional classification of heart failure
*IQR: Inter quartile range
Associations of the anticholinergic exposure with mortality and hospitalisation
137
cal medication classes (1st ATC level) were cardiovascular medications 
(in 86.3% of the population), followed by blood regulating medications 
(56.1%), and nervous system medications (54.5%). The most prescribed 
therapeutic subgroup (2nd ATC level) were antithrombotic medications 
(54.5%). All personal and clinical characteristics, as well as the description 
of the general medication use of the study population are given in Table 
8.1. 
Description of the anticholinergic use
In this population of community-dwelling oldest old, 68.2% had no 
medications with anticholinergic properties prescribed on a chronic ba-
sis; 23% were taking 1 anticholinergic; 7.0% 2; , 1.2% 3, and 0.6% taking 
4 anticholinergics. 
In total, 217 prescriptions of medication with anticholinergic proper-
ties were identified. Most often these anticholinergic prescriptions were 
of low potency (80.0%). The dosages in which anticholinergics were pre-
scribed were rarely considered too low (1.8% below GMinEV), yet often 
high (51.5% above GMainD) or very high (17.1%, above GMaxEV). 
Medications with anticholinergic effects (n=217) were predominant-
ly ATC N (nervous system medications) for the treatment of depression 
(35.0%, predominantly escitalopram, trazodone, and citalopram), or for 
pain (18.4%, predominantly tramadol). Other predominantly prescribed 
medications in ATC A (alimentary medications) were for the treatment of 
gastrointestinal disorders/peptic ulcers (20.7%; predominantly ranitidine 
and domperidon). Anticholinergics in ATC R (respiratory agents), were for 
treatment of asthma (8.8%), or ATC G (genito-urinary medications), for 
the treatment of urinary problems (5.5%). 
Description of the anticholinergic exposure
The scores on the MARANTE Scale ranged between 0 – 7. Based on the 
distribution of the MARANTE, two equal groups were created. One low 
exposure group (MARANTE 0.5 – 1.5, 16.1%), and a high exposure group 
(MARANTE ≥ 2, 15.7%). As a consequence, to be categorised into the high 
exposure group it would sufficient to take one high potency anticholin-
ergic at a low dose (above GMinEV), or a low potency at a very high dose 
(above GMaxEV). To be categorised into the low exposure group, a high 
potency could only be taken at the lowest dose (below GMinEV), or a low 
potency at a dose lower than the GMaxEV, or the combinations of maxi-
mum three low potency anticholinergics at the lowest doses. 
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Table 8.2. Description of anticholinergic use in the study population (n=503).
General description n=503 %
Anticholinergics use 31.8 % 
Range of number of Anticholinergics 0 – 4 
Range of potency scores 0 – 5
Range of dosage scores 0 – 6 
Range of scores on the MARANTE scale 0 – 7 
Details of anticholinergics n=217 %
Potency Low 80.0
 High 20.0
Dosage Below GMinEV (very low) 1.8
Above GMinEV (low) 30.0
 Above GMainD (high) 51.5
Above GMaxEV (very high) 17.1




R03AL01 Ipratropium bromide* (+ Fenoterol) 7.4
N06AX05 Trazodone 7.4
A03AF03 Domperidone 5.5






Anticholinergic Exposure (MARANTE) categories n=503 %
No 0 68.2
Low 0,5 – 1.5 16.1
High ≥ 2 15.7
Medications market with an * are high potency anticholinergics
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Table 8.3. Univariable analysis of personal, clinical, functional characteristics and medica-
tion use of the Belfrail-MED cohort (n=503) in relation to anticholinergic use.
 
 






Mean age (in years) 84.5 84.4 .718
Female gender 68.1 58.0 .030 1.55 (1.04 – 2.30)
Living alone 44.4 42.9 .749
Low education (≤8 years) 78.0 66.3 .008 1.80 (1.16 – 2.79)
Clinical 
Mean comorbidity, CIRS 4.2 3.6 <.001 1.28 (1.14 – 1.44)
Hypertension 65.0 73.1 .064
Osteoarthritis 69.6 52.8 <.001 2.05 (1.37 – 3.06)
Hyperlipidaemia 46.8 44.6 .639
Heart Failure 40.6 37.3 .477
Osteoporosis 32.4 18.9 .001 2.39 (1.52 – 3.75)
Obesity 30.4 27.8 .548
Diabetes 18.9 19.1 .959
Post myocardial infarction, post stroke 20.6 17.9 .472
COPD/Asthma 19.4 12.5 .045 1.68 (1.01 – 2.83)
Depression 26.6 6.5 <.001 5.22 (2.99 – 9.12)
Chronic renal failure 16.8 8.9 .011 2.06 (1.17 – 3.61
Functional 
Most care dependent (ADL) 1 6.3 10.7 .120
Most physical inactive (LAPAQ) 2 34.8 20.6 .001 2.05 (1.34 – 3.12)
Cognitive impairment (MMSE) 3 15.9 14.9 .774
Medication related
Number of medications (0 – 16) 7.2 4.6 <.001 1.39 (1.29 – 1.51)
Polypharmacy users 78.8 47.8 <.001 4.05 (2.62 – 4.24)
1 Highest care dependency was defined as respondents scoring ≥ 13 (9.1%) on the KATZ ADL scale.
2 Lowest physical active was defined as the quartile (25.2%) with the lowest raw score on the LAPAQ.
3 Cognitive impairment was defined using the MMSE, adjusted for age and level of education.
Only significant univariable odds ratios are shown.
Chapter 8
140
The description of the anticholinergic use is given in Table 8.2. 
Patient characteristics associated with anticholinergic use
All personal, clinical, functional, and medication characteristics asso-
ciated with the use of anticholinergics are presented in Table 8.3.
Personal factors associated with anticholinergic use were female gen-
der (OR 1.55, 95% CI 1.04 – 2.30) and low education (OR 1.80, 95% CI 1.16 
– 2.79). Age was not associated with anticholinergic use in this cohort of 
oldest old patients.
Clinical characteristics associated with anticholinergic use included 
the level of multimorbidity (OR 1.28, 95% CI 1.14 – 1.44), predominantly 
depression (OR 5.22, 95%CI 2.99 – 9.12). 
For the functional characteristics, physical inactivity (OR 2.05, 95% 
CI 1.34 – 3.12), but neither cognitive impairment nor care dependency, 
showed associations with anticholinergic use. Both the level of medica-
tion use (expressed as a continuous variable), and the dichotomous vari-
able of polypharmacy were strongly associated with anticholinergic use. 
Survival analysis of anticholinergic exposure on mortality 
and hospitalisation
The unadjusted survival analyses of different categories of anticholin-
ergic exposure on mortality and first hospitalisation are given in Graph 1.
The mortality rate after 18 months was 8.9% (n=45). Most com-
mon causes of death were cardiovascular and/or cerebrovascular re-
lated events (48.9% of deaths), cancer (20.0%),respiratory related events 
(13.3%), or general deterioration (6.7%). The survival rate was lower 
among those who had high anticholinergic exposure, as compared to 
those without. There was only a significant difference in survival per-
centage between those with no (93.3%)versus those with high (85.0%, 
p=0.001) anticholinergic exposure.
The Time-to-event analysis showed that the probabilities of having 
a hospitalisation (31%, n=156) varied among the categories of anticho-
linergic exposures. Those with high anticholinergic potency (45.7%) 
had a significantly lower hospitalisation rate than those with no (74.6%, 
p<0.001) and low anticholinergic exposure (68.2%, p=0.003). There was 
no difference in survival rates (p=0.626) in those with low and no anticho-
linergic exposure. 
Univariable analysis for the association of the MARANTE scale 
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with mortality and hospitalisation
All univariable associations with mortality, and first hospitalisation are 
given in Table 8.4. 
For mortality and for hospitalisation, the continuous variables for the 
number of anticholinergics, the potency score, the dosage score and the 
score on the MARANTE Sale, showed all significant increased risks. The 
Hazard Ratio for the MARANTE scale had a more narrow confidence inter-
val than the potency and dosage scores for both outcomes, potentially 
indicating a higher precision. For the low anticholinergic exposure cat-
egory, no significant increased risks were observed. 
Age, the level of multimorbidity (CIRS), and the number of medica-
tions were also associated with mortality and hospitalisation.
Those with a high anticholinergic exposure (MARANTE scale ≥2) had 
a 2.8 fold increased risk for mortality (HR 2.77, 95% CI 1.43 – 5.38) and 
a 2.4 fold increased risk for hospitalisation (HR 2.36, 95% CI 1.63 – 3.42) 
Table 8.4. Univariable analysis of the place of anticholinergic exposure and confounding 
variables in association with mortality and first hospitalisation.
Anticholinergic Exposure Mortality Hospitalisation
Continuous Range HR (95% CI) HR (95% CI)
Number of anticholinergics 0 – 4 1.40 (1.02 – 1.93) 1.39 (1.17 – 1.67)
Potency score 0 – 5 1.33 (1.04 – 1,70) 1.32 (1.15 – 1.52)
Dosage score 0 – 6 1.26 (1.01 – 1.58) 1.29 (1.14 – 1.45)
MARANTE scale 0 – 7 1.22 (1.02 – 1.47) 1.25 (1.13 – 1.38)
Categorical Cut-off N
Taking anticholinergics 160 2.13 (1.19 – 3.82) 1.69 (1.23 – 2.33)
MARANTE scale 0 343 Ref Ref 
Low (0.5 – 1.5) 81 1.52 (0.68 – 3.39) 1.14 (0.73 – 1.79)
High (≥ 2) 79 2.77 (1.43 – 5.38) 2.36 (1.63 – 3.42)
Confounding variables
Continuous Range
Number of medications 0 - 16 1.12 (1.02 – 1.22) 1.14 (1.08 – 1.20)
Age (years) 80 - 102 1.09 (1.01 – 1.16) 1.04 (0.998 – 1.08)
Categorical
Female gender 0.94 (.52 – 1.70) 0.89 (0.65 – 1.22)
Low education (≤8 years) 0.83 (.45 – 1.55) 1.03 (0.73 – 1.45)
Living alone 1.15 (.64 – 2.07) 1.06 (0.77 – 1.46)
Multimorbidity1 1.36 (1.15 – 1.59) 1.25 (1.14 – 1.36)
Polypharmacy 1.87 (0.98 – 3.56) 1.69 (1.21 – 2.36)
1 Multimorbidity was expressed using the CIRS.
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compared to those with no anticholinergic exposure. 
Multivariable associations with mortality, and first hospitalisation are 
given in Table 8.5. Two models are presented, the first was adjusted for 
the number of medications, and the second for both the number of med-
ications and for the level of multimorbidity. 
Associations between the number of anticholinergics, the potency 
score and dosage score disappeared in the multivariable analysis. 
The analysis based on the scores on the MARANTE scale did yield sta-
tistically significant and clinically relevant results. For both outcomes, the 
Hazard Ratio for the MARANTE scale (continuous variable) had more nar-
row confidence intervals than the potency and dosage scores, potentially 
indicating higher precision
In the multivariable analysis model, the anticholinergic exposure 
quantified by the MARANTE scale was categorised, and adjusted for con-
founding variables. Only significant associations were found for those 
with high anticholinergic exposure for both mortality (HR 2.20, 95% CI 
1.03 – 4.67) and for first unplanned hospitalisation (HR 1.71, 95% CI 1.13 
– 2.59). 
Table 8.5. Multivariable Cox regression analysis of mortality (8.9%) and hospitalisation 
(31%) in association with the anticholinergic exposure in a cohort of oldest old (n=503).
Range
Mortality Hospitalisation
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)




0 – 4 1.18 (0.80 – 1.74) 1.14 (0.77 – 1.67) 1.14 (0.92 – 1.41) 1.12 (0.90 – 1.38)
Potency score 0 – 5 1.17 (0.86 – 1.58) 1.14 (0.84 – 1.55) 1.12 (0.95 – 1.33) 1.12 (0.94 – 1.32)
Dosage score 0 – 6 1.13 (0.86 – 1.47) 1.09 (0.83 – 1.42) 1.13 (0.98 – 1.31) 1.11 (0.96 – 1.28)
MARANTE 0 – 7 1.11 (0.89 – 1.39) 1.09 (0.87 – 1.36) 1.12 (0.99 – 1.26) 1.10 (0.98 – 1.25)
APPROACH 2: Categorical
MARANTE n HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
0 343 Ref Ref Ref Ref 
Low (0.5 – 1.5) 81 1.35 (0.59 – 3.08) 1.31 (0.57 – 3.02) 0.93 (0.59 – 1.49) 0.93 (0.58 – 1.47)
High (≥ 2) 79 2.26 (1.07 – 4.78) 2.20 (1.03 – 4.67) 1.75 (1.16 – 2.64) 1.71 (1.13 – 2.59)
Two approaches models were used. In the first, associations of anticholinergic exposure with the continuous variable 
were analysed (e.g. the number of medications, and the continuous MARANTE score). In the second model, we 
performed categorical analysis to search for trends for a higher risk for mortality or hospitalisation with a higher 
Anticholinergic exposure. 
Two models were used, where model 1 was adjusted for the number of medications (0 – 16), and model 2 was 
additionally adjusted for the level of multimorbidity (0 – 9).
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Figure 8.1. Survival analysis of groups of MARANTE scale (No, Low, and 





In this longitudinal study, we applied for the first time a new anticho-
linergic scale based on both potency and the whole dosage spectrum. 
Our main finding is that the MARANTE scale is a robust and potent ap-
proximation for quantifying anticholinergic exposure.
We were able to show that a third of this community-dwelling cohort 
over oldest old (aged 80 years and older) takes chronically at least one 
medication with anticholinergic properties. Anticholinergics with low 
potency (80% of all anticholinergics) were most consumed, yet dosing 
was considered often high (52%) or very high (17%) in this population. 
Based on the median score on the MARANTE scale in subset of pa-
tients with anticholinergic exposure, equal groups were created. Those 
with a high anticholinergic exposure (a score ≥ 2 on the MARANTE scale) 
showed increased risks for both mortality and hospitalisation in multivar-
iable analysis, controlling for the number of medications and the level of 
multimorbidity. These patients showed a 2.2fold increased risk for mor-
tality, and a 71% increased risk of being hospitalised during an observa-
tion period of 18 months. 
Strengths and limitations
We explored the point-prevalence and intensity of the anticholinergic 
exposure at baseline in a cohort of community dwelling oldest old with 
a new measurement instrument, taking into account potency and dos-
age We studied the intensity of the baseline anticholinergic exposure, by 
looking at associations with mortality, and first unplanned hospitalisation 
using a prospective cohort during an observation period of 18 months, 
The observational nature of this study does not permit to ascertain causal 
relations of the anticholinergic exposure with outcomes. Confounding by 
indication is possible as anticholinergics are used in patients with multi-
ple diseases, all possibly associated with the outcomes. 
In multivariable analysis, taking into account multimorbidity and 
polypharmacy, simple measures of anticholinergic exposure (number 
of anticholinergics, sum of values for potency, sum of values for dosage) 
failed to observe significant results. Only the application of the MARANTE 
Scale, and the subsequent categorisation in two groups of low and high 
exposure revealed that high anticholinergic exposure is associated with 
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mortality and hospitalisation. 
Only the chronic medication use was analysed (no if-needed or over 
the counter medications), potentially underestimating the anticholiner-
gic exposure. All associations with mortality or first hospitalisation were 
based on the baseline chronic medication intake, without control for a 
continuous chronic anticholinergic intake during the observation period.
It should also be remembered that this cohort was limited to commu-
nity-dwelling active and cognitively fit oldest old, limiting the transfer-
ability and interpretation into other populations. 
In this study, only associations with mortality and hospitalisation 
were analysed. The data collection of the original Belfrail cohort was not 
intended to look at the symptomatic adverse events of medications (e.g. 
sedation). All participants were randomly and consecutively selected by 
their GPs, some degree of prevalent user bias cannot be excluded.
The MARANTE scale is built on the premise of a pure additive effect of 
different anticholinergic loads, and does not consider possible synergis-
tic or antagonistic effects of medications at the receptor level. 
In relation to other findings
With advancing age, the consumption of medications will rise as well, 
and consequently the intake of anticholinergics will rise [246]. Other 
studies estimate that up to 51% of the community-dwelling population 
take medications with anticholinergic properties [212], yet interpretation 
of this prevalence should be done with caution. Depending on the meth-
od used for classifying anticholinergics, the prevalence of anticholiner-
gic use in just one population of older community-dwelling men could 
range between 13 – 39% [351]. 
Our findings are in concordance with other studies, searching for asso-
ciations between patient-characteristics and the use of anticholinergics. 
The association of anticholinergic use with female gender, age, depres-
sion, the number of medications, multimorbidity and with the number of 
medications have been observed before [340, 352, 353]. In this study, the 
association with cognitive impairment was absent [49, 218], since older 
adults without dementia were included in the Belfrail-MED cohort.
Anticholinergics have been considered as potentially inappropriate 
[187, 207], and are widely regarded as to be used with caution in older 
persons. However, the definition of medications with anticholinergic 
properties varies significantly, leading to a multiplicity of lists and explicit 
criteria, making a direct comparison difficult to perform. In addition, giv-
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en different samples used, and different cut-offs for what high anticho-
linergic exposure is [58], associations with mortality and hospitalisation 
remain inconclusive, or even contradictory. 
Previous publications did not find consistent associations of anticho-
linergic exposure with mortality or hospitalisation[54, 329, 339–341, 344, 
347, 354]. Limiting the results to the oldest old (aged 80, and older), one 
longitudinal study reported significant associations with mortality [354], 
while others did not [329, 344, 347]. For hospitalisation, in one publica-
tion a significant, yet limited association was found in the oldest old [341]. 
Our findings suggest an increase in mortality and first unplanned 
hospitalisation with high anticholinergic exposure. Although associa-
tions were absent for a low anticholinergic exposure, the risks were still 
increased for both outcomes. The clinical relevance of a low anticholin-
ergic exposure must not be disregarded. A low anticholinergic exposure 
might be associated with other clinical problems (e.g. more anticholiner-
gic side-effects). 
Implications for practice
Medication prescribers will need education and assistance to appreci-
ate the importance of these ‘invisible’ anticholinergic medicines (and the 
patient contexts in which they are prescribed) and to incorporate calcula-
tions of individual patient anticholinergic exposure into their clinical de-
cision-making. This has the potential to reduce patients’ anticholinergic 
exposure and adverse drug events. 
Medications with anticholinergic properties are not always known to 
prescribers [343], nor are anticholinergic side effects recognised. The ar-
ray of tools and methods available, each using different medications, can 
lead to confusion in knowing the true anticholinergic properties of medi-
cations. The MARANTE scale can aid medication prescribers to recognise 
those patients with high anticholinergic exposure, and to monitor these 
patients more systematically for their experienced side-effects.
Past and recent interest on anticholinergics in older adults, under-
stress the importance of a consensus on a unified list of medications with 
anticholinergic properties, with agreements on their potency and dosag-
es. We therefore invite other researchers in an open discussion at https://
secureramit.ugent.be/marante. 
A computerised application of the MARANTE scale in older adults can 
be used to implement particular explicit criteria of inappropriate pre-
scribing in automated systems of decision support and quality assurance, 
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but it should not be used as a substitute for the clinical assessment of the 
pharmacological therapy of an individual patient. 
Implications for research
This cohort existed of relatively healthy and active older adults (aged 
80, and older). It would also be interesting to examine the effects of a 
high anticholinergic exposure in older adults, aged 65 years and older. 
Also the associations of a higher anticholinergic exposure with outcomes 
are to be studied in more frail patients in nursing homes, where there are 
more patients with dementia, who are more susceptible to the anticho-
linergic effects [61, 315]. Older adults in nursing homes have a higher 
medication intake, predominantly a higher psychotropic medications, 
and possibly a higher anticholinergic exposure [152, 355]. 
Finally, it is important to relate the anticholinergic exposure to the an-
ticholinergic burden, e.g. the direct burden perceived by patients. Other 
studies reported associations of anticholinergic exposure with lower 
quality of life [356], possibly due to a higher prevalence of common an-
ticholinergic adverse effects (sedation, hallucinations, dry mouth, or con-
stipation). Therefore, in a following study, we will investigate associations 
of anticholinergic exposure (quantified by the MARANTE scale) with the 
anticholinergic burden. 
8.7 Conclusion
In a cohort of community-dwelling oldest old (aged 80, and over), a 
high prevalence of anticholinergic use was observed, predominantly in 
high and very high dosages. The novel MARANTE scale provided a ro-
bust estimation of the anticholinergic exposure, but further validation is 
still needed. Those with high anticholinergic exposure showed increased 
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n this manuscript, we aimed to explore and appraise the medica-
tion use of Belgian community-dwelling oldest old (aged 80, and 
over). We used medication data from a population characterised 
by a high level of multimorbidity and a high medication intake, all 
obtained from primary research data of a large longitudinal epi-
demiological cohort study (the Belfrail study).
We appraised the medication use during the prescribing step in the 
medication management process, focussing on the electronic applica-
tion of explicit criteria for potential misuse or underuse of medications. 
Methods for assessing potentially inappropriate medications during the 
prescribing step, either implicit or explicit, have the potential to aid cli-
nicians. These tools have been predominantly used in research settings, 
but studies focussing on the oldest old are scarce, certainly in the com-
munity-dwelling oldest old. In the following discussion, we will review 
the findings of our studies, it’s limitations and strengths. Finally, we pro-
pose implications for practice and research. 
9.1 Discussion per research question
Research question 1
What is the prevalence of polypharmacy in the community-dwelling 
oldest old (aged 80 years, and over) in Belgium, and what patient-
related factors attribute to a higher medication intake?
In chapter 3, we aimed to explore the medication use in the community-
dwelling oldest old, in an attempt to unravel the complex interactions 
between the demographic, clinical and functional characteristics of 
polypharmacy.
Polypharmacy (defined as the intake of 5 or more chronic medica-
tions with systemic effect) was high (58%) in Belgian community-dwell-
ing oldest old. The findings from the Belgian Health survey reported a 
lower prevalence of polypharmacy (around one in three Belgians aged 75 
years and older reported having polypharmacy). In comparison with oth-
er studies on polypharmacy in older adults, the prevalence of polyphar-
macy was higher in our study, although the other studies had a younger 
sample [70, 76, 143, 146, 147, 149, 151, 357–359]. 
The oldest old generally have the highest mean number of medica-
tions. The trend for increasing number of medications with higher age is 
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not continuous, as we saw a late-life decrease in the number of medica-
tions. At medication subclass level, the oldest old used predominantly 
cardiovascular medications and antithrombotic agents, but there was 
also a high chronic use of hypno-sedatives and antidepressants. The 
Belgian Health survey reported that the oldest age group in their survey 
(those aged 75 years, and older) had a higher use of antacid agents, an-
tithrombotic agents, beta blocking agents, hypno-sedatives, but not dia-
betes medication, estrogens, thyroid medications, and anti-inflammatory 
agents [360]. A comparison between the oldest age group in the Belgian 
Health Survey and the oldest old in the Belfrail showed similar prevalenc-
es of individual medication classes, although the Belfrail sample had a 
higher prevalence of hypno-sedatives and antithrombotic agents [360].
In comparison with older adults in long-term care, some differences 
were also visible. The medication use was higher in Belgian nursing home 
residents [152]. Belgian community-dwelling oldest old had less medi-
cations, predominantly less psychotropic agents and laxatives. Antipsy-
chotic agents and antidepressants were less prescribed in this cohort, 
potentially due to the exclusion of patients with dementia in the Belfrail 
cohort. 
The novelty of this study lies in the study of the interrelations between 
the determinants of polypharmacy, the confirmation of the dominance 
of multimorbidity as a determinant, and the important relationship with 
the level of physical activity and depressive symptoms. 
Research question 2
Is there a relationship between polypharmacy and health related 
outcomes (hospitalisation, institutionalisation, and mortality) in the 
community-dwelling oldest old? 
Our results suggest that polypharmacy had clear associations with 
hospitalisation, but no significant association with mortality was found. 
The continuous variable (the number of medications) had stronger as-
sociations with the outcomes, yet only associations with hospitalisation 
were significant. Possibly, polypharmacy is too crude to be qualified as 
an indicator for prescribing quality. For a better understanding, the crude 
use of polypharmacy (as defined by a cut-off ) could only be appraised if 
it is matched with the level of multimorbidity [265].
At medication subclass level, some medication classes showed in-
creased risks for mortality (selective calcium channel blockers), hospi-
General discussion
153
talisation (selective calcium channel blockers, loop diuretics, and agents 
used for obstructive airway diseases) and institutionalisation (hypno-
sedative use).
The results suggest that the functional profile was strongly associated 
with outcomes. Other findings also suggest that functionally active old-
est old benefit in terms of reduced mortality or hospitalisation risks [291]. 
However the dominating association was found with the level of multi-
morbidity.
The novelty of this study lies in the longitudinal appraisal of exposure 
and outcome of polypharmacy, and the realisation that even with a sim-
ple quantitative definition, clear associations with hard outcomes can be 
observed. 
Research question 3
Which medications mentioned in international lists of explicit criteria 
of (in)appropriate prescribing are applicable to the Belgian therapeutic 
arsenal? 
The availability of medications mentioned in the EU(7)-PIM list in 
the Belgian medication market was not overwhelming (157 out of 275 
medications were available). In comparison with other countries regard-
ing the availability of PIMs, the Belgian medication market has less PIMs. 
Potentially because medications that enter the market are reviewed and 
all evidence (or lack thereof ) is listed, and suggestions for the therapeu-
tic arsenal, or suggestions on obsolete medications are regularly handed 
out to clinicians by the Belgian Centre for Pharmaceutical Information. 
The applicability of the STOPP/START-2 criteria, purely on the availability 
of the medications, is higher. For Belgium, only the active substance za-
leplon is not available. The STOPP/START-2 criteria mention medication 
classes rather than individual active substances. 
The most consumed medication class mentioned in the EU(7)-PIM 
are proton pump antagonists. Yet, if all separate benzodiazepines were 
considered as a medication group, this group would have had a higher 
prevalence in the oldest old.
The novelty of this study is that the impact of the characteristics of the 
national therapeutic arsenal on the use of the PIM lists was studied, prior 




What is the prevalence of use of potentially inappropriate medications 
(PIMs) in the community-dwelling oldest old, and is there a relationship 
between potentially inappropriate prescribing (misuse and underuse) and 
hospitalisation and mortality? 
There was a high prevalence of underuse (according to START-2) and 
misuse (according to STOPP-2 and EU(7)-PIM) in the oldest old commu-
nity-dwelling. Comparing the prospective cohort study of Moriarty et al. 
on potentially inappropriate medication use in Irish older adults, we saw 
that the prevalence of misuse was comparable to our findings (57% vs. 
56% in our study), yet underuse was less prevalent in the Irish study (42% 
vs 67%), potentially because of the younger cohort used.
Manuscripts looking at potentially inappropriate medications do not 
always include underuse of medications [154]. In the few studies availa-
ble, medication underuse seems relatively common in older adults, either 
using the AOU index (assessment of underuse index, an implicit method 
for detecting underuse) or START criteria [188]. Conform our findings, the 
most prevalently detected START criteria was the potential underuse of 
anticoagulants, calcium or vitamin D, and statins [154, 361–363]. The un-
deruse of ACE inhibitors was higher in our study. This may be explained 
by the recent adaptation in the criterion. Example given, in the latest ver-
sion, more clinical problems were included. In START-1, an ACE inhibitor 
should be started in case of chronic heart failure. In START-2, an ACE in-
hibitor could also potentially be started in case of documented coronary 
artery disease [187, 194].
The high prevalence of underuse in the oldest old is not easy to ex-
plain, yet our findings confirm that underuse is common in this age group. 
Several hypotheses for a high prevalence of underuse can be formulated:
The electronic appraisal of explicit criteria could be less specific than 
the appraisal during a medication chart review by a researcher or clini-
cian, leading to an overestimation of the actual underuse. No informa-
tion was available on the rationale for not being prescribed an underused 
medication. 
Underuse could have been the result of a rational prescribing process. 
Underuse of medications can be desired in the light of an unstable health 
condition. With patients with limited life-expectancy, not prescribing 




Underuse could have been intended, as the result of limited phar-
macotherapeutic evidence in the oldest old. The underrepresentation of 
older adults in clinical trials can lead to inadequate evidence and knowl-
edge regarding medication therapy in older adults. Medication pre-
scribers might refrain themselves from prescribing medications where 
the correct benefit-risk assessment of medications in older adults is not 
known [364]. 
Underuse could have been unintentional, due to little time available 
during the medication prescribing process, to unravel complex medica-
tion regimes, to apply explicit criteria in daily practice [365], or in case of 
shared medication responsibility.
With regard to the application of explicit criteria generated on data 
yielded in primary field research, but not intended for the pharmacologi-
cal evaluation, only a limited set was transformed into codes for auto-
matic appraisal. Only half of the STOPP-2 criteria and 1/3 of the START-2 
criteria could be operationalised, due to lacking data on laboratory tests, 
sometimes unclear defining of explicit criteria, or because the explicit 
criteria referred to dementia patients, who were not considered in the 
Belfrail-Med cohort. It was also not possible to operationalise explicit cri-
teria referring to past medication therapies (e.g. ‘if not used before’, or 
‘if not used as a first-line treatment’), as the rationale for prescribing or 
not prescribing medications was not known. Other manuscripts on po-
tentially inappropriate medication use defined by explicit criteria look for 
direct associations with adverse effects (e.g. the occurrence of a fall, heart 
block). In our database, the reason for being hospitalised was not known 
as well. Despite all these limitations, the subset of explicit criteria for un-
deruse still showed a remarkable positive association with mortality and 
hospitalisation.
The novelty of this study pertains to the electronic application of 
explicit criteria as secondary use of a research database, demonstrating 
co-existence of the different aspects of inappropriate prescribing (poly-
pharmacy, misuse and underuse), and a clear longitudinal relationship 
with hard outcomes. 
Research question 5
Can an automated tool be developed that quantifies the anticholinergic 
exposure in old age?
Anticholinergics are often mentioned as a group, but specific enu-
Chapter 9
156
meration of this group is difficult. Following the systematic review by 
Duran and colleagues, the use of anticholinergics in Belgium was inves-
tigated. Most common anticholinergics were ranitidine (15%), tramadol 
(10%), and various antidepressants (citalopram, amitriptyline, …). 
The MARANTE scale is specifically designed for geriatric patients, and 
combines both potency and the full spectrum of the dosage of anticho-
linergic medications. The MARANTE may prove to be an instrument for 
large-scale surveillance of the risk of exposure to the class of anticholin-
ergics, which are widely used by older adults and known to cause a heavy 
burden of adverse events. Strengths of the MARANTE scale include the 
introduction of four dosage ranges, based on three cut-off points, which 
lowers the chance of over- or underestimation of the true anticholinergic 
exposure.
Several formulas have been proposed to calculate dosage adjust-
ments in older adults, and a general formula is still absent [320]. Also, the 
dose-response relationship is not known. It is however clear that a higher 
dosage will result in a higher risk for the effect or side-effect of a medica-
tion. The most studied method for assessing the anticholinergic exposure 
is the validated Drug Burden Index (DBI) [62]. The DBI has limitations, as 
it includes only one reference value for the dosage, and this value varies 
across national medication guidelines, making international comparison 
difficult [366]. Finally, similar to the theoretical lists, it assumes a linear ad-
ditive effect. In the DBI, it is unclear of a doubling in the dosage will lead 
to a doubling in the response. Therefore, we opted for a scoring system, 
rather than a dosage-response formula.
The novelty of this study was the in-depth, systematic, and transpar-
ent approach to operationalisation of the measurement of a pharmaco-
dynamics interaction, as an explicit criterion of potentially inappropriate 
prescribing. 
Research question 6
What is the prevalence of the anticholinergic use in the community-
dwelling oldest old (aged 80 years, and older), and is there a relationship 
of the anticholinergic exposure with hospitalisation and mortality. 
Anticholinergic use was high, with one in three of the oldest old being 
prescribed a medication with anticholinergic properties. Anticholinergics 
with low potency (80% of all anticholinergics) were most consumed, yet 




Associations between anticholinergic use with personal/clinical/func-
tional characteristics were investigated in univariate analysis only. Female 
gender, age, having depressive symptoms, polypharmacy, the number of 
medications, and multimorbidity were all associations. Only the associa-
tion with cognitive impairment was absent [49, 218], potentially because 
of the exclusion of older adults with dementia in the Belfrail-MED cohort.
In multivariate analysis, those with a high anticholinergic exposure (a 
score≥ 2 on the MARANTE scale) showed increased risks for both mor-
tality and hospitalisation. Similar to the design of the study in chapter 
6, associations with intermediate outcomes were not performed. It was 
not known if common anticholinergic symptoms (e.g. sedation, dry eyes, 
constipation, …) were the reason for being hospitalised, or for death.
The novelty of this study was the longitudinal observation of the as-
sociation between an automated and interoperable measure of anticho-
linergic exposure with hard outcomes. 
9.2 Strengths and limitations
Strengths
This thesis has contributed to the understanding of the medication 
use in the community-dwelling oldest old in Belgium, with an explora-
tion in the appraisal of the appropriateness of the medication use. 
The Belfrail-MED cohort included a comprehensive assessment of 
personal, clinical, functional characteristics, and medication data in a 
representative cohort of community-dwelling oldest old patients [238], 
making this a high quality and practice based epidemiological study. The 
main strength is the longitudinal design of the study. All patients were 
followed for several years, making it possible to look for associations of 
the medication use with outcomes.
The Belfrail-MED cohort had a specific focus on the oldest age group. 
The patients were included in a relevant setting, so that the risk of bias 
of a temporary situation (e.g. admittance to the emergency department, 
hospital stays …) was minimalised. 
Limitations
The studies presented in this thesis use cross-sectional (chapter 3, 5) 
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and longitudinal (chapter 4, 6, 8) observational data. The observational 
nature of the data only allows to look at potential associations, but it does 
not allow to conclude any causal relations. 
All studies presented in this thesis use secondary data. Using second-
ary data can provide several benefits (accessibility and feasibility to per-
form longitudinal studies), but also has limitations. The data collected in 
the Belfrail cohort was not intended for the appraisal of the medication 
use. In chapter 6, only a subset of all STOPP/START-2 criteria could be 
used, partly due to missing variables in the dataset. The data were also 
limited to the community-dwelling oldest old population, which may 
limit the transferability of our findings to younger populations.
Another important limitation presented in our studies, is that all as-
sociations were investigated between the medication use at baseline and 
hard outcomes happening in a period of time, without accounting for 
intermediate outcomes (adverse drug effects). The reason for a hospitali-
sation, or the reason for death were not noted. In order to fully grasp the 
effect of potentially inappropriate medications, adverse drug reactions 
should be part of the outcomes.
Although several sets of explicit criteria have been published, most 
lack evidence. The STOPP/START-2 criteria show promising but not con-
vincing evidence when using the lists as an intervention to reduce drug 
related problems [228]. Yet, also at the level of explicit criteria, evidence 
is much needed. Explicit criteria are generally generated through expert 
consensus. Only recently, in the 2015 updated version of the Beers crite-
ria, explicit criteria were graded according to the strength and quality of 
evidence. Approximately 48 out of 250 criteria were matched with a high 
level of evidence [367]. In the STOPP/START-2 criteria, a number of refer-
ences is given for each criterion, but these are not matched with a level of 
evidence. The lack of evidence must be remembered in the interpretation 
of the results presented in this thesis. 
In the optimisation of the pharmacotherapy of older adults, there are 
hardly any simple solutions. As to date, no software-driven interventions 
have been found reliable or effective for the purpose of minimizing inap-
propriate prescribing [368]. In the studies presented here, only a limited 
set could be automated. Electronic applications have the advantage to 
be straightforward and easy to apply [369], yet for an optimal implemen-
tation of explicit criteria, these should be made as specific, explicit and 
universally adaptable as possible [237]. In chapter 6, only a limited set of 
explicit criteria in the STOPP/START-2 list could be automated.
The automatic electronic application of explicit criteria using second-
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ary data can yield false-positives. The rationale for prescribing, depre-
scribing or not starting medications was not known in the Belfrail-cohort. 
Patients might be wrongfully classified as not being prescribed an essen-
tial medication (having underuse), because their medication history (e.g. 
allergic reaction to a medication) was not known. 
With all these limitations stated here, it can only be concluded that 
the automatic electronic application of explicit criteria for appraising the 
potential inappropriateness of medication cannot replace actual clinical 
judgement. At most, the automatic application of explicit criteria can be 
used as a supportive to clinicians and human experts.
9.3 Implications for clinical practice
In the following point, we review future implications for clinical prac-
tice. 
In this manuscript, focus was on the choice of medications during the 
prescribing phase in the medication management process. We reviewed 
one potential adjuvant method (e.g. explicit criteria to appraise poten-
tially inappropriate medications), but other recommendations can be 
made for the whole medication management process.
Actions can be taken to promote a better coordinated care across dif-
ferent health care settings (during or after a hospital stay, after entering 
a nursing home) in order to exclude any errors due to miscommunica-
tions or uncertain responsibilities (e.g. is it the general practitioner or the 
medical specialist who reviews the medication list after a hospital stay) 
[370, 371]. A study has shown that the promotion and optimisation of 
communications between general practitioners and medical specialists 
for instance can lead to a better outcome for patients [372]. 
The validity and informative nature of secondary data for 
appraising the medication use
The validation process of these explicit criteria is still ongoing. Most 
explicit criteria were designed in expert meetings, and validated through 
consensus techniques. Few PIM tools state the level of evidence for each 
criterion. Almost all explicit criteria are developed through consensus in 
expert panels, and lack therefore robust evidence. Only in the most re-
cent version of Beers, explicit criteria were reviewed and graded accord-
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ing to their level of evidence. Approximately 48 out of 250 criteria had a 
high level of evidence [367]. For each STOPP/START-2 criterion, a number 
of references is given, but the criteria are not matched with a level of evi-
dence. 
Despite the significant associations found in this thesis, no associa-
tions with direct adverse effects were studied. The obtained data did not 
include the rationale for prescribing, nor for being hospitalised. It must 
be remembered that of all hospital admissions, only a portion of 10-15% 
is medication-related, and that in those cases, half of it was deemed pre-
ventable [96]. 
Next, explicit criteria do not cover all aspects of the medication 
choice. Explicit criteria can be broader, and also include the convenience 
of medication therapies. For instance the EU(7)-PIM mentions the insulin 
gliding scale as potentially inappropriate for older adults for its complex-
ity in use, and increased risk for over/under dosing [180]. 
Another aspect often not mentioned is the cost of certain medica-
tions, as this can also be a limiting factor for patients [373]. Future ver-
sions of explicit, criteria could include the cost-effectiveness of the select-
ed criteria, and the proposed alternative medication or non-medication 
therapy. Unfortunately, the evidence on non-pharmacological alterna-
tives is still scant and inconsistent [374, 375]. 
The feasibility, and validity of automatic electronic appraisal of the 
medication use
Using secondary data for the appraisal of the medication use, ob-
tained from secondary data from dispensing databases or health care re-
cords is possible and can be informative. The application of medication-
only explicit criteria is more feasible, and can be highly informative for 
policy makers to notice the most prevalent medications associated with 
DRPs. The application of explicit criteria that need medication data ànd 
clinical data is less obvious. A full application of explicit criteria needs a 
vast amount of data registration, and not all criteria can be assessed with-
out the clinical information of the patient. 
One possible approach is the introduction of national electronic appli-
cations or e-Health applications. Electronic applications can aid prescrib-
ers by screening the patient, his/her medications and clinical problems 
for potentially inappropriate medications. Electronic applications have 
the advantage to be straightforward, stable, and easy to apply [369], yet 
for an optimal implementation of explicit criteria, these should be made 
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as specific, explicit and universally adaptable as possible [237]. Now, this 
is not always the case. 
With the findings in our studies, it is feasible to apply a substantial 
number of the criteria from the STOPP/START-2, and EU(7)-PIM list in an 
e-Health application. Medication prescribers could be guided towards 
prescribing safe and balanced medication therapy. 
The challenge of underuse in clinical practice
There is growing interest in potentially underused medications. Un-
deruse of medications has been found to be associated with a more frail 
profile. Example given, preventive cardiovascular medications (antiplate-
lets or statins) are not always prescribed to more frail older adults, be-
cause this is not always considered as a serious co-morbidity [295].
For statins, a recent review in the Lancet stated that underuse may be 
caused by exaggerated claims about side-effect rates, as suggested ear-
lier in the PROSPER study [376]. The risk for myopathy or muscle-related 
symptoms attributed to statin use is low, and is resolved rapidly if the 
treatment is stopped. This potential risk does not weigh up to the poten-
tial fatal effect of no treatment (e.g. heart attacks, strokes) [377]. 
A high underuse (50%) of anticoagulants in patients with atrial fibril-
lation was also reported before [378]. Dalleur et al. concluded that there 
was no clear clinical rationale for withholding anticoagulant therapy in 
this indication [378]. 
The challenge of misuse in primary care
The chronic use of psychotropic agents (benzodiazepines, antidepres-
sants, but not antipsychotics), and the prevalence of duplicate therapies 
in a substantial part of the community-dwelling oldest old population in-
dicate potential incentives towards an optimisation in pharmacotherapy. 
The high use of benzodiazepines in Belgium has been noted before 
[379, 380], and our findings suggest it is still an actual problem. Benzo-
diazepine use has been associated with cognitive impairment, cognitive 
decline, higher risk of falling, and finally increased mortality risks, yet the 
literature is inconclusive (due to methodological differences including 
design, outcome, time of follow-up, or sample) [381, 382]. Nonetheless, 
chronic hypno-sedative use could lead to habituation, impeding their 
efficacy in the long-term [383], or could lead to dependence (including 
withdrawal symptoms in case of therapy cessation, e.g. agitation, irri-
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tability, headaches, nausea, …)[384], and side-effects inherent to their 
working mechanism (e.g. sedation, impaired alertness or increased risk 
of falling) [385]. Discontinuation of benzodiazepines can reduce poten-
tial costs (e.g. hospitalisations for fall incidents can cost up to €11426 per 
patient [386]). Changing misused medications is not an easy task, and is 
not the sole responsibility of the prescriber. In a Belgian nursing home, 
a significant drop in prevalence of psychotropic medication users was 
noted through a transition towards a more patient-centred care model 
[387]. Patients, nurses and other allied health-personnel were all involved 
in offering credible and sustainable alternatives to psychotropics. 
Anticholinergics can be a problem in older adults, because anticholin-
ergics and their side effects are not always recognised [43], or prescribers 
don’t perceive the prescribed medication as an anticholinergic [343]. In-
centives may be needed to raise awareness of these ‘hidden’ anticholiner-
gics. Medication prescribers and dispensers are less aware that routinely 
used medications, unintended for their primary indication, can have an-
ticholinergic properties [337]. Some anticholinergic medications are also 
available as over-the-counter medications (e.g. cetirizine), and can add to 
the potential risk for a higher anticholinergic exposure [315]. The applica-
bility of the MARANTE in electronic applications used by both medication 
prescribers and dispensers can be investigated, so it could alert them on 
the high prevalence of (sometimes unknown) anticholinergics.
The duplication of a medication subclass was present in 13% of the 
community-dwelling oldest old, similar to earlier findings of hospital-
ised older adults (9%) or in the British Clinical Practice Research Datalink 
(11.3%) [195, 388], and hence a drug related problem, that is prevalent 
and merits attention.
Similarly, the overuse of medications (medications without an indica-
tion, a combination therapy where a monotherapy has not been tried 
before, and medications in a prescribing cascade) can be addressed as 
well. Recent government initiatives (reduction in the amount of copay-
ment) focused on other examples of overuse, namely the overutilization 
of proton pump inhibitors, nasal sprays and antibiotics. 
The place of explicit criteria for potentially inappropriate 
medications in the medication management process
Explicit criteria can aid medication prescribers in finding potentially 
inappropriate medications. The manual application in clinical practice of 
these sets of explicit criteria is however time-consuming, needs motiva-
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tion of the medication prescribers, and needs some knowledge. Short 
consultation times may not be feasible to perform individual medication 
chart reviews. 
Now, most sets of explicit criteria are used in research and seldom in 
clinical practice, despite general practitioners’ beliefs that explicit criteria 
are useful, and having an added value [389]. In Norway, general practi-
tioners use the NORGEP (derived from the Beers criteria) in daily practice, 
and it is also used for the evaluation of the prescribing of medications by 
GPs across different settings [390].
When the aim is to identify inappropriate medication use in older pa-
tients, the STOPP/START-2 criteria are recommended. They are valid, inte-
grate the clinical status of a patient, and most importantly, they also focus 
on underuse. An added bonus is that the STOPP/START-2 criteria mention 
only a few medications not on the Belgian medication market. Yet, the 
STOPP/START-2 are not complete, and have limitations. They are not al-
ways explicit, or clear to use, and do not propose alternatives for a poten-
tially inappropriate medication, nor provide a graded level of evidence. 
A possible suggestion for clinicians, who want to implement this in 
daily practice, is the targeted selection of PIMs. This could decrease the 
number of patients that need to be reviewed, based on age alone, and 
thus decrease the workload. Example given, clinicians could solely focus 
on the rational prescribing of cardiovascular medications and hypno-
sedative medications. 
Suggestions for explicit criteria, and the automatic application 
thereof
Explicit criteria for the detection of potentially inappropriate medica-
tions are not often used in clinical practice. More often, the application of 
these sets in medication review is performed mainly manually, and in the 
context of research. 
Our findings suggest that the automatic application is feasible, but 
more research into its validity is needed. There were many limitations, 
including the usage of a subset of explicit criteria, limitations to using 
data not intended for pharmacological evaluations, limitations to not in-
cluding direct adverse outcomes or patient’ preferences and all that in an 
automated way. Still, we could find associations between explicit criteria 
on underuse with mortality and being hospitalised. The validity of our 
findings needs to be confirmed in other settings, before it can be imple-
mented routinely in clinical practice. 
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The appraisal of pharmacotherapy cannot rely on the use of explicit 
criteria only. It must be embedded within a patient’s global assessment 
of his clinical status and his preferences and needs. Explicit criteria can be 
used as a supplementary to other initiatives to improve the medication 
management process. Still, due to the non-standardised nature of the al-
gorithms when applying explicit criteria automatically, a direct compari-
son of studies is difficult. Future incentives can be taken to strive towards 
an optimal semantic operability of these criteria.
It can be interesting to study the added value of the combination of a 
medication review, and the use of explicit criteria as a preparation for the 
medication review. For pragmatic reasons (availability of patients, health 
care professionals, electronic health records) a parallel-group cluster ran-
domised controlled trial in long-term residential care facilities (nursing 
homes) could be conducted. The pragmatic cluster trial can be consid-
ered as a superiority trial, since an improvement in pharmacotherapy 
(less potentially inappropriate prescribing) is expected in favour of the 
intervention group. The intervention could be the automated appraisal 
of the medication use for potentially inappropriate medications. Nurses 
conduct monitoring observations for specific medication-related symp-
toms, and enquire with the patient about his/her preferences regarding 
medication changes. The report will be discussed in a medication review, 
held between the general practitioners, nurse, and pharmacist. 
9.4 Implications for research
The challenge of deprescribing
Explicit criteria offer the option to clinicians to notice potentially inap-
propriate medications, but do not offer solutions. In the light of depre-
scribing potentially inappropriate medications, future PIM tools could in-
troduce guidelines for the discontinuation of pharmacotherapy in older 
adults. The EU(7)-PIM list handles dose reductions and alternatives to a 
current potentially inappropriate medication [292]. 
Recently, the STOPP-2 criteria have been adapted to older adults with 
limited life-expectancy, the STOPPFrail criteria [391]. It includes 26 explicit 
criteria, who were included in the list based on consensus of specialists in 
geriatric medicine. The first two criteria address potential deprescribing 
in case an indication lacks or in case of poor adherence to medications. 
The other criteria are similar to the current majority of STOPP criteria, ad-
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dressing the discontinuation of medication classes (e.g. proton pump in-
hibitors, anti-spasmodics …). The STOPPFrail criteria do not include the 
discontinuation of anticoagulants and antidepressants. 
Study suggestions for explicit criteria and anticholinergics
Studies with strong methodological designs are needed to establish 
causal relationships of potentially inappropriate medications or the an-
ticholinergic exposure with outcomes [337]. The recent meta-analysis on 
the effectiveness of the START/STOPP criteria did not offer convincing 
results [228], and similar analyses of other sets of explicit criteria are lack-
ing as well. Explicit criteria need to be studied more using randomised 
controlled trials using sets of explicit criteria as an intervention, and in 
relation with direct outcomes. 
Now, different sets of explicit criteria emerge, that are mostly embed-
ded into national drug markets. Following the European Science Funds 
meeting with experts on the development and usage of explicit criteria, 
forces should be combined to create a comprehensive repository of ex-
plicit criteria of potentially inappropriate medications instead of refining 
or adapting individual sets of PIMs [170]. This repository should combine 
explicit criteria from already established lists, with frequently used and 
validated PIM lists as a starting point. The clinical applicability of explicit 
criteria is often low, mainly because of lack of adaptability to national 
medication markets, a low suitability for automated electronic assess-
ment, a sometimes-low level of evidence, and the limited access to high-
quality medical information in electronic health records. The repository 
can be used in different settings (either for patients at home, in a hospital 
or in a nursing home), and for different purposes (for research and clinical 
research, as a feedback tool for prescribers on a national level, for bench-
marking, or for health purposes).
For, anticholinergics, it could be investigated whether the application 
of the MARANTE could be used as an intervention in patients to reduce 
the anticholinergic exposure. Another step in the validation of the MA-
RANTE scale, is establishing associations with direct anticholinergic ef-
fects. In other words, it could be investigated whether a higher score on 
the MARANTE scale leads a higher burden of common anticholinergic 
symptoms (including peripheral effects as dry mouth, dry eyes, constipa-
tion, urinary retention, and central effects as confusion, delusions, hal-
lucinations, and sedation). The relationship of anticholinergic exposure 
with quality of life is also inconclusive. One study (a secondary analysis 
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of an RCT using a sample of palliative patients) reported a significant as-
sociation, but did not adjust for other medication effects, or the illness 
status [392]. Investigating the relationship with the quality of life, could 
also open up the debate of the potential impact of a reduction of the 
anticholinergic exposure. A single-blind RCT investigated a pharmacists-
led intervention to reduce the anticholinergic exposure in nursing home 
residents and the impact on the cognitive function and mouth dryness 
after four to eight weeks [393]. No significant changes were found, pos-
sible due to the short follow-up time, the sample, protopathic bias or be-
cause dosing of medications was not included in the quantification of the 
anticholinergic exposure. 
This could be investigated in a randomised controlled trial including 
patients in primary care. For each patient, a medication review will be 
started where anticholinergics are reviewed on their potency and dos-
age, in order to reduce the anticholinergic exposure in patients. For the 
primary outcome, the reduction in proportion of patients with an an-
ticholinergic exposure can be used. Secondary, the link with common 
anticholinergic symptoms can be investigated, in order to know if an-
ticholinergic exposure is linked with burden. Secondary outcomes may 
include the number of medication-related symptoms, the level of alert-
ness or sedation, the quality of life, cognitive function, activities of daily 
living, to even health care usage (hospital admissions). 
Specific research options for PIMs and for the MARANTE 
More evidence regarding dose adaptations or dose recommenda-
tions for older populations is needed, possibly by the inclusion of older 
people in pharmacological research.
A next step in the implementation for explicit criteria and for the 
MARANTE scale could be the introduction of alternative medications or 
discontinuation strategies. For most medications mentioned in explicit 
criteria, and for most anticholinergics, alternatives can be proposed (e.g. 
for most antidepressant medications, sertraline has been demonstrated 
as a safe alternative with no anticholinergic properties) [394, 395], and 
discontinuation strategies can be offered (e.g. using existing withdrawal 
guidelines for antipsychotic agents [396].
From the original 100 active substances listed in Durán et al [397], 63 
were available in Belgium. Further refining is needed for both national 
and international use. For Belgium, other anticholinergics that were not 
included into the systematic review (e.g. pentoxyverine) are to be re-
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viewed. Alternatively, dosages could be reviewed for active substances 
that are processed in the pharmacy. For international usage, the anticho-
linergics not available in Belgium, need to be reviewed. To allow future 
collaboration, an electronic platform was created were researchers, clini-
cal, and pharmacological experts are invited to participate, ensuring that 
the remaining gaps are filled in. 
Explicit criteria are not always explicit [237]. One aspect often lacking 
in all sets of explicit criteria are pharmacodynamic interactions. The risk 
of bleeding by cumulative effects of different medications is addressed in 
some list by a considerable number of complex explicit criteria, indicat-
ing its clinical importance. Also, there is often not enough specification to 
address anticholinergic interactions or interactions among medications 
prolonging QT-interval.
The role of the prescriber
Future research initiatives towards more appropriate prescribing of 
medications may focus on the role of the GP. A multitude of interdepend-
ent intrinsic (beliefs, attitudes, knowledge …) and extrinsic (patient, 
setting, health system …) factors shape the behaviour of medication 
prescribers towards the (dis)continuation of potentially inappropriate 
medications. To empower the role of the GP, barriers (time consumption, 
comprehensiveness…) and facilitators (as a support in medication re-
views) need to be explored for a successful implementation of electronic 
decision support systems intended for an optimisation of the pharmaco-
therapy in older adults.
Another possible addition to the current health care practice, is the 
possible inclusion of geriatricians in the context of an interdisciplinary 
pharmacotherapeutic evaluation of older adults in primary care. A new, 
integrated and comprehensive approach to the care (e.g. collaborative 
care) for older adults can be explored, where age-related problems and 
disorders in clinical practice are integrated with clinical decision making. 
The shift towards this paradigm is essential in order to apply appropriate 
strategies to adequately address pharmacotherapy in vulnerable older 
patients with multiple chronic diseases and polypharmacy. The evalua-
tion of older adults and their medications should be done in the knowl-
edge of an overall assessment of personal, clinical and functional param-
eters (e.g. comprehensive geriatric assessment). This assessment based 
on an interdisciplinary multi-step process integrates the skills of different 
healthcare providers (doctors, pharmacists, nurses) and is crucial to map-
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ping and adequately addressing the medical complexity of this hetero-
geneous patient group [398]. 
It is possible, that the focus of care shifts from ‘to cure’ towards ‘to care’ 
in a more goal-oriented care. The focus in goal-oriented care can be the 
extension of life, but also the sole avoidance of unwanted side-effects 
[399]. Prescribers can overlook the possibility of other diseases and medi-
cations in one patient, leading to more potentially inappropriate medica-
tions for that patient [400]. 
There is some evidence of the added value of multidisciplinary meet-
ings [401–403], but more research is needed within the context of the 
patient, to ensure an optimal medication therapy [105]. Barriers and fa-
cilitators need to be addressed, for different health care settings and for 
different long-term impact of multidisciplinary meetings needs to be 
investigated. The automated detection of any potentially inappropriate 
medications could decrease the requirements placed on the participants 
in the meetings, and could speed up the process of the review. 
Challenges for deprescribing
The evidence for deprescribing medications in patients with a low life 
expectancy is low [404]. Some studies support evidence for deprescrib-
ing in oncological or palliative care [405–413], and one study described 
an improved quality of life [405]. More high-quality research is needed 
under which deprescribing yields a maximal benefit in terms of clinical 
outcomes [78]. 
  What medications or medication classes are to be considered for 
deprescribing? 
  How to involve the patient in the process of deprescribing? Is depre-
scribing related to a higher level of adherence, and what are the clini-
cal consequences?
  Is deprescribing of medications safe, or is deprescribing associated 
with adverse events in both short and long term?
  Are deprescribing programs cost-effective, and can they be routinely 
applied in clinical settings?
9.5 Implications for health policy 
The assessment of the quality of prescribing in old age at a public 
health level should evolve towards the use of quality indicators. Quality 
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indicators can be derived, but are not limited to PIMs. A PIM may or may 
not evolve into a QI, provided additional validation research has been 
performed [170]. Explicit criteria for assessing PIMs should evolve to the 
status of a Quality Indicator. In this endeavour, the possibility of record 
linkage with epidemiological patient registries with more detailed clini-
cal content could be explored. 
The validity of polypharmacy as an indicator for appropriate 
medication use
Polypharmacy has been the subject of various studies, showing as-
sociations with potential adverse outcomes. However, polypharmacy 
should not be equated as a characteristic of care that inevitably leads to 
adverse outcomes [265].
Polypharmacy can be both appropriate and inappropriate. Evidence 
undeniably suggest that polypharmacy is often non-desirable, as previ-
ous studies have shown associations with encountering adverse drug re-
actions [414], yet it is an ill-defined term. Too many medications should 
not automatically be equalled with unsafe medications, despite a high 
correlation. The accent could shift from a pure crude cut-off for the num-
ber of medications towards the clinical indication for each medication. 
Many older adults have multiple clinical problems, and may benefit from 
multiple medications. 
Addressing the overuse of medications in relation to the clinical prob-
lems of the patient, could improve the predictive value for addressing 
patients at risk for adverse outcomes, hospitalisation or mortality. Again, 
a full appraisal can only be done with the knowledge of the level of mul-
timorbidity. 
Now, polypharmacy and extreme polypharmacy are being used as 
quality indicators for the care for older adults in nursing homes. Our find-
ings suggest that the usage of these sole quality indicators is crude, can 
be used to signal out problematic settings, but may not be useful as an 
alert for individual patients. More elaborate sets of quality indicators and/









n this thesis, we appraised the medication use of the community-
dwelling oldest old (aged 80 years, and older) by the electronic 
application of explicit criteria for the detection of potentially inap-
propriate medications (PIMs) during the prescribing phase in the 
medication management process. We reviewed the applicability 
and validity of explicit criteria on the Belgian medication market, and we 
looked into associations with health related outcomes (mortality, hospi-
talisation, and institutionalisation) using secondary data.
Explicit criteria in the STOPP/START-2 criteria and the EU(7)-PIM list 
are applicable to the Belgian medication market. The electronic applica-
tion of explicit criteria is possible and feasible, but requires a vast amount 
of personal and clinical data of patients. Less than half of the explicit crite-
ria in the STOPP/START-2 criteria could be applied electronically. 
There is still further need for validation of explicit criteria, since they 
are often not specific enough, and can miss pharmacodynamic interac-
tions. In casu, anticholinergics are often ill-defined in lists of PIMs, and 
dosages are not mentioned. We propose a new method, the MARANTE 
scale, that quantifies the anticholinergic exposure by the intrinsic poten-
cy of medications and by the dosage. The application of the MARANTE 
scale showed promising results, with clear associations with mortality 
and hospitalisation, but needs further validation.
Main findings were that community-dwelling oldest old Belgian pop-
ulation were relatively healthy and active, but there was a high preva-
lence of polypharmacy, underuse, and misuse. In one in three oldest old 
patients, these concepts were present. Polypharmacy showed no clear 
associations with long-term hard outcomes, nor did misuse. Surprisingly, 
underuse of medications had clear associations with mortality, and hos-
pitalisation. 
Clinicians must be aware that explicit criteria cover some and not all 
aspects of the medication management process, that automated use 
of explicit criteria is possible but requires access to reliable medication 
and clinical data. The exclusive use of explicit criteria in clinical practice is 
therefore not possible beyond the scope of a medication review, and can 





he older population is growing globally. Especially in Europe-
an countries, the number of older adults (65 years, and older) 
is expected to grow. Also in Belgium, the higher share of 
older adults will pose a challenge for the health care system. 
The older population will age itself, as the share of oldest old 
will grow (those aged 80 years, and over). For Belgium (a western European 
high-income country with over 11.000.000 inhabitants), an increase of ap-
proximately 120.000 adults over 80 years is expected by 2030.
With ageing, the risk for developing more clinical problems will rise (e.g. 
hypertension, osteo-arthritis, cognitive impairment …). With more clini-
cal problems, more medications will be prescribed. This can be a potential 
problem, since older adults are more sensitive to medications due to age-
related pharmacokinetic and pharmacodynamic- changes. Older persons 
have a higher risk for encountering certain medication side-effects such as 
dry mouth, dry eyes, a higher risk for bleeding, a higher risk for a fall, which 
can affect the quality of life in a patient, but can also have an impact on the 
health care system (by prescribing more medications to counter these side-
effects, or by a higher risk for a hospitalisation).
The overall aim was to extend the knowledge on the pharmacotherapy in 
the community-dwelling oldest old adults (aged 80 years, and over) so that 
the quantity and quality of life can be improved by (1) quantifying the actual 
chronic medication use in terms of prevalence, medications involved, and 
identifying patient-related risk factors for a higher medication intake. (2) As-
sessing the appropriateness of the medication use, in terms of prevalence of 
polypharmacy on the one hand and underuse or misuse on the other hand by 
using the electronic application of screening tools for potentially inappropri-
ate prescribing to evaluate the predictive validity and the clinical relevance. 
Chapter 3 describes the Belfrail-Med cohort (n=503) of Belgian communi-
ty-dwelling oldest old (aged 80 years, and over), in terms of personal, clinical, 
and functional characteristics. In this cross-sectional study, a high prevalence 
of polypharmacy (intake of 5 or more chronic medications) was noted; 58%. 
There was a high use of hypno-sedative agents and antidepressants. Apart 
from the dominant association of multimorbidity, a lower physical activity 
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and more depressive symptoms were also found to be associated with 
polypharmacy. 
In chapter 4, the influence of the medication use on mortality, the first 
unplanned hospital admission and the transfer to long-term care was 
analysed. More medications was associated with a hospitalisation, inde-
pendently from the level of multimorbidity. The association with mortal-
ity was only present in univariate analysis, and no association with insti-
tutionalisation was found. A deeper look at specific medication groups, 
showed that a higher use of hypno-sedative agents was associated with 
entering the long-term care system, and the intake of anticholinergics 
(see lower) was associated with mortality and hospitalisation, but only in 
univariate analysis.
In chapter 5 and 6, the (in)appropriateness of medications was as-
sessed using explicit criteria for potentially inappropriate medications. 
Explicit criteria can aim to assess underuse (when a medication can still 
be beneficial, but is not prescribed) or misuse (when a medication is pre-
scribed, despite a higher risk for adverse effects). Using the EU(7)-PIM list 
or STOPP/START-2 criteria, a high prevalence of misuse (56 – 73%) and 
underuse (67%) was found. The concepts of underuse, misuse and poly-
pharmacy were found to be interrelated. More medications prescribed, 
meant more misused medications, but also more underused medica-
tions. One in three oldest old had a combination of misuse, underuse and 
polypharmacy. Only in 9%, these three concepts were not found. Surpris-
ingly, only underuse showed associations with mortality and hospitalisa-
tion. For each medication that was underused, a 39% increased risk for 
mortality, and a 26% increased risk for hospitalisation was found. 
In chapter 7, a closer look was taken at the role of medications with 
anticholinergic properties (from now on anticholinergics). Anticholin-
ergic use can cause a plethora of side effects, including dry eyes, dry 
mouth, urinary retention, constipation, blurry vision, hallucinations, se-
dation, dizziness, or agitation. Anticholinergics are a hot item, due to the 
preventable unwanted effects, and the higher risks for cognitive decline, 
hospitalisation, and mortality. Theoretical lists of anticholinergic medica-
tions were constructed. Yet, there is no uniformity on which medications 
to include, nor on the potency (the affinity at receptor level). In addition, 
the dosage of medications is not taken into account in most methods.
In chapter 7, the development of the Muscarinic Acetylcholine Re-
ceptor ANTagonist Exposure (MARANTE), where potency and dosage is 
combined, is described. Starting from a systematic review of anticholiner-
gic risk scales, 100 medications were identified. In this systematic review, 
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these medications are categorised on their potency (strong or weaker af-
finity at receptor level). From these 100 medications, dosage information 
was given for all medications actively taken in the Belfrail-Med cohort 
and in a cohort of newly admitted nursing home residents. The MARANTE 
scale was tested for its’ clinimetric properties in these two cohorts.
In chapter 8, the anticholinergic use is described, and associations 
of a high anticholinergic use with mortality and hospitalisation were in-
vestigated. Anticholinergics were taken by 32% of the population, most 
commonly agents for depression, pain, or gastrointestinal complaints. 
In most cases (80%) low potency anticholinergics were prescribed, yet 
often high (52%) or very high (17%). Those with a high anticholinergic 
exposure (score of two or higher on the MARANTE scale) had a 2.2 fold 
increased risk for mortality, and a 71% increased risk for hospitalisation. 
This manuscript aimed to give more insights in the oldest old, an 
underrepresented age cohort in scientific literature, and especially on a 
crucial aspect of their lives and for their health; their medication use. The 
results indicate that the medication use of the oldest old can still be im-
proved. The oldest old consume many medications, with a specific high 
use of hypno-sedatives and antidepressants. The electronic applications 
for screening for potentially inappropriate medications and the identifi-
cation of anticholinergics could support medication prescribers, or medi-






et aandeel oudere personen neemt wereldwijd toe. Voor-
namelijk in Europese landen wordt een enorme toename 
van oudere personen (boven 65 jaar) verwacht. Ook in Bel-
gië wordt een vergrijzingsgolf verwacht, welke een impact 
zal hebben op de huidige gezondheidszorg. De oudere 
populatie wordt ook verwacht te verouderen, getuige het groeiende aandeel 
personen boven 80 jaar. In 2030 wordt verwacht dat er meer dan 120.000 
extra personen boven 80 jaar in België zullen zijn.
Door veroudering zal de kans op het krijgen van een ziekte toenemen 
(bijvoorbeeld hypertensie, artrose, mentale achteruitgang, …), waarvoor 
geneesmiddelen kunnen voorgeschreven worden. Meer geneesmiddelen 
bij oudere personen vormt een potentieel probleem. Oudere personen zijn 
gevoeliger aan de werking en bijwerkingen van geneesmiddelen door al-
lerlei farmacokinetische en –dynamische veranderingen. Oudere personen 
hebben hierdoor bijvoorbeeld een grotere kans op bepaalde bijwerkingen; 
droge mond, droge ogen, constipatie, een hoger bloedingsrisico, een hoger 
risico voor een valincident, wat een impact kan hebben op de kwaliteit van 
leven van de patiënt, maar ook op de gezondheidszorg (door een hoger aan-
tal hospitalisaties, of door een hoger aantal geneesmiddelen om die bijwer-
kingen te behandelen). 
Deze doctoraatsthesis had als doel de kennis rond farmacotherapie bij 
oudere thuiswonende personen te verhogen, om indirect de kwaliteit en 
kwantiteit van leven te verhogen. Dit door (1) het chronische geneesmid-
delengebruik in kaart te brengen; de hoeveelheid, de geneesmiddelengroe-
pen die werden voorgeschreven, en patiënt-gerelateerde risicofactoren aan 
te duiden die geassocieerd zijn met een hoger geneesmiddelengebruik. (2) 
Het tweede doel betrof het in kaart brengen van potentieel ongeschikte ge-
neesmiddelen (ondergebruik, en verkeerd gebruik), en het beoordelen van 
het medicatiegebruik door een elektronische toepassing te maken van geva-
lideerde expliciete criteria, om zo bij te dragen tot de predictieve validiteit en 
klinische relevantie van deze criteria. 
Hoofdstuk 3 vormt de basis voor de verdere hoofdstukken. In dit hoofdstuk 
wordt het Belfrail-MED cohorte beschreven; een cohorte van 503 thuiswo-
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nende oudste ouderen (80 jaar en ouder) in België, met een uitgebreide 
dataverzameling van persoonlijke, klinische, en functionele karakteris-
tieken. In deze paper werd een hoge prevalentie van polyfarmacie (de 
inname van vijf of meer chronische geneesmiddelen) aangetoond, na-
melijk 58%. Een belangrijk aandeel nam ook op chronische basis slaap- 
en kalmeermiddelen, en antidepressiva in. Naast de dominante factor 
multimorbiditeit (het tegelijk voorkomen van meerdere ziektebeelden) 
waren hogere mate van fysieke inactiviteit en depressieve symptomen 
geassocieerd met polyfarmacie.
In hoofdstuk 4 werd de invloed van het medicatiegebruik op mortali-
teit, de eerste ongeplande hospitalisatie, en op de opname in een woon-
zorg centrum. Meer voorgeschreven medicatie was geassocieerd met 
hogere risico’s tot hospitalisatie, onafhankelijk van de graad van multi-
morbiditeit. De associatie van een hoger medicatiegebruik met mortali-
teit was enkel aanwezig in univariate analyse, en er was geen associatie 
met een opname in een woonzorgcentrum. Kijkend naar medicatie sub-
klassen, was het gebruik van een slaap- of kalmeermiddel (benzodiaze-
pines en derivaten) geassocieerd met een opname in een woonzorgcen-
trum, en het nemen van medicatie met anticholinerge eigenschappen 
(zie later) geassocieerd met mortaliteit en hospitalisatie, hoewel enkel in 
univariate analyse.
In hoofdstuk 5 en 6 werd de (on)geschiktheid van het geneesmidde-
lengebruik uitgediept. De geschiktheid van het medicatiegebruik werd 
beoordeeld aan de hand van expliciete criteria. Expliciete criteria kun-
nen enerzijds op ondergebruik (wanneer een geneesmiddel niet werd 
voorgeschreven, hoewel het mogelijks nut kan hebben), of foutief ge-
bruik (wanneer een geneesmiddel meer risico’s dan baten heeft) gericht 
zijn. Aan de hand van de EU(7)-PIM list en STOPP/START-2 criteria werd 
een hoge prevalentie mogelijks foutieve medicatie was (56 – 73% afhan-
kelijk van de gehanteerde lijst van expliciete criteria), en ondergebruik 
(67%) gemeten. De drie concepten (ondergebruik, verkeerd gebruik en 
polyfarmacie) waren ook aan elkaar verwant. Hoe hoger het aantal ge-
neesmiddelen, hoe meer mogelijks foutieve geneesmiddelen een pati-
ent had, maar ook hoe meer ondergebruikte geneesmiddelen er waren. 
Ongeveer een derde van de oudste ouderen (31%) had te veel, te weinig, 
of mogelijks gevaarlijke geneesmiddelen. Anderzijds had slechts 9% van 
de oudste ouderen geen enkel van de drie concepten. Het ondergebruik 
van geneesmiddelen toonde verrassend genoeg associaties met morta-
liteit en hospitalisatie. Per geneesmiddel dat mogelijks nuttig was, maar 
niet werd voorgeschreven bij de start van de studie, was er een 39% ver-
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hoogd risico op mortaliteit, en een 26% verhoogd risico voor een opna-
me in een ziekenhuis. 
In hoofdstuk 7 werden medicatie met anticholinerge bijwerkingen 
(vanaf nu anticholinergica) uitgediept. Anticholinergica kunnen tot al-
lerlei bijwerkingen leiden, zoals onder andere droge mond, droge ogen, 
urineretentie, constipatie, wazig zicht, hallucinaties, sedatie, sufheid, dui-
seligheid, of verwardheid. Anticholinergica zijn een hot item, omwille van 
de vele vermijdbare bijwerkingen, maar ook omdat studies verbanden 
met cognitieve achteruitgang, hospitalisatie of mortaliteit hebben aan-
getoond. Er werden daarom theoretische lijsten opgemaakt met anticho-
linerge geneesmiddelen. Echter, er is geen eenduidigheid over wat nu 
juist een geneesmiddel met anticholinerge werking is, in welk mate een 
receptor geblokkeerd wordt. Daarenboven wordt het aspect van dose-
ring slechts in geringe mate beoordeeld. Daarvoor werd de Muscarinic 
Acetylcholine Receptor ANTagonist Exposure (MARANTE) schaal ontwik-
keld, waarin de kracht (van affiniteit op receptorniveau) met de dosis 
van het geneesmiddel wordt gecombineerd. Van 100 geneesmiddelen 
geïdentificeerd in een systematische review werd vervolgens dosisinfor-
matie gezocht van courant gebruikte geneesmiddelen in enerzijds het 
Belfrail-MED cohorte en anderzijds in een populatie nieuwe woonzorg-
centra bewoners. De klinimetrische eigenschappen van deze nieuwe 
schaal werden getest in deze twee cohorten.
In hoofdstuk 8 werd het anticholinergica gebruik in kaart gebracht. 
Medicatie met anticholinerge werking werd door 32% van de populatie 
genomen, vaak voor de indicatie van depressie, pijn, of gastro-intestina-
le klachten. In de meeste gevallen (80%) werden geneesmiddelen met 
een zwakke affiniteit op receptorniveau voorgeschreven. Kijkende naar 
de dosering, waren de dosissen vaak hoog (52%) of te hoog (17%) voor 
oudere personen. De MARANTE schaal toonde ook verbanden met mor-
taliteit en hospitalisatie. Zij met een hoge anticholinerge blootstelling 
hadden een 2.2 keer verhoogd risico op sterfte, en 70% meer risico op 
hospitalisatie. 
Dit manuscript heeft als doel meer inzicht te brengen in een popu-
latie die weinig bestudeerd is, over een bepaald aspect van hun leven 
dat hun gezondheid mee bepaalt, maar eveneens weinig onderzocht is. 
De resultaten van de verschillende studies tonen aan dat het geneesmid-
delengebruik mogelijks nog verbeterd kan worden. Er is een aanzienlijk 
deel van de oudste populatie die te veel geneesmiddelen neemt, met 
een belangrijke consumptie van slaap-en kalmeermiddelen. De elek-
tronische toepassing voor het herkennen van mogelijkse ongeschikte 
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geneesmiddelen, of de identificatie van anticholinergica kan medicatie 
voorschrijvers ondersteunen om een optimaal en veilig geneesmidde-
lenvoorschrift op te stellen voor oudere personen.
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skills training
Publications
• Wauters M, Versluys K, Steeman E, Petrovic M. Ontwikkeling en vali-
datie van een kennistest over psychofarmaca voor verpleegkundigen 
op de afdeling acute geriatrie. Verpleegkunde. 2013;28(4):4–11. 
• Wauters M, Elseviers M, Vaes B, Degryse J, Dalleur O, Vander Stichele 
R, Van Bortel L, Azermai M. Polypharmacy in a Belgian cohort of com-
munity-dwelling oldest old (80+). Acta Clin Belg. 2016 Jun;71(3):158–
66. 
• Wauters M, Elseviers M, Vaes B, Degryse J, Vander Stichele R, Chris-
tiaens T, Azermai M. Mortality, hospitalisation, institutionalisation 
in community-dwelling oldest old: The impact of medication. Arch 
Gerontol Geriatr. 2016 Jul;65:9–16. 
• Wauters M, Elseviers M, Azermai M, Vander Stichele R. Availability and 
actual use in the Belgian market of potentially inappropriate medica-
tions (PIMs) from the EU(7)-PIM list. Eur J Clin Pharmacol. 2015;(7):2–4. 
• Wauters M, Elseviers M, Vaes B, Degryse J, Dalleur O, Vander Stichele 
R, Christiaens T, Azermai M. Too many, too few, or too unsafe? Impact 
of inappropriate prescribing on mortality, and hospitalisation in a 
cohort of community-dwelling oldest old. Br J Clin Pharmacol. 2016 
Nov;82(5):1382–92. 
• Klamer TT & Wauters M, Azermai M, Duràn C, Christiaens T, Elseviers 
M, Vander Stichele R. A novel scale linking potency and dosage to 
estimate anticholinergic exposure in older adults: the Muscarinic Ace-
tylcholinergic Receptor ANTagonist Exposure (MARANTE) scale. Basic 
Clin Pharmacol Toxicol. 2017 Jun;120(6):582-590.
• Wauters M, Klamer TT, Elseviers M, Vaes B, Degryse J, Dalleur O, Duran 
CE, Christiaens T, Azermai M, Vander Stichele R. Anticholinergic 
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Exposure in a cohort of adults aged 80 and over: Associations of the 
MARANTE score with mortality and hospitalisation. Basic Clin Phar-
macol Toxicol. 2017 Jun;120(6):591-600.
• Wauters M, Azermai M, Perehudoff K, Versluys K, Steeman E, Petrovic 
M. Development and validation of the Psychotropic Education and 
Knowledge (PEAK) test on psychotropic drugs for nurses in an acute 
geriatric care setting. Eur Geriatr Med. 2016;80(2):135–41. 
• Perehudoff K, Azermai M, Wauters M, Van Acker S, Versluys K, Steeman 
E, Petrovic M. The psychotropic education and knowledge test for 
nurses in nursing homes: striving for PEAK performance. Aging Ment 
Health. 2015;(July):1–8. 
• Azermai M, Wauters M, De Meester D, Renson L, Pauwels D, Peeters L, 
Warie H, Petrovic M. (2017) A quality improvement initiative on the 
use of psychotropic drugs in nursing homes in Flanders. Acta Clin 
Belg 1–9. doi: 10.1080/17843286.2017.1287230
• Leten L, Azermai M, Wauters M, De Lepeleire J (2017) A qualitative ex-
ploration of the chronic use of psychotropic drugs in nursing homes. 
Tijdschr Gerontol Geriatr. doi: 10.1007/s12439-017-0223-7
Presentations
• Wintermeeting Geriatrie 2012 – Oostende (Belgium). Poster pres-
entation: De ontwikkeling en validatie van een kennistest omtrent 
psychofarmaca bij verpleegkundigen op de dienst  acute geriatrie.
• EuroDURG 2014 – Groningen (The Netherlands). Poster presentation: 
Drug prescribing patterns in the very old: baseline observation.
• BESPE 2014 – Gent (Belgium). Oral presentation: Het medicatiege-
bruik van de oudste thuiswonende ouderen: Resultaten uit de BELF-
RAIL studie.
• Winter meeting 2015 – Oostende (Belgium). Poster presentation: 
Polypharmacy in a Belgian cohort of community-dwelling oldest old: 
baseline observations and associated risk factors.
• Research Day Ghent University 2015 – Gent (Belgium). Bullet point 
presentation: Polypharmacy in a Belgian cohort of community-dwell-
ing oldest old: baseline observations and associated risk factors 
• EACPT 2015 – Madrid (Spain). Oral presentation: Polypharmacy in a 
Belgian cohort of community-dwelling oldest old: Baseline observa-
tions and associated risk factors.
• EACPT 2015 – Madrid (Spain). Poster presentation: Impact of Medica-
tion use on mortality in community-dwelling oldest old.
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• Wintermeeting Geriatrie 2016 – Oostende (Belgium). Oral presenta-
tion: Mortality, hospitalisation, institutionalisation in community-
dwelling oldest old: The impact of Medication.
• Research Day Ghent University 2016 – Gent (Belgium). Bullet point 
presentation: Mortality, hospitalisation, Institutionalisation in com-
munity-dwelling oldest old: The impact of Medication.
• ICPE 2016 – Dublin (Republic of Ireland). Oral presentation: Too many, 
too few, or too unsafe? Impact of inappropriate prescribing on mor-
tality, and hospitalisation in community-dwelling adults, aged 80 and 
older.
• ICPE 2016 – Dublin (Republic of Ireland). Poster presentation: STOPP-2 
versus PIM-EU(7): Comparing prevalence, and impact of inappropri-
ate prescribing on mortality and hospitalisation
• Wintermeeting Geriatrie 2017 – Oostende (Belgium). Poster presenta-
tion: A novel scale linking potency and dosage to estimate anticholin-
ergic exposure in older adults: the MARANTE scale.
• Wintermeeting Geriatrie 2017 – Oostende (Belgium). Poster pres-
entation: Too many, too few, or too unsafe? Impact of inappropriate 
prescribing on mortality, and hospitalisation in a cohort of communi-
ty-dwelling oldest old.
• Wintermeeting Geriatrie 2017 – Oostende (Belgium). Oral presenta-
tion: Anticholinergic Exposure in a cohort of adults aged 80 and over. 
Associations of the MARANTE scale with mortality and hospitalisation
• EuroDURG 2017 – Glasgow (UK). Poster presentation: Electronic as-
sessment of the anticholinergic exposure using the MARANTE scale.
• EuroDURG 2017 – Glasgow (UK). Poster presentation: Anticholinergic 
exposure in primary care and in long-term care: differences in medi-
cations involved and intensity?
• Winter meeting Geriatrie 2018 – Oostende (Belgium): Anticholinergic 
exposure in primary care and in long-term care: differences in medi-




et dankwoord is naar alle waarschijnlijkheid de sectie die 
vaak als eerste, maar daarnaast ook het meeste zal worden 
gelezen in dit werk. Ik kan je geen ongelijk geven. Echter, 
voor mij was het lastig om iedereen (rechtstreeks of on-
rechtstreeks) betrokken tijdens mijn doctoraat op gepaste 
wijze te bedanken.
Mijn hele doctoraat was een ontdekkingsreis, waar ik de kans heb gekre-
gen vaardigheden aan te leren of verder aan te scherpen. Daarom gaat in de 
eerste plaats men dank uit naar diegenen die potentieel in me zagen op de 
sollicitatie enkele jaren terug. Allereerst, mijn academische ouders, prof.dr. R. 
Vander Stichele en prof. dr. M. Elseviers, a.k.a. Bob en Monique. 
Bob, samenwerken met jou is een avontuur op zich. Jouw taalgevoel en 
kritische reflecties (die soms, ietwat laat in het proces van het schrijven van 
een artikel komen), en jouw gave om rake conclusies te geven na een moei-
lijk debat, zijn eigenschappen om te bewonderen. Bovenal zal jouw hartelijk-
heid en jouw (haast legendarische wordende) verstrooidheid me bijblijven.
Monique, ik moet toegeven dat ik in het begin heb moeten leren samen-
werken met jou. Eens dat overwonnen was bleef enkel bewondering voor 
jouw heldere statistische blik en jouw complete overgave om mij vooruit 
te helpen (getuige de soms uren durende telefoongesprekken om me toch 
maar feedback te geven). Je gaf ook tegengewicht aan discussies met Bob, 
waar jullie (wonderlijk) complementair in zijn. Beiden, enorm bedankt voor 
alles! Daarnaast wil ik ook prof. Van Bortel en prof. Christiaens bedanken voor 
hun heldere blikken en de mogelijkheid te voorzien om aan het Heymans 
instituut te kunnen werken. Beiden hadden de gave problemen met kernza-
ken op te merken, terwijl ik mij soms verloor in details. 
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Na de academische ouders en suikernonkels, de academische grote 
zus, Majda. Majda, we zaten in verschillende teams, die niet verenigbaar 
waren. Jij in team Sahara en ik in team Alaska. Mijn raam stond bijna altijd 
open, terwijl jij dan de verwarming net dat tikkeltje hoger zou zetten. 
Het was altijd aanpassen als we elkaars bureau bezochten. Je was meer 
dan een collega. Naast de talloze fijne tijden (in Madrid, Groningen, maar 
evengoed in downtown Gent) zal ik jouw wetenschappelijk inzicht en 
blijvende motivatie herinneren. 
Evengoed zijn er veel anderen geweest die met kostbare opmerkin-
gen, raad en steun klaarstonden. Gaande van de Belfrail collega’s prof.
dr. Degryse, dr. Vaes en dr. Dalleur, de enthousiaste medewerkers van 
Leiehome, tot mijn examencommissie. Ook zonder hun feedback zou ik 
niet staan waar ik nu sta. Dirk, bedankt om mijn boek onder handen te 
nemen! 
Werken op het Heymans was een aangename ervaring, enkel maar 
mogelijk gemaakt door de verschillende collega’s. Jelle, Wendy, Ilse, Joly-
ce, Elien, Isabel, Katrina, Therese, Carlos, Ivana, Nele, Ellen, Hanne en het 
Benzo-team. Hoewel iedereen zijn eigen project of werk had, stond ie-
dereen voor iedereen klaar met raad, steun, iets zelfgebakken lekkers, of 
eens een leuke babbel. You guys rock.
Ook wil ik al mijn vrienden bedanken om me te steunen en mijn geest 
even het doctoraat weg te halen. Al is het met hun geïnteresseerde vra-
gen (wat doe jij dan een hele dag?), hun oprechte verwondering (zo saai! 
Ik zou dat nooit kunnen! Word jij daar echt voor betaald?), en weer hun 
geïnteresseerde vragen (en wat ga je er dan later mee doen?). Bovenal 
zou ik mijn Oma willen bedanken om de cover te sieren van dit werk.
Verder eervolle vermeldingen aan onbekende koffieboeren (het zijn 
niet de doctoraatsstudenten maar koffie, die de drijvende kracht zijn in 
academia), Mendeley software (om citeren en refereren makkelijk en 
draaglijk te maken). Geen speciale vermelding voor Microsoft Word (ta-
bellen laat je in het formaat staan dat ik wil, begrepen? Neen, we ver-
springen niet van pagina, capiche?) en de chart editor van SPSS (hoe 
een figuur opmaken van uitdagend en leuk zo snel naar vervelend en 
tijdsrovend kon gaan…). 
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De laatste dankbetuigingen gaan naar de belangrijkste personen. 
Mama en Papa, om altijd klaar te staan. Lief Lientje, om er te zijn, om zo 
lief te zijn. Als er iemand is zonder wie dit proefschrift niet mogelijk was 
geweest, dan ben jij het. Nu kunnen we erop terug kijken en lachen, hoe 
we beide nerveus aan ons project bezig waren. Jij je masterproef en arti-
kel, ik mijn doctoraat. Nu enkele maanden later is het ons beide gelukt.  Je 
haalt het beste in me naar boven, en je bent bovendien de meest liefde-
volle mama voor Robbe die ik maar kon wensen. Liefste Robbe (wobje), 
jouw onvoorwaardelijke liefde is vertederend. Jouw kamerbrede lach is 
enorm aanstekelijk. Jij maakt me echt bewust van wat belangrijk is in het 
leven, namelijk van elkaar genieten. Nu dit doctoraat echt achter de rug 
is, kijk ik uit naar de avonturen die we samen gaan beleven.
If I have seen further than others,
it is by standing upon the shoulders of giants
Maarten Wauters
22 december 2017

